Pharmaceutical Cocrystal Eutectic Analysis: Study of Thermodynamic  Stability, Solubility, and Phase Behavior by Good, David John
PHARMACEUTICAL COCRYSTAL EUTECTIC ANALYSIS: STUDY OF 








A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
(Pharmaceutical Sciences) 















 Associate Professor Naír Rodríguez-Hornedo, Chair 
Professor Gordon L. Amidon  
Professor Vincent L. Pecoraro 
Research Professor Gregory E. Amidon 
©  David John Good 













To my wife, Jessica, and my parents, Kathleen and David
  iii 
ACKNOWLEDGEMENTS 
I wish to thank the many individuals who have helped and supported me in the 
pursuit of my graduate studies and made these years such a rich and enjoyable 
experience.  First and foremost, I would like to express my sincerest gratitude to Dr. Naír 
Rodríguez-Hornedo.  The challenges and excitement of this research have been 
immensely rewarding because of your enthusiasm, encouragement, and excellence.  It has 
been a great privilege to work in your laboratory and benefit from your instruction.  I will 
forever cherish the experiences of being your student and the enormous influences you 
have had on my scientific interests and my personal development.  Thank you to my 
dissertation committee members, Dr. Gordon Amidon, Dr. Gregory Amidon, and Dr. 
Vincent Pecoraro for your valuable insights, guidance, and suggestions. 
This doctoral research was made possible by financial contributions from the 
American Foundation for Pharmaceutical Education Fellowship, and the Gordon and 
Pamela Amidon, Fred W. Lyons, Jr., Warner Lambert/Parke Davis and Upjohn 
Endowment Fellowships from The University of Michigan College of Pharmacy. 
Funding from the Purdue-Michigan Consortium on Supramolecular Assemblies and Solid 
State Properties and a research gift from Boehringer Ingelheim are also acknowledged.  
Thank you to all who gave financial support to this research and my education. 
  iv
Special thanks to past and present members of the Rodríguez laboratory including 
Sarah Bethune, Adivaraha (Jay) Jayasankar, Neal Huang, Chinmay Maheshwari, Lilly 
Roy, Sreenivas Reddy, and Phil Zocharski as well as Crystal Miranda and Toshiro 
Fukami who spent time studying with the group.  I greatly appreciate all of your 
assistance including many contributions and discussions that enabled aspects of this 
work.  We have had some good fun amidst the hard work and I am lucky to be 
surrounded with such great people to share the experiences of graduate school.   
 I would like to acknowledge the extensive support of my family and friends for 
which I am truly grateful.  Thank you to my parents, Kathleen and David, who have 
always supported my interests and education and given me all the encouragement and 
guidance I could ever hope for.  Your perspective and advice give me strength, cheer, and 
helped me focus on the important things in life.  Thank you to my sisters Rebecca and 
Rachel and my brother Dan for your thoughts and encouragement.  To Dorothea, Bill, 
and Katherine Henry as well as Bert, Vickie, Andrew and Becky Steck and the Ivie 
family, thank you for making Michigan feel like home since we arrived.   
Above all, I thank Jessica, my wife, for your patience, support, and for changing 
your career path so I could pursue my studies.  I cannot possibly recount all the support 
you have provided since our first visit to Ann Arbor, and the ways you have sacrificed for 
me to achieve my goals.  You are my constant joy and inspiration. 
 
  v 
  
TABLE OF CONTENTS 
DEDICATION ............................................................................................................................................... ii
ACKNOWLEDGEMENTS ......................................................................................................................... iii
LIST OF FIGURES...................................................................................................................................... ix




1.1. BACKGROUND ................................................................................................................................. 7
1.1.1. Cocrystal Design .......................................................................................................................... 7
1.1.2. Cocrystal Synthesis .................................................................................................................... 10
1.1.3. Cocrystal Properties .................................................................................................................. 13
1.2. SOLUBILITY AND SOLUTION CHEMISTRY OF MULTICOMPONENT CRYSTALS ............ 20
1.2.1. Cocrystals................................................................................................................................... 20
1.2.2. Pharmaceutical Salts ................................................................................................................. 24
1.2.3. Racemic Compounds .................................................................................................................. 25
1.3. STATEMENT OF DISSERTATION RESEARCH........................................................................... 29
1.4. REFERENCES .................................................................................................................................. 32
CHAPTER 2
THE STOICHIOMETRIC SOLUBILITY OF COCRYSTALS FROM SOLUTION EUTECTIC 
CONCENTRATIONS OF COCRYSTAL COMPONENTS................................................................... 45
2.1. THEORETICAL ................................................................................................................................ 50
2.1.1. Cocrystal solubility (SCC) and solubility product (Ksp) .............................................................. 50
2.1.2. Cocrystal solubility (SCC) and the phase solubility diagram (PSD)........................................... 51
2.1.3. Cocrystal solubility and chemical potential at the eutectic concentration ................................ 56
2.1.4. Thermal analysis and predictions of cocrystal solubility (SCC). ................................................ 57
2.2. MATERIALS AND METHODS ....................................................................................................... 58
2.2.1. Materials .................................................................................................................................... 58
  vi
2.2.2. Determination of eutectic concentrations ([A]eu and [B]eu) ...................................................... 59
2.2.3. High performance liquid chromatography (HPLC) .................................................................. 62
2.2.4. X-ray powder diffraction (XRPD) .............................................................................................. 63
2.2.5. Thermal Analysis........................................................................................................................ 63
2.3. RESULTS AND DISCUSSION ........................................................................................................ 65
2.3.1. Cocrystal solubility from eutectic concentrations...................................................................... 65
2.3.2. Cocrystal solubility, eutectic concentration, and coformer solubility relationship................... 69
2.3.3. Cocrystal coformers that increase drug solubility ..................................................................... 73
2.3.4. Cocrystal stoichiometry and solubility....................................................................................... 75
2.3.5. Cocrystal and drug solubility..................................................................................................... 76
2.3.6. Accuracy of solubility product measurements ........................................................................... 78
2.3.7. Ideal solubilities from thermal properties.................................................................................. 80
2.4. CONCLUSIONS................................................................................................................................ 87
2.5. REFERENCES .................................................................................................................................. 88
2.6. APPENDIX........................................................................................................................................ 95
CHAPTER 3
COCRYSTAL EUTECTIC CONSTANTS AND PREDICTION OF SOLUBILITY BEHAVIOR ... 96
3.1. THEORETICAL ................................................................................................................................ 98
3.1.1. Cocrystal eutectic constants and solution equilibrium .............................................................. 98
3.1.2. Keu values and triangular phase diagrams for cocrystals with multiple solution eutectic points
............................................................................................................................................................ 103
3.2. MATERIALS AND METHODS ..................................................................................................... 109
3.2.1. Calculation of solubility product from phase solubility diagrams........................................... 109
3.2.2. High performance liquid chromatography (HPLC) ................................................................ 114
3.2.3. X-ray powder diffraction (XRPD) ............................................................................................ 114
3.2.4. Materials .................................................................................................................................. 115
3.3. RESULTS AND DISCUSSION ...................................................................................................... 116
3.3.1. Solution properties of cocrystals and cocrystal components ................................................... 116
3.3.2. Validation of solution models and calculated eutectic constants ............................................ 121
3.4. CONCLUSIONS.............................................................................................................................. 132
3.5. REFERENCES ................................................................................................................................ 133
3.6. APPENDIX...................................................................................................................................... 138
CHAPTER 4
THERMODYNAMIC STABILITY OF COCRYSTALS AND THE TEMPERATURE 
DEPENDENCE OF EUTECTICS ........................................................................................................... 147
  vii
4.1. THEORETICAL .............................................................................................................................. 148
4.1.1. Thermodynamic models for temperature dependence of Sdrug, Ksp, and Keu. ........................... 148
4.2. MATERIALS AND METHODS ..................................................................................................... 152
4.2.1. Solubility analysis of cocrystal and drug ................................................................................. 152
4.2.2. High performance liquid chromatography (HPLC) ................................................................ 154
4.2.3. X-ray powder diffraction (XRPD) ............................................................................................ 154
4.2.4. Materials .................................................................................................................................. 155
4.3. RESULTS AND DISCUSSION ...................................................................................................... 156
4.3.1. Carbamazepine-nicotinamide and sulfamethazine-benzoic acid............................................. 156
4.3.2. Observed temperature dependence of other cocrystals and racemates ................................... 165
4.3.3. Eutectic temperature dependence and triangular phase diagrams (TPD) .............................. 169
4.4. CONCLUSIONS.............................................................................................................................. 171
4.5. REFERENCES ................................................................................................................................ 172
4.6. APPENDIX...................................................................................................................................... 175
CHAPTER 5
COCRYSTAL ACTIVITY AND SOLVENT EFFECTS ON SOLUBILITY AND 
THERMODYNAMIC STABIILTY......................................................................................................... 181
5.1. THEORETICAL .............................................................................................................................. 182
5.1.1. Ideal cocrystal solubility and activity ...................................................................................... 182
5.1.2. Ksp and Keu predictions for different solvents........................................................................... 184
5.1.3. Critical coformer activity ......................................................................................................... 189
5.2. MATERIALS AND METHODS ..................................................................................................... 190
5.2.1. Materials .................................................................................................................................. 190
5.2.2. Solubility analysis of cocrystal, drug, and coformer ............................................................... 191
5.2.3. High performance liquid chromatography (HPLC) ................................................................ 191
5.2.4. X-ray powder diffraction (XRPD) ............................................................................................ 192
5.2.5. Differential scanning calorimetry (DSC)................................................................................. 192
5.3. RESULTS AND DISCUSSION ...................................................................................................... 193
5.3.1. Cocrystal activity from observed and ideal solubility values .................................................. 193
5.3.2. Prediction of cocrystal solubility product and stability in other solvents ............................... 199
5.4. CONCLUSIONS.............................................................................................................................. 202
5.5. REFERENCES ................................................................................................................................ 203
CHAPTER 6
STABILITY AND PHASE BEHAVIOR OF CARBAMAZEPINE-SARCOSINE ANHYDRIDE ... 206
  viii
6.1. MATERIALS AND METHODS ..................................................................................................... 208
6.1.1. Materials .................................................................................................................................. 208
6.1.2. Cocrystal synthesis and screening ........................................................................................... 208
6.1.3. Eutectic concentrations of drug and coformer......................................................................... 209
6.1.4. High performance liquid chromatography (HPLC) ................................................................ 210
6.1.5. X-ray diffraction....................................................................................................................... 210
6.2. RESULTS AND DISCUSSION ...................................................................................................... 212
6.2.1. Crystal structure of 2:1 carbamazepine-sarcosine anhydride................................................. 212
6.2.2. 1:1 and 2:1 carbamazepine-sarcosine anhydride cocrystals................................................... 215
6.2.3. Phase solubility diagram.......................................................................................................... 218
6.3. CONCLUSIONS.............................................................................................................................. 221
6.4. REFERENCES ................................................................................................................................ 222
CHAPTER 7
HYGROSCOPIC ADDITIVES AND THE MECHANISMS BY WHICH MOISTURE GENERATES 
COCRYSTALS .......................................................................................................................................... 225
7.1. MATERIALS AND METHODS ..................................................................................................... 228
7.1.1. Materials .................................................................................................................................. 228
7.1.2. Eutectic concentrations of drug and coformer......................................................................... 229
7.1.3. Moisture sorption of solid mixtures and cocrystal formation .................................................. 230
7.1.4. Raman Spectroscopy ................................................................................................................ 232
7.1.5. Polarized Optical Light Microscopy Studies ........................................................................... 232
7.1.6. Gravimetric Vapor Sorption .................................................................................................... 233
7.1.7. High performance liquid chromatography (HPLC) ................................................................ 234
7.1.8. X-ray powder diffraction (XRPD) ............................................................................................ 234
7.1.9. Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy ............................... 235
7.2. RESULTS AND DISCUSSION ...................................................................................................... 237
7.2.1. Microscopy of vapor sorption and cocrystal formation........................................................... 237
7.2.2. Moisture sorption of solid mixtures and cocrystal formation .................................................. 241
7.2.3. Discussion of solution-mediated cocrystal formation.............................................................. 249
7.3. CONCLUSIONS.............................................................................................................................. 253
7.4. REFERENCES ................................................................................................................................ 254
7.5. APPENDIX...................................................................................................................................... 258
CHAPTER 8
CONCLUSIONS AND FUTURE WORK............................................................................................... 259
  ix
LIST OF FIGURES 
Figure 1.1: Classification/nomenclature of solids and crystalline phases with 
multiple components. Adapted in part from Weber et al., Stahl et al., and Qiu 
et al., and Halebian.22-25 .............................................................................................. 6
Figure 1.2: Schematic examples of synthon arrangements including homosynthon 
(I-II) and hetersynthons (III-X) interactions. .............................................................. 8
Figure 1.3: Solubility of 1:1 CBZ-NCT cocrystal (solid points) and CBZ(III) 
(open points) at 25˚C as a function of total NCT concentration in ethanol 
(squares), 2-propanol (tiangles), and ethyl acetate (circles).  The solid lines 




Figure 1.4: Gabapentin-(3-hydroxybenzoic acid) solubility dependence on pH.  




Figure 1.5:  Schematic triangular phase diagram (TPD) of conglomerate (left) and 
racemic compound (right). D and L represent enantiomers and each apex 
represents a pure phase corresponding to the label................................................... 28
Figure 2.1:  Diagram of carbamazepine-succinic acid cocrystal structure with 
hydrogen bonds indicated by dashed lines.  Each carboxylic acid of the 
succinic acid forms two hydrogen bonds with the carbamazepine amide.
28
............ 49
Figure 2.2:  Schematic phase solubility diagram of two different cocrystals based 
on the Ksp of a stable (case 1) or metastable (case 2) cocrystal. Drug 
solubility is indicated and is much lower than the solubility of the coformer, 
which is not shown. X marks represent the eutectic points (i.e. invariant 
point) used to calculate equilibrium solubility.  Circles represent the 
solubility of cocrystal in pure solvent. Dashed line illustrates stoichiometric 
concentrations of cocrystal components which dissolution could follow. This 
line represents a drug to coformer ratio equal to the cocrystal stoichiometric 
ratio of the components............................................................................................. 53
  x 
Figure 2.3:  a) Flowchart of method used to establish the invariant point and 
determine equilibrium solution eutectic concentrations of cocrystal 
components. b) Schematic PSD illustrating two pathways to reach the 
eutectic marked with an X. The solubility curve is generated from drug and 
coformer concentrations that equal the cocrystal solubility product. ....................... 60
Figure 2.4: XRPD patterns of reference materials and solid phases isolated from 
suspensions at the eutectic concentration: a) CBZ(III), b) CBZ(D), and c) 
CBZ-SUC followed by solid phases isolated from d) water, e) ethanol, f) 
ethyl acetate, and g) 2-propanol................................................................................ 68
Figure 2.5:  a) The relationship between [coformer]eu and coformer solubility for 
CBZ cocrystals in water. Log axes are shown to aid visualization of the 
individual points due to the large range of values. The linear regression for 
the untransformed data in Table 2.1 is r
2
=0.986. b) The ratio of coformer to 
drug solubility plotted against the cocrystal solubility ratio (filled circles) and 
the ratio of coformer to drug eutectic concentrations (open circles). All 
aqueous samples are shown in red.  Several cocrystals with the same 
coformers are labeled. [coformer]eu in a) and b) refers to the non-ionized 
[coformer] at the eutectic based on pH values listed in Table 2.1. ........................... 72
Figure 2.6: Solubility ratio of CBZ cocrystal to CBZ(D) as a function of the 
constituent coformer solubility (molal).  The graphs represent: (a) ethanol, 
(b) 2-propanol, (c) ethyl acetate, (d) water.  The points in each graph 
represent the cocrystal CBZ-coformer by the corresponding coformer 
component ( :GTA, +:NCT, :SUC, :SAC)..................................................... 73
Figure 2.7: Aqueous solubility ratio of CBZ cocrystals to CBZ(D) (i.e. 
[drug]Scc/Sdrug) plotted against coformer solubility. Data labels indicate the 
coformer component of the cocrystal. Cocrystal solubility calculated from 
Equation 2.5 ( : [drug]eu measured) or from Equation 2.6 ( : [drug]eu 
approximated by drug solubility (Sdrug) in pure solvent). *hydrated cocrystal 
2:1 cocrystal stoichiometry...................................................................................... 75
Figure 2.8: a) Aqueous solubility of salicylic acid cocrystals (with CBZ, THP, or 
CAF) plotted against the solubility of the hydrated drug.  b) Solubility of 
NCT cocrystals of CBZ and THP in water, EtOH, EtOAc, and IPA plotted 
against the respective NCT solubility.  The numerical data points represent 
dug solubility from Table 2.1 in mmolal. ................................................................. 77
Figure 2.9: DSC for cocrystals of: (a)THP-NCT, (b)CBZ-NCT (c)CBZ-GTA, 
(d)CBZ-SAC, (e)CBZ-SUC, (f)CBZ-SLC, and (g)CBZ-OXA. ............................... 81
  xi
Figure 2.10: Equilibrium cocrystal and reactant solubilities or solubility ratios in 
water( ), EtOH( ), IPA(X), and EtOAc( ). Solubility as a function of 
melt temperature for (a) reactants and (b) cocrystals. (c) Experimental 
cocrystal solubility versus ideal solubility.  (d) Experimental against ideal 
cocrystal solubility ratio (cocrystal/CBZ form III). .................................................. 84
Figure 3.1: Plot of Keu against  from Equation 3.5 for a 1:1 cocrystal.  The color 
change of the line from red to blue is representative of the eutectic 
concentrations changing from mostly drug (low Keu) to mostly coformer 
(high Keu)................................................................................................................. 102
Figure 3.2: Phase diagram of cocrystal (incongruently saturating) indicating the 
three regions saturated with respect to (1) drug, (2) cocrystal, or (3) 
coformer. The two eutectics are represented by E1 and E2 with lines 
extending from the solvent apex to the base to indicate the eutectic solution 
compositions x1 and x2. Drug and coformer solubilities in pure solvent are 
represented by d and c, respectively. ...................................................................... 107
Figure 3.3: a) Typical literature Bs type phase solubility diagram indicating region 
I (complexation), II (conversion and precipitation of excess component A), 
and III (solubility of precipitated complex is decreased with increasing B in 
solution).  b) Conversion of Bs type PSD into equilibrium PSD where the 
region three is shifted to the leftmost end of the region II plateau. Grey 
segments indicate original portions of the Bs PSD that were shifted or 
removed. Schematic based on Higuchi and Connors data for the 






Figure 3.4: Ksp determined by nonlinear fit of the PSD for 2,3-diketo-1,2,3,4-
tetrahydroquinoxaline and phenol.  The solid line represents the best fit from 







and K11 = 1.6M
-1
. Dotted lines represent the 95
th
 percent confidence interval 
based on the standard error.  Data taken from reference 
16
..................................... 113
Figure 3.5: Phase solubility diagrams for the cocrystals listed in Table 3.2. The 
solid lines represent the predicted solubility behavior based on the calculated 
Ksp and K11 values listed in Appendix 3.6. Group I and II samples from Table 
3.2 are shown in plots (a) and (b), respectively. Group III samples are shown 
in plot (c) and IV-V samples are in plot (d). Data points were taken from 
references in Table 3.2. ........................................................................................... 119
  xii
Figure 3.6: Predicted Keu from Equation 3.3 using Ksp, K11, and Sdrug values 
against observed Keu for cocrystals in Table 3.2.  Dashed line indicates 
equality of predicted and observed Keu.  Error bars represent the 95
th
 
percentile confidence interval based on the Ksp standard error obtained from 
fit of phase solubility diagrams according to references.
14, 15, 20
 Labeled 
points correspond to Table 3.2 notation with pH values in superscript.................. 123
Figure 3.7: a) Predicted eutectic coformer excess (Equation 3.5) against observed 
excess. b) Observed Keu plotted against the cocrystal to drug solubility ratio. 
Curve corresponds to Keu =  
2
. The points in a) and b) correspond to 
carbamazepine cocrystals of salicylic acid (triangles-blue) and saccharin 
(circles-black) at various pHs or in different solvents. Solvents indicated in 
Table 3.2 (superscript is pH)................................................................................... 130
Figure 3.8: Scheme to determine cocrystal solution phase stability for systems 
with ideal solution behavior and no complexation. ................................................ 131
Figure 3.9: Solubility data for group I cocrystals listed in Table 3.2. Lines 
represent best fit according to Equation 3.7-3.9.
21-24
.............................................. 141
Figure 3.10: Solubility data for group II cocrystals listed in Table 3.2. Lines 
represent best fit according to Equations 3.7-3.9.
16
................................................ 142
Figure 3.11: Solubility data for group III cocrystals listed in Table 3.2. Lines 
represent best fit according to Equations 3.7-3.9.
26
................................................ 143
Figure 3.12: Solubility data for group IV-V cocrystals listed in Table 3.2. Lines 
represent best fit by Equations 3.7-3.9.
9, 11, 14, 15, 27
................................................. 144
Figure 3.13: Aqueous solubility of carbamazepine as a function of nicotinamide 
(circles) and glutaric acid (triangles) at 25˚C. Dashed lines indicated the 
slopes used to calculate K11 values of 7.3 and 3.4 m
-1
 for nicotinamide and 
glutaric acid, respectively. ...................................................................................... 145
Figure 3.14: Aqueous solubility of carbamazepine as a function of nicotinamide at 
25˚C.  Points are shown at or above the eutectic concentration where the 
solution is the saturated with respect to cocrystal (open circles) and below 
the eutectic (filled circles) where carbamazepine is saturated................................ 145
Figure 4.1: Eutectic constant of carbamazepine-nicotinamide in water as a 
function of temperature. The solid line represents predicted behavior based 




=19.4 kJ/mol. ................................................... 159
  xiii
Figure 4.2: CBZ-NCT ln Keu against inverse temperature.  Error bars represent the 
standard error for each measured Keu.  Lines represent the best linear fit and 
the slopes are reported in Table 4.3. ....................................................................... 161
Figure 4.3: Plot of ln SMZ-BA Keu (open circles), Ksp (filled circles), and SMZ 
solubility (triangles) against inverse temperature.  Slope and standard error 
values are listed in Table 4.3................................................................................... 161
Figure 4.4: Plots of ln solubility against inverse temperature for a) CBZ and b) 
CBZ-NCT.  Error bars represent the standard error for each measured 
solubility.  Lines represent the best linear fit and the slopes are reported in 
Table 4.3.  Solvents: ethanol (triangles), ethyl acetate (squares), and water 
(diamonds). a) Water: CBZ(D). .............................................................................. 162
Figure 4.5: Schematic triangular 1:1 cocrystal phase diagram at two temperatures 
T1 (low) and T2 (high).  The two points indicate the composition of solvent 
with equimolar components that is saturated with drug (red/ T1) cocrystal 
(blue/ T2).  Cocrystal is stable in pure solvent at T2 and unstable at T1.  Keu 
values at each temperature are indicated (Keu>1 at T1, Keu<1 at T2). ...................... 170
Figure 5.1: ln solubility for a) CBZ and b) THP c) NCT d) SAC e) CBZ-SAC f) 
CBZ-NCT g) THP-NCT in water, ethanol, isopropanol, and ethyl acetate. 
The solubilities are split into the ideal solubility/crystal fusion (light grey) 
and activity coefficient/solvation (dark grey) components according to 
Equation 5.3.  The values of each component are reported in Table 5.2................ 197
Figure 6.1: Chemical structure of carbamazepine and sarcosine anhydride................... 207
Figure 6.2: Amide-carbonyl heterosynthons in the crystal structure of 2:1 
carbamazepine-sarcosine anhydride form I. ........................................................... 213
Figure 6.3: Supramolecular synthons in the in 2:1 carbamazepine-sarcosine 
anhydride form I crystal structure. Left: R2
2(8) , right: R4
2 (8) ................................ 213
Figure 6.4: Comparison of carbamazepine-sarcosine anhydride cocrystal X-ray 
patterns a) simulated pattern b) experimental XRPD of 2:1 form I........................ 214
Figure 6.5: Comparison of carbamazepine-sarcosine anhydride cocrystal XRPD 
patterns a) 1:1, b) 2:1 form II, and c) 2:1 form I..................................................... 216
Figure 6.6: DSC of CBZ-SAR cocrystals a) 1:1, b) 2:1 form I and c) 2:1 form II......... 217
Figure 6.7: TGA of CBZ-SAR cocrystals a) 1:1 (red), b) 2:1 form I (blue) and c) 
2:1 form II (black) and the approximate weight loss of the first stage after the 
melt. ........................................................................................................................ 217
  xiv 
Figure 6.8: Phase solubility diagram of CBZ-SAR in acetonitrile at 25 ±0.5˚C 
indicating the two eutectic points (filled circles). The Ksp of the 2:1 form I 
cocrystal (blue line) and the 1:1 cocrystal (red line) were calculated by fitting 
Equations 3.6-3.9. Marks (x) illustrate concentrations ratios that lead to 
different cocrystal forms when the volume of solvent is reduced. ......................... 219
Figure 7.1: Optical microscopy images showing moisture sorption, deliquescence, 
dissolution and cocrystallization in CBZ/NCT/sucrose at 25°C and 95%RH. 




Figure 7.2: Optical microscopy images showing moisture sorption, dissolution 
and cocrystallization in CBZ/NCT (equimolar) mixture with PVP (50wt%) at 
25°C and 75%RH.................................................................................................... 240
Figure 7.3: Vapor sorption isotherm for K40 (triangles), PVP K30 (squares), and 
50/50 weight percent mixture of PVP K30 and NCT (diamonds).  The weight 
percent change of the mixture is scaled by 2x to compare with the pure PVP 
moisture sorption. ................................................................................................... 240
Figure 7.4: Influence of RH and sugar composition on CBZ-NCT cocrystal 
formation in CBZ/NCT/sugar mixtures. Six separate panes corresponding to 
two relative humidity conditions and three different sugar compositions are 
shown. Each pane has the same time and composition axis scaling presented 
for the top right pane. The maximum of the y-axis corresponds to pure 




Figure 7.5: Aqueous solubility of carbamazepine against wt% PVP. PVP K12 
(circles), K30 (triangles), and K90 (squares).  K values are proportional to 
the polymer molecular weight. ............................................................................... 247
Figure 7.6: CBZ-NCT eutectic concentrations in aqueous a) 10wt% PVP 
solutions, b) 0, 5, and 10 wt% PVP K90 solutions, c) 10 and 30wt% PVP 
K30 solutions, and d) 10 and 30wt% PVP K12 solutions. ..................................... 248
Figure 7.7: Solubility of cocrystal (SAB) as a function of coformer concentration 
(B).  Solubility of pure A is assumed to be independent of coformer 
concentration.  Eutectic concentration and regions of supersaturation and 
undersaturation are indicated. Cocrystal solubility in pure solvent is 
represented by a filled circle. Dashed arrow indicates component 
concentrations due to unequal dissolution rates of components. ............................ 250
Figure 7.8: Infrared spectroscopy validation data set for Quant2 calibration.  
CBZ-NCT and component wt% predicted against observed values....................... 258
  xv 
LIST OF TABLES 
Table 1.1: Examples of multi-component crystals containing BCS class II drugs............. 3




Table 2.1: Cocrystal eutectic concentrations ([drug]eu and [coformer]eu), 
component solubilities, and calculated cocrystal Ksp values, solubilities and 
solubility ratios. Table is sorted by solvent and descending [coformer]eu. At 
eutectic cocrystal and hydrated or anhydrous drug exist in equilibrium with 
solution...................................................................................................................... 67
Table 2.2: Melt temperature and enthalpy used in calculation of ideal solubility 
and comparisons with experimental solubility values. ............................................. 82
Table 3.1: Relationships of eutectic compositions and cocrystal/component 
solubilities based on ideal behavior for systems with negligible solution 
complexation........................................................................................................... 109
Table 3.2: Cocrystals analyzed for solubility behavior and eutectic constants. ............. 117
Table 3.3: Range of cocrystal and component parameters. ............................................ 118
Table 3.4: Statistical analysis of observed and calculated Keu with respect to linear 
behavior (dashed line) shown in Figure 3.6............................................................ 127
Table 3.5: Solubility behaviors that can cause deviation of predicted Keu values 
from ideal behavior as represented in Figure 3.6.................................................... 127
Table 3.6: Observed Keu values and calculated  values for carbamazepine 
cocrystals with acidic ligands in water as a function of pH.................................... 129
Table 3.7: Summary data for solution behavior of cocrystals listed in Table 3.2: ......... 138
Table 4.1: The eutectic constants in terms of cocrystal and component solubilities 
listed according to the solid phases at the eutectic.  Temperature dependence 
of Keu is also indicated in terms of cocrystal and component enthalpies of 
solution based on ideal solution behavior. .............................................................. 152
  xvi 
Table 4.2: Eutectic concentrations and Keu values for CBZ-NCT and SMZ-BA in 
aqueous and organic solvents. Concentrations are in mmolal. ............................... 160
Table 4.3: Enthalpy of solution for CBZ, CBZ-NCT, SMZ, and SMZ-BA 
calculated from Figure 4.4 and Figure 4.2 using the slope indicated.  The 
observed temperature dependence of  Keu as well as the predicted value from 
the enthalpies. All enthalpy values have units of kJ/mol. *CBZ(D) ...................... 163
Table 5.1: Fusion properties and ideal solubilities (Equation 5.1) of cocrystals and 
cocrystal components. Solubility and Ksp values are in mole fraction.................... 195
Table 5.2: Calculated cocrystal and component  values from observed and ideal 
solubilities (Equation 5.3). ln Ksp values are based on mole fraction units (Ksp 
from Table 5.1). ...................................................................................................... 198
Table 5.3: Observed (italics) and estimated Ksp values for a) CBZ-SAC and b) 
THP-NCT cocrystals from Equation 5.10 are listed by row according to 
solvent. Columns list the solvent used for reference in estimating Ksp values 
for the other solvents. The average predicted Ksp from the three solvents is 
listed with the standard deviation and percent error relative to the observed 
value.  All Ksp and solubility units are mole fraction.............................................. 201
Table 5.4: Observed (italics) and estimated Keu values for CBZ-SAC from 
Equation 5.12 are listed by row according to the solvent. Columns list the 
solvent used for reference in estimating Ksp values for the other solvents. The 
average predicted Keu from the three solvents is listed with the standard 
deviation.................................................................................................................. 201
Table 6.1: Screening and synthesis methods and conditions for CBZ-SAR 
cocrystal.  All solution methods were done at 25˚C. Solvents are acetonitrile 
(ACN) and ethanol (EtOH). .................................................................................... 209
Table 6.2: Crystallographic data of 2:1 carbamazepine-sarcosine anhydride form 
I. .............................................................................................................................. 214
Table 6.3: Eutectic concentrations for CBZ-SAR in acetonitrile. The solubility of 
CBZ(III) in acetonitrile was measured as 0.24 ±.008m.......................................... 220
Table 6.4: Cocrystal solubility products for CBZ-SAR in acetonitrile calculated 
from data in Figure 6.8 using Equations 3.6-3.9..................................................... 220
Table 7.1: Calibration fit of IR standards (cocrystal and components) from 
Quant2..................................................................................................................... 236
  xvii 
Table 7.2: CBZ-NCT formation from CBZ/NCT/PVP stored mixtures as function 
of RH.  Cocrystal composition was quantified by infrared spectroscopy.  
Values indicate the weight percent cocrystal formed relative the total weight 
of the initial cocrystal components. ........................................................................ 245
Table 7.3: Moisture sorption by PVP K12/K90 observed over six days as function 
of RH. Values at 24 hours were within five percent of the six-day average.  
Scaled values represent the moisture sorption in the mixtures with CBZ and 
NCT......................................................................................................................... 245
Table 7.4:  CBZ-NCT Keu values for aqueous solutions with PVP K12, K30, or 






Pharmaceutical Cocrystal Eutectic Analysis: Study of Thermodynamic 






David John Good 
 
Chair: Naír Rodríguez-Hornedo 
 
Cocrystals are an emerging solid-state form to change physicochemical and 
biopharmaceutical drug properties. This dissertation focuses on the thermodynamic 
stability and solubility of pharmaceutical cocrystals. Specifically, the objectives are to: (i) 
develop methods to measure the thermodynamic solubility of metastable cocrystals, (ii) 
provide models that describe the equilibrium phase behavior of cocrystals based on 
component and cocrystal properties, (iii) explain the effect of temperature on cocrystal 
thermodynamic stability, (iv) estimate solubility and stability for different solvents based 
on component activity coefficients and measured cocrystal solubility in one solvent, and 
xix 
(v) identify mechanisms by which hygroscopic additives affect the stability of mixtures 
of solid cocrystal components. 
Cocrystal solubilities were calculated from eutectic concentration measurements 
where solution is in equilibrium with solid drug and cocrystal.  Cocrystal solubility was 
directly proportional to coformer eutectic concentration and to the solubility of cocrystal 
components for carbamazepine, caffeine, and theophylline cocrystals.  Cocrystal eutectic 
constants (Keu), the ratio of solution activities of cocrystal components at the eutectic, are 
fundamental indicators of phase behavior and are a function of the cocrystal to drug 
solubility ratio ( ) in pure solvent. More than forty eutectic constants are presented that 
demonstrate Keu dependence on i) solvent, ii) complexation, and iii) ionization, as does 
the solubility of cocrystals.  Applications of these findings to the discovery and phase 
stability of carbamazepine-sarcosine anhydride cocrystals are presented.  A solution-
mediated mechanism of cocrystal formation is shown for cocrystal components mixed 
with hygroscopic additives that sorbed moisture.  More cocrystal formation occurred for 
additives that lowered the Keu. 
Keu temperature dependence is explained by thermodynamic models based on 
cocrystal and component enthalpies of solution, which are solvent specific.  The Keu and 
 values of carbamazepine-nicotinamide in water decreased with temperature, but for 
several organic solvents Keu was temperature independent (4-47˚C). Cocrystal solubility 
and stability was also shown to depend on the component activity coefficients, which 
xx 
were estimated using the component solubilities. The models developed based on 
component and cocrystal properties combined with methods to estimate cocrystal 
solubilities from eutectic concentrations provide a useful guide for cocrystal design, 
synthesis, and selection.  
 




Research in the design and utility of pharmaceutical cocrystals has received 
interest in recent years from a variety of disciplines including crystal engineering, 
chemistry, material sciences and the pharmaceutical sciences. Cocrystals are able to alter 
the physicochemical properties of active drug substances through combining drugs and 
additional components (i.e. coformers) in the same crystal structure thereby altering 
solid-state properties and solution behavior without modifying chemical structure.  
Coformers are substances that are solids at ambient conditions in their pure form and in 
the presence of drug can form crystalline solids that exhibit non-ionic intermolecular 
interactions and contain both components. Cocrystals are a single homogenous crystalline 
phase containing multiple distinct molecules; they are not physical blends of pure 
components.  Cocrystal physical and chemical properties are a function of the unique 
solid-state crystalline arrangement and interaction of the multiple components.  All 
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For the systematic design, screening, synthesis, and selection of effective 
pharmaceutical cocrystals there is a need for fundamental descriptions of their 
physicochemical properties.   This is especially true for the solution behavior and stability 
of cocrystals because of their potential to address poor aqueous solubility issues that 
persist for at least one-third of current and new drug substances.
5, 6
  Alternatively, 
solubility control is sought for sustained and controlled release dosage forms, as well as 
to address chemical stability concerns and for taste masking of certain drugs.   
The bioavailability of oral drug substances is a function of their solubility and 
dissolution in gastric/intestinal fluids as well as the drugs ability to permeate cellular 
membranes if efficacy requires distribution away from the gastric/intestinal fluids.  
Together solubility and permeability are the basis for the biopharmaceutical classification 
system (BCS) that segments drugs into four classifications based on these two 
properties.
7
  Solubility improvements are particularly desirable for BCS class II 
compounds that have low solubility and high permeability.  Class II drugs exhibit 
solubility limited oral adsorption and bioavailability.  Numerous cocrystals and other 
multi-component crystals of class II drugs have been identified and several examples are 
listed in Table 1.1.  Selecting a suitable coformer from many options requires effective 
material sparing methods for determining solubility and stability. Furthermore, 
indentifying correlations between cocrystal, coformer, and drug physicochemical 
properties is essential to the efficient design of new cocrystals.  
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Table 1.1: Examples of multi-component crystals containing BCS class II drugs. 
Drug Coformers (acids) Reference 
Piroxicam L-tartaric, citric, fumaric, adipic acid succinic, L-malic, 
glutaric, DL-malic, oxalic, (+)-camphoric, ketoglutaric, 
benzoic, 4-hydroxybenzoic, malonic, salicylic, glycolic, 
1-hydroxy-2-naphthoic, gentisic, DL-tartaric, maleic, 
caprylic, hippuric, L-pyroglutamic acid 
8 
Carbamazepine succinic, benzoic, ketoglutaric, maleic, glutaric, malonic, 
oxalic, adipic, (+)-camphoric, 4-hydroxybenzoic, 
salicylic, 1-hydroxy-2-naphthoic, DL-tartaric, L-tartaric, 
glycolic, fumaric, DL-malic, L-malic, acetic, butyric, 5-




Itraconazole succinic, fumaric, L-malic, L-tartaric, D-tartaric, DL-
tartaric 
11 
Sulfamethazine 2-aminobenzoic, 4-aminobenzoic, 4-aminosalicylic, 




Cocrystals are unique relative to current options for altering physicochemical drug 
properties in pharmaceutical development because of the number of suitable drugs and 
possible coformers as well as the large number of intramolecular associations and 
supramolecular structures that can lead to cocrystal formation.  However, there are few 
commercial examples of cocrystal drug products and therefore a presumed risk associated 
with cocrystal drug products.
4
  A more established practice to improve physicochemical 
drug properties is modification of the chemical structure.  These structural changes also 
typically alter activity and toxicology and can adversely affect drug performance.  
Various solid-state forms of drugs including salts, polymorphs, and solvates or hydrates 
are familiar to pharmaceutical scientists and offer some valuable but limited options for 
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physicochemical property changes.  Only drugs with ionizable groups are candidates for 
salt formation and successful salt formation is in part a function of the drug pKa value(s) 
and the properties of the limited group of pharmaceutically acceptable counterions.  
Using amorphous solids can significantly change the solubility of a drug by eliminating 
crystal lattice energy as a barrier to dissolution, however thermodynamic stability issues 
limit their applications.  Crystallization of the stable thermodynamic form is a major risk 
for amorphous drugs and formulation additives or solid dispersions are used to improve 
amorphous form stability.
15-21
  Cocrystals expand the options for drugs with challenging 
physicochemical properties by offering a large number of suitable coformers to change 
solution and solid-state chemistry.  Furthermore cocrystals afford the preferred solid-state 
stability of a crystalline solid form for oral delivery.  An overview of the classification 
and nomenclature of solid forms relevant to pharmaceutical development presented in 
Figure 1.1 includes multi-component crystalline forms and cocrystals. 
This chapter introduces background related to the structure, design, synthesis, and 
properties of cocrystals.  Established solution phase behavior of other multi-component 
crystalline solids such as racemates, salts, solvates and hydrates are included because of 
their relevance toward understanding cocrystal behavior.  The model compounds 
considered throughout the work are too numerous to address and therefore the reader is 
referred to relevant descriptions included in introduction and materials sections of 
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subsequent chapters.  This chapter concludes with a statement of the dissertation research 
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1.1. BACKGROUND 
1.1.1. Cocrystal Design 
The fields of crystal engineering and supramolecular chemistry have sought to 
discover and design novel intermolecular interactions, extended molecular architectures, 
and recognition phenomena relevant to crystal packing.  The nature of noncovalent 
intermolecular interactions between cocrystal components can be used to control the 
three-dimensional ordered cocrystal structure.  Supramolecular retrosynthetic analysis of 
intermolecular units for a target cocrystal structure can be readily preformed using the 
Cambridge Structural Database (CSD).  This process can identify suitable coformer 
attributes based on preferred orientations and geometries of specific known instances of 
intermolecular interactions from this database.  The use of favorable and frequently 
occurring substructural units and geometric considerations from the CSD enable 
identification of reasonable candidate components for cocrystallization.  Many solid-state 
cocrystal design considerations focus on hydrogen bonding associations because of their 
strength and directionality.  Often coformers are selected based on functional groups 
capable of complimentary hydrogen bonding with the drug substance.   
Hydrogen bond synthons are intermolecular arrangements of functional groups 
resulting in one or more hydrogen bonds. Synthons formed between two identical 
functional moieties, such as synthons I and II in Figure 1.2, are called homosynthons.  
The other synthons II-X are between different functional moieties and are classified as 
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heterosynthons.  Both homosnthons and heterosythons are important interactions in the 
design and structure of cocrystals.  Further classification of intermolecular associations 
distinguishes whether the interacting molecules are the same (homomer) or different 
(heteromer).26-31 
 
Figure 1.2: Schematic examples of synthon arrangements including homosynthon (I-II) 
and hetersynthons (III-X) interactions.  
 
The types of hydrogen-bond synthons and molecular aggregates likely to form 
between cocrystals components can be predicted by several general rules developed by 
Donohue and Etter.32-35  The first rule states that all available acidic hydrogen atoms will 
be incorporated in hydrogen bonds in the crystal structure.  Additionally, all good 
hydrogen-bond acceptors form bonds if an adequate number of donors exist. A third rule 
suggests that the best donor (most acidic) will preferentially form a hydrogen bond with 
the best acceptor (most basic). 26-31 Hydrogen bonds with six member intramolecular 
rings have also been indicated to preferentially form with respect to intermolecular 
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hydrogen bonds.  While these rules are good general considerations they do not predict 
crystal structure, molecules capable of cocrystallizing with each other, conditions that 
promote cocrystallization, or the properties of cocrystals that might form.36 Exceptions to 
these guidelines often occur due to competition of multiple hydrogen bonding, dipole, or 
ionic sites as well as steric or conformational limitations. 
For selecting complementary drug and coformer components, hydrogen bond 
guidelines are good considerations, however they do not alone indicate cocrystal 
formation or structure. Considerations of van der Waals interactions and stereochemistry 
of the components are also relevant for cocrystal design and coformer selection.36  
Symmetry elements and conformational energies of molecules play essential roles in 
determining crystal structures.  The formation of stable crystal structures is additionally 
based on minimizing electrostatic energies (e.g. bond or molecular dipoles) and 
minimizing free volume (i.e. maximizing density).  Kitaigorodskii’s Principle of Close 
Packing is considered the primary rule for crystal packing and states that void space is 
always unfavorable.36, 37 Recent analysis of coformers published in the CSD indicated 
that shape, polarity, and available synthons were key parameters for designing cocrystals, 
however the number of hydrogen bond donors and acceptor was not statistically 
significant.38  Together all these structural considerations of the crystalline state influence 
the design and stability of cocrystals.  
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1.1.2. Cocrystal Synthesis 
Reaction crystallization method (RCM) was recently established for the synthesis 
and screening of cocrystals and was carried out by slurrying cocrystal component(s) in a 
nonstoichiometric solution of the components.  RCM has been used to create conditions 
favorable for cocrystal formation by maintaining one component at or near saturation in 
solution while slurrying the other component.39  The RCM is based on nonstoichiometric 
solution conditions where cocrystal is typically the most stable solid phase (i.e. least 
soluble) that could exist in equilibrium with solution based on cocrystal solubility product 
behavior.  This method does not require an exhaustive use of various solvents to find 
conditions suitable for cocrystal formation.9, 40 The solubility product behavior of 
cocrystals described by Nehm and Rodríguez-Hornedo et al. provided the basis for their 
development of RCM wherein cocrystal had lowest solubility, was thermodynamically 
stable, in solutions containing excess of one of the cocrystal components.41  
RCM has been carried out in many solvents, however green solvents are favored 
including water and alcohols.  Also, because RCM is based on thermodynamically stable 
cocrystal conditions it is an attractive process for any reaction scale.  In situ monitoring 
of cocrystal formation by RCM has recently been demonstrated for carbamazepine-
nicotinamide cocrystals and can be used to effectively control and scale cocrystallization 
processes.42, 43 
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Other solution processes have been used wherein stoichiometric ratios of the 
components were dissolved in solvent that was subsequently evaporated or was heated to 
facilitate dissolution then cooled (solvo-thermal).  These empirically based methods have 
an inherent risk of crystallizing one or more undesirable phases including pure 
components and often require the screening of many solvents and or experimental 
conditions.  Difficulties could be encountered when attempting different size 
crystallization processes due to variability in evaporation or temperature changes. 
Solid-state cocrystal synthesis methods have been used in which the crystalline or 
amorphous components are combined.  Mechanical activation by grinding cocrystal 
components together is a common method to form cocrystals.9, 33-35, 44-49  Cocrystal 
components have been shown to proceed through and intermediate amorphous phases in 
some cases.50 The glass transition temperature (Tg) and melt temperature of components 
are important material properties for any mechanochemical methods that induce phase 
transformations and therefore should be considered along with process temperature in the 
synthetic outcome.  The addition of solvent drops to grinding reactions often impacts the 
synthetic outcome and cocrystal formation can occur through solution and/or solid 
phases.   
A recent screening of twenty-seven carbamazepine cocrystals by four different 
methods including RCM identified all of the forms generated by grinding of components 
were also found by at least one of the other solution methods.9  While grinding 
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experiments are attractive because of small requisite quantities of components and rapid 
synthesis some limitations include the difficulty of readily discerning the formation 
mechanism or pathway, the chemical stability of components subjected to high kinetic 
energy process, purity of products (i.e. extent of transformation), empirical nature, and 
challenges regarding scalability. 
Less common synthetic methods include melt processes such as the Kofler mixed 
fusion method and differential scanning calorimetry (DSC) of components in physical 
blends.   Kofler’s methods have been used to efficiently determine the formation and 
phase behavior of many multicomponent crystals and their polymorphs.51-57  A recent 
example is the work of Berry et al. who screened for cocrystals of seven drugs with 
nicotinamide and determined the structures of three novel cocrystals including that of 
R/S-ibuprofen-nicotinamide.58  DSC was also shown as an efficient thermal method for 
screening cocrystals of carbamazepine, theophylline, caffeine, and sulfamethazine.  
Sixteen of twenty cocrystals were resolved from thermal analysis of physical blends and 
confirmed by variable temperature X-ray diffraction.59  In addition to these thermal 
methods cocrystal synthesis has also been demonstrated from supercritical fluids and 
vapor phase mediated crystallizations.60, 61  
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1.1.3. Cocrystal Properties 
The structure and properties of cocrystals are distinct from that of their individual 
components. Cocrystals have been shown to change the hygroscopicity, melt 
temperature, chemical stability, morphology, solubility, dissolution rate, bioavailability, 
thermal stability, hydrate/solvate formation, mechanical properties, and many others.  
Any chemical or physical properties that are a function of the supramolecular structure 
are potentially modified by cocrystal formation.  The design and formation of a cocrystal 
to change a particular physicochemical drug property will likely change additional 
properties since the structure and supramolecular chemistry are not exclusive to any one 
physicochemical property.  If designing a cocrystal for improved drug solubility one 
should anticipate changes to many other properties, such as possibly the crystal density or 
habit, that are dependent on supramolecular structure. 
Bioavailability and dissolution 
Increased bioavailability or maximum plasma concentration (Cmax) has been 
demonstrated for several drug substances.  McNamera et al. showed the 1:1 glutaric acid 
cocrystal of 2-[4-(4-chloro-2-fluorophenoxy)phenyl]pyrimidine-4-carboxamide, a 
developmental sodium channel blocker, had greater Cmax and AUC levels in  beagle dogs 
given equivalent doses of cocrystal and drug at both 5 and 50mg/kg levels.62  These in 
vivo studies were in agreement with aqueous rotating disk intrinsic dissolution results that 
indicated significant improvement for the cocrystal (~18-fold increase) over the pure 
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drug at 37˚C.  Similarly, reports of an Amgen investigational drug (AMG 517) 
cocrystallized with sorbic acid (1:1) exhibited faster powder dissolution in fasted 
simulated intestinal fluids and improved bioavailability in rats.63  A 10mg/kg dose of 
cocrystal was shown to produce similar Cmax values and about half the AUC of a 
500mg/kg dose of the free drug substance.  Normalizing these results by the dose 
indicates the cocrystal had approximately a 50 and 25-fold increase in Cmax and AUC, 
respectively.  Additionally a cocrystal of Merck L-883555, a developmental 
phosphodiesterase-IV inhibitor, and L-tartaric acid (0.5:1) showed more than 10 and 20-
fold increase of Cmax and AUC, respectively, for 3mg/kg dose given orally in methocel to 
rhesus monkeys.64   
Carbamazepine-saccharin (1:1) cocrystal has exhibited higher average cocrystal 
Cmax and AUC values relative to the marketed form III of carbamazepine in beagle dogs.  
Despite these higher average observed pharmacokinetic parameters corresponding high 
error levels indicated no statistically significance differences between the cocrystal and 
drug forms.65  Three different cocrystals of lamotrigine-nicotinamide were shown to have 
powder dissolution rates that were improved or equivalent to free lamotrigine at acidic 
and neutral pH conditions, respectively.  However, the two nicotinamide cocrystal forms 
administered to rats demonstrated lower serum concentrations.66  This discrepancy could 
be caused by several factors such as the influence of the coformer on oral absorption or 
the oral suspension vehicle (PEG400 and methyl cellulose) that could change the 
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thermodynamic stability or solubility of the cocrystal.   Whatever the case, future animal 
experiments should carefully consider the thermodynamic solubility of cocrystals and the 
relevant solubility equilibrium associated with excipients and in vivo or biorelevant 
conditions. 
Remenar et al. showed itraconazole cocrystals of various carboxylic acids had 
much improved aqueous powder dissolution rates.  The itraconalzole-(L)malic acid 
cocrystal had a dissolution profile similar to that of the marketed amorphous form.  The 
three cocrystals studied achieved sustained (>400 minutes) dissolution concentrations 
from 4 to 20-fold of the crystalline itraconazole level.11  Remenar also showed for the 
celecoxib-nicotinamide cocrystal that formulation with surfactant (SDS) and polymer 
(PVP) provided similar dissolution rates as amorphous blends of drug and PVP.  Here the 
cocrystal formulation produced an amorphous/crystalline blend with small particulates 
(~380nm) of a metastable drug polymorph (celecoxib IV).67  This study demonstrated 
formulation methods to exploit the high cocrystal solubility relative to celecoxib to 
design rapidly dissolving drug products. 
Hygroscopicity 
  The interaction of water with drugs and pharmaceutical dosage forms is 
critically important to the stability, efficacy, and safety of these materials.  
Pharmaceutical drug products may come into contact with water during production and 
formulation or at any point through exposure to humid environmental conditions.  Drug 
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products that incorporate materials containing water have the potential to transfer it to 
other components, subject to water sensitive stability.68  Water can interact with crystals 
through adsorption on the surface of particles, absorption or capillary condensation, 
hydrate formation, and deliquescence.  The structure, form, composition, and material 
properties of a crystalline phase contribute to its hygroscopic nature.  Studies of 
carbamazepine cocrystals each showed no hydrate formation and less than 0.2% weight 
change after either two or three weeks storage at 98% and 100% relative humidity for 
saccharin and nicotinamide coformers, respectively.  However, anhydrous carbamazepine 
readily formed dihydrate at these humidity levels.69  These studies confirmed that 
cocrystal formation could change hygroscopic drug properties.  Numerous theophylline 
and caffeine cocrystals have also shown similar results wherein the cocrystals do not 
transform under conditions that pure drugs form hydrates.70, 71 
Deliquescent and hygroscopic cocrystal components or excipients have been 
shown to facilitate solution-mediated formation of cocrystals.  Deliquescent excipients 
including sucrose, fructose, and citric acid led to cocrystal formation for various 
components listed in Table 1.2.72  The mechanism indicated consisted of deliquescence of 
the excipient, followed by dissolution of the cocrystal components in the sorbed moisture, 
then subsequent crystallization of cocrystal from solution.  In this solution mediated 
mechanism supersaturation with respect to cocrystal was generated from dissolution of 
components in the sorbed moisture.  Cocrystal nucleation was observed near the surface 
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of undissolved carbamazepine crystals presumably due to the high drug concentrations at 
this boundary producing the greatest supersaturation in the concentrated 
nicotinamide/sucrose solution.  The formation of cocrystal depends on the deliquescent 
material and its potency for moisture uptake as well as its ability to modify the mode and 
rate of nucleation.   Chapter 7 presents the stability and solubility of carbamazepine 
cocrystals in the presence of the hygroscopic additive polyvinylpyrrolidone (PVP). 
  
Table 1.2: Drug and corresponding coformers that formed cocrystals by both slurrying 
and deliquescence.72 
Drug Carbamazepine Caffeine Theophylline Sulfamethazine 
Coformers Nicotinamide Oxalic acid Oxalic acid Salicylic acid 
 Saccharin Maleic acid Maleic acid Anthranilic acid 
  Glutaric acid Glutaric acid  
  Malonic acid Malonic acid  
 
Mechanical properties 
The mechanical properties of drug substances determine the formulation and 
processing methods required to make drug products.  The crystalline structural properties 
influence these mechanical properties. Four new cocrystals of paracetamol and two 
known polymorphs demonstrated mechanical properties differences in relation to the 
crystallographic structural features.73  Tablet formation and associated mechanical 
properties (tensile strength, breaking force, etc.) of each tablet form were studied and 
each of the four cocrystals improved over the two polymorphs.  Three of the four 
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cocrystals exhibited arrangement of drug and coformer layers in the crystal structures and 
corresponding weak shear planes nearly parallel these molecular layers. It was suggested 
these shear planes contributed to the improved elasticity and tabletability.  Similarly, slip 
planes in the 1:1 caffeine-methyl gallate cocrystal have also been correlated with 
improved tabletability.74  The caffeine cocrystal produced higher tensile strength than 
pure caffeine and pure methyl gallate across all compaction pressures (~40-400 MPa).  
These studies demonstrated the feasibility of using cocrystals and molecular level design 
of synthons to create structural features that improve the mechanical properties of drug 
substances for pharmaceutical processing of oral solid dosage forms. 
Chemical stability 
Chemical stability changes have been demonstrated for solid-state reactions that 
involve cocrystals of carbamazepine or 1,4,5,8-naphthalenetetracarboxylic dianhydride 
(NTCDA).  Carbamazepine cocrystals of saccharin and nicotinamide do not have azepine 
ring distances (<4.1 Å) and alignment that facilitate formation of the cyclobutyl dimer by 
photodegradation.  In comparison the known polymorphs of carbamazepine do undergo 
photodegredation due to their azepine ring distances.69  Cocrystals of NTCDA with 3-
aminobenzoic acid or 2-methyl-4-nitroaniline have solid-state alignment of the anhydride 
carbonyl carbon atom and the coformer amino nitrogen atom sufficient to facilitate 
condensation reactions and formation of the diimide NTCDA derivative upon heating.75  
In this example the cocrystal formation altered the chemical stability of the components 
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by aligning reactive functional groups to produce specific high yield products through 
solid-sate topochemical synthesis. 
Fusion properties 
The fusion properties reported for cocrystals can vary significantly from that of 
their components due to the differences in the nature and extent of intra and 
intermolecular interactions associated with the new crystal structure.  Thermal analysis of 
twenty-seven carbamazepine cocrystals showed melt temperatures (Tm) that are less 
than, between, and greater than those of the pure components.9  Since the intermolecular 
interactions present in the pure components are no indicator of the cocrystal interactions 
it is reasonable that fusion temperature will not be described solely by the components.  
Indeed several studies have indicated correlations between coformer and cocrystal melt 
temperatures for a given drug substance.  Regression values for large cocrystal sets (>10) 
with the same drug and various coformers have indicated approximately 80% of the 
cocrystal Tm is explained by the coformer Tm.9, 76, 77  A set of five 
hexamethylenebisacetamide cocrystals with dicarboxylic acid coformers of sequential 
chain lengths showed nearly linear correlations between cocrystal and coformer Tm.78  
This high correlation could in part be due to the limited diversity and size of the data set.  
The design of low melting cocrystals could be desired for thermally labile drugs where 
melt processing is needed.  Additionally low Tm is typically associated with greater 
  20 
solubility, however the reported aqueous solubilities in these studies did not confirm such 
behavior. 
 
1.2. SOLUBILITY AND SOLUTION CHEMISTRY OF 
MULTICOMPONENT CRYSTALS  
1.2.1. Cocrystals 
Higuchi, Connors, and coworkers examined the solution chemistry of cocrystals 
as early as the 1950’s, however the majority of this work related to the solution 
complexation of components.79-86  The methodology presented and the determination of 
stability constants (i.e. solution complexation constants) for a variety of pharmaceutical 
substances was valuable to advancing the understanding of solubilization phenomena and 
its utility for drug delivery and formulation.  Recently published work has described 
detailed equilibrium solution behavior of cocrystals and demonstrated solubility product 
(Ksp) and solution complexation behavior for carbamazepine-nicotinamide in several 
organic solvents.41  This work established the fundamental solution behavior of cocrystals 
wherein cocrystal solubility was dependent on the component concentrations.  Higher 
solution coformer concentrations were shown to decrease cocrystal solubility and 
corresponding drug concentrations.  Figure 1.3 represents the reported carbamazepine-
nicotinamide (CBZ-NCT) cocrystal solubility as a function of nicotinamide concentration 
in several organic solvents.41  
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Figure 1.3: Solubility of 1:1 CBZ-NCT cocrystal (solid points) and CBZ(III) (open 
points) at 25˚C as a function of total NCT concentration in ethanol (squares), 2-propanol 
(tiangles), and ethyl acetate (circles).  The solid lines represent the predicted solubility 
behavior from the solubility product and solution complexation.41 
 
Cocrystal solubilities have been commonly expressed using a variety of 
equilibrium and kinetic measurements. Kinetic solubility measurements reported are 
typically powder dissolution or intrinsic rotating disk dissolution.  Both equilibrium and 
kinetic experiments present valuable information on the solution properties and 
performance of cocrystals relative to the components.  Several examples of cocrystal 
dissolution results are listed in section 1.1.3.  Crystallization of other drug forms can 
occur in kinetic studies particularly when cocrystal is highly soluble relative to the 
components.  Stanton et al. performed powder dissolution on 14 cocrystals of Amgen 
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investigational drugs (TRPV1 antagonsits) and observed conversion to the free base drug 
form in 12 of the 14 cases.77  All cases indicated maximum dissolution concentrations 
above that of the free base. These supersaturated drug levels depend on cocrystal 
dissolution and free base crystallization and related parameters including particle size, 
powder wetability, supersaturation, nucleation and growth rates.  Since many parameters 
influence the observed maximum concentration there is a need for equilibrium 
measurements that can be used to calculate the thermodynamic solubility of highly 
soluble cocrystals. 
The measurement of an equilibrium or steady state drug concentration from a 
cocrystal placed in solution does not always reflect the actual stoichiometric solubility 
depending on the final solid phase(s) that persist at equilibrium point. Isolation and 
analysis of solid phase(s) is critical in describing solubility because the final solid form is 
associated with the measured concentration(s).  Only when the initial cocrystal form is 
observed as the single solid phase after equilibration with pure solvent are the 
equilibrium concentrations descriptive of the true stoichiometric solubility.  In this case 
the concentration ratio of the two components in solution should equal the stoichiometric 
cocrystal ratio.  The true stoichiometric solubility of a cocrystal is often difficult to 
measure directly because of purity issues, unknown or complex solubility phase behavior, 
and potential transformations to other solid forms such as components or other cocrystal 
stoichiometries or solvates.  When a solid phase other than the starting cocrystal is 
  23 
observed, the corresponding steady state drug concentration is not the true cocrystal 
solubility.  In these instances both component concentrations should be recorded to best 
describe solubility behavior of the solid phase(s) in equilibrium with the solution.  If one 
of the stable equilibrium solid phases is a cocrystal of known stoichiometry, the Ksp can 
be calculated and reported to describe the thermodynamic cocrystal solubility. 
Ionizable coformers have been used to design pH dependent cocrystal solubility.  
Solution models and solubilities of cocrystals with ionizable components have been 
determined.  Examples of pH dependent cocrystal solubility were provided for neutral 
drug (carbamazepine) with acidic and amphoteric coformers (saccharin, salicylic acid, 
and 4-aminobenzoic acid).87  Additionally, the solubility data and models for gabapentin 
(zwiterionic) and 3-hydroxybenzoic acid (diprotic acid) were reported.88  Figure 1.4 
contains the predicted pH dependent cocrystal aqueous solubility and the measured 
solubilities for pH conditions where cocrystal was the stable phase in equilibrium with 
solution.  These models, and several other recent reports, have described how pH 
dependent solubility can be designed for neutral or ionizable drugs using cocrystals.88, 89 
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Figure 1.4: Gabapentin-(3-hydroxybenzoic acid) solubility dependence on pH.  Symbols 
represent experimental data.  Predicted solubility curve was based on measured Ksp.
88 
 
1.2.2. Pharmaceutical Salts 
The principles of salt solubility and the relevant solution equilibria have been well 
established and widely used in the successful design of commercial drug products.  
Numerous texts and reviews have been written to establish the appropriate solubility 
considerations for developing and screening new salt forms.24, 90, 91  The solubility of a 
salt is described by solubility product behavior and the salt solubility is lower when 
counterion concentration is increased.  For this reason hydrochloride salts are often 
studied to determine the extent in vivo solubility will be affected by chloride ion 
concentrations.  Because salts are ionizable they also display pH dependent solubility.  
The solubility of salts have been shown in some cases to depend on the counterion 
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hydrophobicity or the melting point of the salt, which is related to the strength and nature 
of the solid-state interactions.92, 93 
The maximum solubility of a salt (pHmax) is the pH value where the free acid or 
base and its corresponding salt form are equally soluble.  pHmax is dependent on the 
intrinsic solubility and pKa value(s) of the ionizable drug as well as the salt Ksp.  The 
calculation of salt solubility profiles and Ksp values according to ideal behavior can be 
achieved by in situ screening in solutions of the target counterion acid or base (e.g. 
maleic acid, ammonia).94  
Salt solubility behavior is relevant to the descriptions of cocrystal solubility, 
despite the absence of cocrystal proton transfer/ionic interactions, because solution phase 
equilibria apply to these two dissociable crystal forms.  Furthermore cocrystals can form 
salts with one component having ionic interactions (e.g. fluoxetine-benzoic acid HCl) or 
the components can be ionizable in solution and salt conversion can occur and affect the 
solution behavior of the cocrystal.95 
 
1.2.3. Racemic Compounds 
The resolution, phase behavior, and solubility of racemates have been the subject 
of considerable work and therefore serve as good references for the solubility behavior of 
cocrystals.  Racemic compounds are a specific subset of cocrystals wherein the two 
crystal components differ only in their stereochemistry. For achiral solvents both 
individual enantiomers have equal solubility and the thermodynamic stability of the 
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racemate is greater or equal to the enantiomers in pure solvent.  Since racemic 
compounds are stable and do not transform to the individual enantiomers in pure achiral 
solvent they have a lower chemical potential.  The thermodynamic equilibrium solubility 
of racemic compounds in pure achiral solvent is equal or lower than that of the pure 
enantiomers and therefore dissolution of racemic compound does not produce 
supersaturation with respect to the enantiomers (i.e. congruently saturating).  In contrast 
cocrystals are often comprised of components with different solubilities/activities and can 
be thermodynamically unstable or stable in pure solvent.  Cocrystals that are unstable (i.e. 
incongruently saturating) in pure solvent have a higher chemical potential and higher 
thermodynamic solubility relative to the more stable phase that is formed.  The solubility 
and activity differences of cocrystal components account for their disparate solution 
behavior relative to racemic compounds. The solubility of cocrystals presented in 
Chapters 3 and 4 reveal several important differences relative to the solubility behavior of 
racemic compounds. 
Despite being the thermodynamically stable phase in solution racemic compounds 
are commonly reported as more soluble than either pure enantiomer.  Of course this is not 
possible and merely reflects the standard practice of adding the concentration of each 
enantiomer in a saturated racemate solution to indicate the racemic compound solubility. 
These reported solubilities are not the thermodynamic solubility of the racemic 
compound and are based on the definition of one total mole of the two enantiomers 
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forming one mole of the racemate.  That is, one mole of a racemate represents a total of 
one mole of the two enantiomers. However, a 1:1 cocrystal AB is defined as comprising 
one mole of component A and one mole of component B (i.e. 2 total moles of 
components).    
The Meyerhoffer double solubility rule that states the sum of the two equal 
enantiomer solubilities should reflect the solubility of a racemic conglomerate is based on 
the common description of racemate solubility as the additive enantiomer concentrations.  
Therefore conglomerates, blends of crystals of the two pure enantiomers, ideally exhibit 
twice the solubility of a single enantiomer.96  Figure 1.5 shows an isothermal triangular 
phase diagram (TPD) corresponding to a conglomerate that exhibits ideal solubility for 
enantiomers are not salt forms.   The solubility lines of each enantiomer run parallel to 
the sides of the phase diagram.  A 50/50 blend of the ideal conglomerate racemate 
demonstrates double the solubility of either pure enantiomer.  For dissociable 
enantiomers (e.g. salts of the two eantiomers) the solution equilibrium behavior for 
conglomerates can be extended to show the ideal solubility is that of the enantiomer salt 
times the square root of two.  Reported values for free and salt forms (i.e. dissociable and 
nondissociable) of enantiomers that are conglomerates have shown close agreement to 
their predicted solubilities.97  
The practical limit for the ideal solubility of racemic compounds, which are 
homogeneous solid phase addition compounds of the components, is the sum of the 
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solubility of each enantiomer in pure solvent.  In other words the equilibrium solubility of 
a stable racemic compound can not exceed the conglomerate solubility.97  Racemic 
compound solubility diagrams include an additional region in the center where racemic 
compound is the stable phase.  The curved boundary of this phase region is defined by 
the solubility product (i.e. equilibrium constant for racemic compound dissociation) and 
indicates solution concentrations that are saturated with respect to the racemic compound. 
Racemic compound phase solubility diagrams are similar to those of two component 
cocrystals, however enantiomers have equal solubility and their triangular phase 
diagrams have vertical symmetry.  This is often not the case for cocrystals where the 
components are unlikely to have identical solubilities.  
 
Figure 1.5:  Schematic triangular phase diagram (TPD) of conglomerate (left) and 
racemic compound (right). D and L represent enantiomers and each apex represents a 
pure phase corresponding to the label.   
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1.3. STATEMENT OF DISSERTATION RESEARCH 
The purpose of this dissertation is to investigate the physicochemical properties of 
pharmaceutical cocrystals and provide fundamental descriptions of their thermodynamic 
stability and solubility.  Emphasis is placed on determining cocrystal properties in 
relation to their structure and components in order to improve the systematic methods for 
cocrystal design, synthesis, screening, selection, and formulation.   Phase behavior and 
solution equilibria are considered to provide general and robust descriptions of the 
stoichiometric solubility of cocrystals that are either thermodynamically stable or 
unstable in pure solvent.  Cocrystal solubility can be influenced by solid-state chemistry 
and solution chemistry including solute-solvent and solute-solute interactions as well as 
ionization.  The chapters presented describe important aspects of both solution and solid-
state chemistry of cocrystals.   
Chapter 2 introduces the concept of eutectic points (i.e. isothermal invariant 
points) for calculating the stoichiometric solubility of cocrystals in pure solvent.  This 
theoretical framework enables the same measurement to be used in determining the 
solubility of cocrystals that are thermodynamically stable or unstable in pure solvent.  
Methods are developed to measure cocrystal eutectic points from conditions that are 
undersaturated or saturated with respect to the cocrystal.  Together these eutectic 
concentrations are used to calculate cocrystal solubilities, which are further analyzed in 
the context of the cocrystal component solubilities.  It is shown that cocrystal solubility is 
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proportional to the solubility of the coformer for a set of carbamazepine cocrystals.  
Likewise the solubility of several nicotinamide cocrystals show a direct correlation to the 
drug component solubility.  Thermal analysis and ideal solubility calculations show that 
crystal melt temperature is a fair indicator of cocrystal solubility in the organic solvents 
studied, but are poor indicators of aqueous solubility.  This chapter presents the 
fundamental solubility and phase behavior of cocrystals as well as the eutectic 
measurements used throughout this research. 
Chapter 3 presents a thermodynamic cocrystal eutectic constant (Keu) which is the 
activity ratio of coformer to drug at the eutectic.  Keu is derived from a series of relevant 
cocrystal solution equilibrium expressions.  Keu is a function of cocrystal solubility 
behavior including ionization and complexation and was demonstrated for more than 
forty cocrystal and solvent combinations.  
Chapter 4 describes the thermodynamic relationships for Keu as a function of 
temperature.  The stability and solubility of cocrystals relative to their components is 
shown to be temperature dependent.  These thermodynamic expressions make it possible 
to predict thermal conditions where cocrystal or its components are the most stable phase 
in equilibrium with solution. The carbamazepine-nicotinamide cocrystal is considered in 
various organic solvents along with enthalpies of solution for the components. 
Cocrystal activity coefficients that account for non-ideal solution behavior are 
derived from experimental and ideal solubility values in Chapter 5. Together ideal 
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solubility values and activity coefficients represent the solid-state and solution 
contributions to cocrystal solubility, respectively.   
The synthesis and solubility of three new carbamazepine-sarcosine anhydride 
cocrystals are presented in Chapter 6.  The phase behavior and solubility of these 
cocrystals are examined as well as the crystal structure of one of the 2:1 cocrystals. 
In Chapter 7 hygroscopic and deliquescent excipients are shown to induce 
cocrystal phase transformations.  The moisture sorbed by these excipients facilitates the 
solution-mediated transformation from crystalline components to cocrystal.  Dissolution 
of components in the sorbed moisture creates supersaturation and subsequent 
crystallization of cocrystal based on known solubility product and phase behavior. 
Finally, the conclusions and future work of this dissertation research are provided 
in Chapter 8.  Future challenges include those associated with determining solubility for 
cocrystal and solvent combinations where cocrystal does not follow solubility product 
behavior, solution behavior is dominated by complexation, or is not readily stabilized. 
Several of these chapters have been published.  Cocrystal solubility and eutectic 
point relationships described in Chapters 2 and 3 are the subject of two publications in 
Crystal Growth and Design (1) 2009 vol. 9 pp. 2252-2264 and (2) 2010 vol. 10 pp. 1028-
1032.  Chapter 7 is part of a publication that presents the mechanisms by which moisture 
leads to cocrystal formation in Molecular Pharmaceutics 2007 vol. 4 pp. 360-372. 
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2.  
CHAPTER 2 
THE STOICHIOMETRIC SOLUBILITY OF COCRYSTALS 
FROM SOLUTION EUTECTIC CONCENTRATIONS OF 
COCRYSTAL COMPONENTS 
An important goal of solid-state pharmaceutical development is to increase drug 
solubility while maintaining a stable form.  This objective is critical because solubility 
and permeability are the major factors used to describe oral absorption according to the 
biopharmaceutics classification system (BCS).  Oral absorption of BCS class II drugs is 
solubility limited.  This class of drugs is currently estimated to account for about thirty 
percent of both commercial and developmental drugs.1, 2  Class I and III BCS drugs have 
high solubility and oral absorption primarily limited by dissolution rate and permeability, 
respectively.  Increased solubility can significantly improve the oral absorption of class II 
drugs and would have lesser impact for the already soluble class I and III drugs.3  
Cocrystals have emerged as a promising means to modify solubility, dissolution, and 
other physicochemical properties of drug substances.4-8 Pharmaceutical cocrystals 
provide an alternative to chemical modification of the drug substance as well as 
established salt, amorphous, solvate, and polymorphic drug forms that all have limitations 
in their utility.  Cocrystals can be made for non-ionizable drugs, which are restricted from 
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salt formation.  Also, for ionizable drugs the number of suitable cocrystal coformers can 
exceed the number of suitable counterions.  One example is the ionizable drug piroxicam 
that has over fifty reported cocrystal coformers.9  With unique properties for each drug 
form, there is great potential to form highly soluble and stable pharmaceutical cocrystals.  
The purpose of this work is to establish how cocrystal solubility and stability are 
related to the properties of the pure components.  To determine these relationships, 
methods are developed to calculate the true equilibrium solubility of cocrystals, which 
are often not the most stable solid phase in solution.  Indeed some of the most relevant 
pharmaceutical cocrystals are more soluble than the pure drug form and therefore prone 
to transformation when exposed to solvent.  This paper addresses the need for a readily 
measurable equilibrium between cocrystal and solution that can be used to calculate the 
often inaccessible equilibrium cocrystal solubility in pure solvent.  The majority of 
studies relating to cocrystal solubility have focused on kinetic measurements of 
dissolution.  Kinetic dissolution results are influenced by phase transformations, surface 
area, and particle size distribution of the drug as well as fluid dynamics and experimental 
apparatus.10-13  These factors can be difficult to quantify and reproduce. Kinetic and 
equilibrium solubility measurements provide alternative and complementary 
characterization of drugs useful for addressing oral absorption limitations highlighted in 
the BCS.  This paper focuses on methods for equilibrium measurements of cocrystal 
solubility that are experimentally accessible and reproducible.  
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Earlier reports from our laboratory have shown that cocrystal solubility is 
dependent on the concentration of coformer in solution. The dissociation of cocrystal in 
solution is described by the solubility product (Ksp) which is defined as a product of drug 
and coformer solution concentrations.14 This is analogous to the Ksp of salt forms defined 
by the product of ionized drug and counterion concentrations.13, 15  Ksp is a constant that 
reflects the strength of cocrystal solid-state interactions of drug and coformer relative to 
interactions with the solvent.  The cocrystal solubility product behavior indicates that 
high coformer concentrations are associated with low solution drug levels.  In a similar 
manner salt forms of drugs exhibit a common-ion effect where solubility decreases as the 
counterion concentration increases.13, 16-18  Cocrystal solubility is also a function of the 
solubility product such that high Ksp values equate to high cocrystal solubility.  
Exceptions to this solubility product behavior can occur when cocrystal does not 
dissociate to its components in solution, there is high solution complexation, or the drug 
is highly solubilized by coformer.14, 19, 20 
The cocrystal eutectic point is a key parameter that establishes the regions of 
thermodynamic stability of cocrystal relative to its components.14, 21-24  This is an 
isothermal invariant point where two solid phases coexist in equilibrium with solution. 
The pharmaceutically relevant eutectic point in this work involves the equilibrium of 
drug and cocrystal solid phases because drug is often the least water soluble component 
(e.g. class II BCS drugs).   It was previously shown that coformer in excess of the molar 
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ratio in the cocrystal is needed to reduce the cocrystal solubility to equal that of the 
drug.14  Also it was predicted that cocrystals with high Ksp values require high coformer 
concentrations to achieve equivalent drug and cocrystal solubilities.14 These concepts are 
developed in the current chapter to provide methods for calculating cocrystal solubility in 
pure solvent and understanding relationships between eutectic concentrations, cocrystal 
and component solubilities. 
Carbamazepine (CBZ) cocrystals serve as the model system for this research.  
Carbamazepine is a widely used anti-epileptic drug that has low aqueous solubility and 
requires high blood levels for therapeutic efficacy.  The low bioavailability of 
carbamazepine is due to low solubility and auto-induced metabolism.5, 25  Carbamazepine 
has four known polymorphs and a dihydrate form.26, 27  Over forty cocrystals of 
carbamazepine have been identified to date.23, 28  One recent publication synthesized 
more than twenty-five carbamazepine cocrystals by screening carboxylic acid 
coformers.23  Cocrystals of carbamazepine typically form through hydrogen bonding of 
the primary amide group with a coformer.  One example of this bonding is shown in 
figure 1.1 for carbamazepine-succinic acid cocrystal.  Pharmacokinetic studies of 
carbamazepine cocrystallized with saccharin have shown blood level increases due to 
dissolution improvement over the marketed pure drug (form III - monoclinic).5  The 
carbamazepine cocrystals in this study have several coformers in common with reported 
cocrystals of theophylline and caffeine.  Both these drugs are used to compare 
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physicochemical properties of carbamazepine cocrystals.  Carbamazepine is a class II 
BCS drug while theophylline and caffeine are both class III.2 
 
Figure 2.1:  Diagram of carbamazepine-succinic acid cocrystal structure with hydrogen 
bonds indicated by dashed lines.  Each carboxylic acid of the succinic acid forms two 
hydrogen bonds with the carbamazepine amide.28 
 
This chapter has three principal objectives.  Objective (1) is to enable the 
measurement of equilibrium cocrystal solubility from a single measurement of solution in 
equilibrium with solid drug and cocrystal.  This includes cocrystals that are either stable 
or metastable when exposed to pure solvent.  Objective (2) is to determine how the 
physicochemical properties of the reactants are related to cocrystal solubility and 
stability.  Included in this is understanding how diverse cocrystal solubility can be 
relative to alternative drug forms (e.g. salt or amorphous).  Objective (3) is to determine 
if crystal lattice properties such as melting temperature and enthalpy are sufficient 
indicators of cocrystal solubility. 
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2.1. THEORETICAL  
2.1.1. Cocrystal solubility (SCC) and solubility product (Ksp) 
For cocrystal A B  where A is drug and B is coformer, solubility is described by 
the chemical equilibrium of solid cocrystal with solution and the corresponding 
equilibrium constant given by: 
A B (s )
K
A(soln) + B(soln)  
K =
aA(soln)aB(soln)
aA B (s )
 2.1 
Defining solid cocrystal activity as unity (aA B (s ) = 1) and assuming the activity 
coefficients ( ) of A and B equal unity for low solute levels Equation 2.1 reduces to: 
Ksp = [A] [B]  2.2 
where Ksp  is the solubility product of the cocrystal.  Considering the equilibrium reaction 
above, the mass balance for  [A] = SA B and [B] = SA B can be substituted into 
Equation 2.2 to provide the cocrystal solubility: 
SA B =
Ksp+  2.3 
Cocrystal solubility always refers to intrinsic solubility in pure solvent, unless otherwise 
noted, as defined by Equation 2.3.  This derivation of intrinsic cocrystal solubility is 
based on chemical equilibria for all solvents in which the drug and coformer substances 
are non-ionizing.  Extensive considerations of ionization have been recently published 
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and indicate cocrystal Ksp is based on the concentrations of non-ionized drug and 
coformer; however, the expression of cocrystal solubility includes appropriate pH and 
pKa factors for ionizing substances.
29-33  One case is the cocrystal of a neutral drug (e.g. 







+  2.4 
where pH and coformer pKa are reflected in the hydrogen ion concentration and the acid 
dissociation constant.   
 
2.1.2. Cocrystal solubility (SCC) and the phase solubility diagram (PSD) 
Phase solubility diagrams (PSDs) and triangular phase diagrams are used to 
represent the solubility and stability of cocrystals.  The PSD in Figure 2.2 represents two 
different cocrystals, which are either stable (case 1: low solubility and Ksp) or metastable 
(case 2: high solubility and Ksp) with respect to the pure drug form in a given solvent.  
These curves represent cocrystal solubility product behavior with the drug concentration 
as a function of coformer given by [drug] = Ksp[coformer]  from Equation 2.2. The 
drug solubility (horizontal line) is assumed to be much lower than the coformer 
solubility, which is not shown.  A dashed line represents stoichiometric solution 
concentrations or stoichiometric dissolution of cocrystal in pure solvent and its 
intersection with the cocrystal solubility curves (marked by circles) indicates the 
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maximum drug concentration associated with the cocrystal solubilities.  Unless otherwise 
specified the term cocrystal solubility refers to stoichiometric solubility in pure solvent at 
conditions where the components are non-ionized.  For a metastable cocrystal (case 2) the 
drug concentration associated with the cocrystal solubility is greater than the solubility of 
the stable drug form (horizontal line).  The solubility of a metastable cocrystal is not 
typically a measurable equilibrium and these cocrystals are referred to as incongruently 
saturating.  As a metastable cocrystal dissolves the drug released into solution can 
crystallize due to supersaturation.  This supersaturation is a necessary, but not sufficient 
condition for crystallization.  In certain instances slow nucleation or other kinetic factors 
might delay crystallization of the favored thermodynamic form and enable measurement 
of the true equilibrium solubility.  In the other case, a congruently saturating cocrystal 
(case 1) has a lower drug concentration than the pure drug form at their respective 
solubility values.  Therefore, the solubility of congruently saturating cocrystals can be 
readily measured from solid cocrystal dissolved and equilibrated with solution.   
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Figure 2.2:  Schematic phase solubility diagram of two different cocrystals based on the 
Ksp of a stable (case 1) or metastable (case 2) cocrystal. Drug solubility is indicated and is 
much lower than the solubility of the coformer, which is not shown. X marks represent 
the eutectic points (i.e. invariant point) used to calculate equilibrium solubility.  Circles 
represent the solubility of cocrystal in pure solvent. Dashed line illustrates stoichiometric 
concentrations of cocrystal components which dissolution could follow. This line 
represents a drug to coformer ratio equal to the cocrystal stoichiometric ratio of the 
components.  
 
For both congruently and incongruently saturating cocrystals an isobarothermal 
invariant point (i.e. eutectic point), indicated by X marks in Figure 2.2, is the point where 
both solid drug and cocrystal are in equilibrium with a solution containing drug and 
coformer.  Together the drug and coformer solution concentrations at the invariant point 
are referred to as the eutectic concentrations.14, 19, 23, 34-37   Eutectic concentrations in this 
paper define the solution concentrations ([drug]eu and [coformer]eu) that separate regions 
where either the solid cocrystal or drug are thermodynamically stable.  Other invariant 
points and eutectic concentrations exist to describe the equilibria between solid cocrystal 
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and coformer, cocrystals of different stoichiometry, or cocrystal solvates.  Systems where 
the coformer is less soluble than drug could utilize the eutectic associated with solid 
cocrystal and coformer to readily calculate cocrystal solubility.38  For CBZ and the high 
solubility coformers in this study the equilibrium of solid cocrystal and drug is most 
relevant for calculating solubility of the cocrystal form in pure solvent.  
Gibbs’ condensed phase rule defines a system with three components (solvent, 
drug, and coformer) and three phases (drug, cocrystal, and solution) as having only one 
degree of freedom.  At constant temperature the phase rule indicates zero degrees of 
freedom (invariant point) where the solution composition is fixed (eutectic 
concentration).  At the eutectic concentration the free energy of solid cocrystal and drug 
are equal (i.e. G = 0 ).  Below or above the eutectic point either the drug or the cocrystal 
is less soluble, the free energy difference is nonzero, and only one solid phase is stable.  
A solid phase of cocrystal is stable beyond the eutectic while pure drug is stable below 
this concentration. 
Any cocrystal eutectic concentration wherein [drug]eu equals or exceeds 
[coformer]eu by a factor equivalent to the cocrystal’s stoichiometric coefficient ratio ( / ) 
is known to be congruently saturating provided the coformer is more soluble, while all 
others are incongruently saturating.  If we assume Figure 2.2 represents a 1:1 cocrystal, 
where drug is the least soluble component in pure solvent, the eutectic concentration for 
the low solubility cocrystal is above the dashed line representing stoichiometric 
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concentrations.  Therefore, [drug]eu>[coformer]eu and the cocrystal is congruently 
saturating.  
The eutectic concentration is a readily measurable equilibrium state that can be 
used to determine cocrystal solubility. Furthermore, for incongruently saturating 
cocrystals the eutectic is the nearest accessible solid-solution equilibrium to the solubility 
and a good surrogate measurement from which to calculate cocrystal solubility.  Only 
kinetic measurements can provide alternative quantitative solubilities to those based on 
the solubility product.  While these kinetic measurements are useful for a variety of 
pharmaceutical analyses there is a need for direct information regarding the magnitude of 
thermodynamic cocrystal solubility.  For cocrystal-solvent systems where solubility, 
dissolution behavior, or phase stability are unknown, determining the eutectic 
concentrations provides the cocrystal solubility and solution stability.  Additionally, 
eutectic concentrations can be measured with small amounts of drug since only slight 
excess of the solubility is needed to generate the requisite solid phases in amounts 
detectable by a variety of analytical methods.  
The solubility product expresses all possible solution concentrations of drug and 
coformer in equilibrium with solid cocrystal and is directly related to cocrystal solubility 
by Equation 2.3.  Inserting the cocrystal eutectic concentrations ([A]eu and [B]eu) into 
Equation 2.2 allows Equation 2.3 to be rewritten as: 
SA B =
[A]eu[B]eu+  2.5 
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Equation 2.5 can be used to calculate cocrystal solubility from measurement of the 
eutectic concentration.  Drug and coformer eutectic concentrations describe both the 
solubility and thermodynamic stability of the cocrystal in a given solvent, thus the 
eutectic concentrations are a logical first measurement for evaluating and comparing 
cocrystals.  For the case where drug solubility (SA) is unchanged with coformer 
concentration in a particular solvent system, as shown in Figure 2.2, Equation 2.5 can 
further simplify by the substitution of [A]eu with SA to give: 
SA B =
SA [B]eu+  2.6 
The estimation of cocrystal solubility based on the coformer eutectic concentration 
([B]eu) and drug solubility is possible from Equation 2.6.  Equation 2.5 uses the full 
measure of eutectic concentrations (both [A]eu and [B]eu) to calculate cocrystal solubility; 
however, the constant drug solubility assumption of Equation 2.6 is valid for many 
solute-solvent systems and can simplify the requisite experimental methodology. 
 
2.1.3. Cocrystal solubility and chemical potential at the eutectic concentration 
Cocrystal solubility is a function of chemical potential (μ).  The chemical 
potential expression for the equilibrium of cocrystal with solution is: 
 




soln ) + (μB
soln )
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At the eutectic concentration the solution is saturated with drug (A).  The chemical 





When considering only one drug substance μA
solid  remains constant and substituting 
μA
solid
= C = μA




soln ) + C  2.7 
Therefore, the cocrystal chemical potential is proportional to that of the coformer solute.  
From Equation 2.7 it can be stated that cocrystal solubility is proportional to coformer 
solubility. 
 
2.1.4. Thermal analysis and predictions of cocrystal solubility (SCC). 
Melting temperatures and enthalpies of pharmaceutical crystals have found 
prevalent utility as indicators of ideal solubility.  These are readily measurable properties 
associated with the crystal lattice energy that must be overcome for dissolution to occur.  
Among structurally similar pharmaceutical crystalline drug substances, those with high 
melt temperatures are generally recognized to possess lower solubility.39, 40  Equation 2.8 
is a fundamental and common thermodynamic model for the relation between solubility 
and melt properties.40  For an ideal solution the solute solubility, x (mole fraction), is a 
function of the heat of fusion, melt temperature, and solution temperature. 









where     Hm Hs
ideal  
The two main assumptions in the derivation of this ideal solubility expression are that 
enthalpy of fusion is temperature independent (i.e. heat capacity is zero) and is 
approximately equal to the ideal enthalpy of solution.  More involved expressions have 
been derived to address these assumptions by including additional thermodynamic 
parameters such as solute heat capacity. The Equation 2.8 approximation of ideal 
solubility, often regarded as an upper solubility limit, provides a good comparison for 
experimental cocrystal solubilities.39 
 
2.2. MATERIALS AND METHODS  
2.2.1. Materials 
Anhydrous monoclinic form III carbamazepine (CBZ(III)) as well as anhydrous 
theophylline (THP) and caffeine (CAF) were obtained from Sigma-Aldrich (99+% 
purity) and were used as received.  Carbamazepine dihydrate (CBZ(D)) was prepared by 
stirring CBZ(III) in water for at least twenty-four hours.  Hydrates of theophylline and 
caffeine were prepared in the same manner.  The cocrystal coformers nicotinamide 
(NCT), malonic acid (MLN), glutaric acid (GTA), saccharin (SAC), anhydrous oxalic 
acid (OXA), succinic acid (SUC), and salicylic acid (SLC) were obtained from Sigma-
Aldrich (99+% purity) and used as received.  All crystalline drugs and coformers were 
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characterized by X-ray powder diffraction (XRPD) and Raman spectroscopy before 
carrying out experiments.  No impurities in the form of additional peaks were resolved 
during HPLC analysis of solutions containing the drugs or coformers in this study.  
Ethanol (EtOH), isopropyl alcohol (IPA), and ethyl acetate (EtOAc) were obtained from 
Fisher Scientific and dried using molecular sieves prior to use.  All the cocrystals used for 
solubility studies were precipitated from coformer solutions by adding solid drug 
according to the reaction crystallization method (RCM).21, 23  Cocrystals of CBZ-NCT 
and CBZ-SAC throughout the paper refer to the form I polymorphs.41  CBZ-MLN is the 
form B polymorph which is a hydrated crystal form.23 
 
2.2.2. Determination of eutectic concentrations ([A]eu and [B]eu) 
The measurements of cocrystal eutectic concentrations were preformed by 
precipitating cocrystal as a result of stirring excess solid drug in a coformer solution 
wherein cocrystal synthesis occurs through RCM.21, 23    Eutectic concentrations were 
also obtained by dissolution of cocrystal in saturated drug solutions containing excess 
solid drug.  Each cocrystal eutectic concentration was determined from both 
supersaturated cocrystal conditions by RCM and from undersaturation by cocrystal 
dissolution.  Samples were confirmed to have two solid phases (drug and cocrystal) at 
equilibrium for at least twenty-four hours before the solution was isolated from the solids 
and analyzed by HPLC.  A flowchart of the processes used to determine cocrystal 
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eutectic concentrations is given in Figure 2.3(a).  An aliquot of the solid phase was 
isolated from solution for x-ray analysis then solid reactant(s) were added as required to 
reach mixed solid phase equilibrium.  This process was repeated in twenty-four hour 
iterations until a stable mixed solid phase was achieved.  Samples were held between 23-
25oC for all eutectic concentration measurements.   
 
a) b)  
Figure 2.3:  a) Flowchart of method used to establish the invariant point and determine 
equilibrium solution eutectic concentrations of cocrystal components. b) Schematic PSD 
illustrating two pathways to reach the eutectic marked with an X. The solubility curve is 
generated from drug and coformer concentrations that equal the cocrystal solubility 
product. 
 
 Figure 2.3(b) is a PSD illustrating theoretical pathways for the two methods used 
to establish cocrystal eutectic concentrations.  The method utilizing RCM starts to the 
right of the eutectic (graphically) with a near saturated coformer solution to which excess 
drug is added.  As the drug dissolves in coformer solution the cocrystal becomes 
supersaturated (i.e. solution reactant concentrations increase above the cocrystal 
solubility curve) and crystallizes from solution.  Precipitation of cocrystal continues until 
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coformer becomes the limiting reagent and the excess solid drug remains in equilibrium 
with the cocrystal formed.  In the cocrystal dissolution method a pre-saturated drug 
solution, which lies to the left of the eutectic (graphically), is combined with solid 
cocrystal and drug.  When starting with saturated drug solution the driving force to reach 
equilibrium is cocrystal dissolution and the concurrent increase of coformer solute.  As 
cocrystal dissolves the drug released into solution is likely to crystallize in the pre-
saturated drug solution.  Cocrystal dissolution may not lead to drug crystallization in 
instances where the coformer solubilizes the drug.  In these instances, when drug 
solubilization by coformer occurs, the excess solid drug initially added with the cocrystal 
maintains drug saturation.  Together these methods confirm the eutectic is reached by 
converging to the same equilibrium from two different initial states.  Eutectic 
concentrations can be expressed as the range established from the two methods.  Steps for 
both methods to reach the eutectic are: 
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Cocrystal Precipitation Method:
Step 1 - Prepare ligand solution
B(s )
solvent B(soln)   (slightly undersaturated)
Step 2 - Add excess drug
A(s )xs
B( soln ) A(soln) + A B (s )
Cocrystal Dissolution Method:
Step 1 - Presaturate solution with drug
A(s )xs
solvent
A(soln)   (saturated)
Step 2 - Add excess cocrystal
A B (s )xs
A( soln ) B(soln) + A(s )
 
 
2.2.3. High performance liquid chromatography (HPLC) 
Solution concentrations of drug and coformer were analyzed by Waters HPLC 
(Milford, MA) equipped with a UV/Vis spectrometer detector. A C18 Atlantis column 
(5 m, 4.6 x 250mm; Waters, Milford, MA) at ambient temperature was used to separate 
the drug and the coformer.  A gradient method with a water, methanol, and trifluoroacetic 
acid mobile phase was used with a flow rate of 1mL/min.  Sample injection volume was 
20 L.  Absorbance of the drug and coformer analytes was monitored between 210-
300nm.  Empower software from Waters was used to collect and process the data. All 
concentrations are reported in molality (moles solute/kilogram solvent).  
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2.2.4. X-ray powder diffraction (XRPD) 
XRPD was used to identify crystalline phases after slurrying samples to determine 
cocrystal eutectic concentrations and confirm the proper two solid phases (drug and 
cocrystal) were in equilibrium with the solution. XRPD patterns of solid phases were 
recorded with a Rigaku MiniFlex X-ray diffractometer (Danvers, MA) using Cu K  
radiation (  = 1.5418 Å), a tube voltage of 30 kV, and a tube current of 15 mA. The 
intensities were measured at 2  values from 2° to 30° with a continuous scan rate of 
2.5°/min. Samples, prior to and after slurry reactions, were analyzed by XRPD. Results 
were compared to diffraction patterns reported in literature or calculated from crystal 
structures published in the Cambridge Structural Database. THP-NCT is the only 
cocrystal in this study whose XRPD pattern has not been published to our knowledge.  
This diffraction pattern is provided in Appendix 2.6. 
 
2.2.5. Thermal Analysis 
Crystalline samples of 3-6 mg were analyzed by differential scanning calorimetry 
(DSC) using a TA instrument (Newark, DE) 2910 MDSC system equipped with a 
refrigerated cooling unit. DSC experiments were performed by heating the samples at a 
rate of 10oK per minute under a dry nitrogen atmosphere. Temperature and enthalpy 
calibration of the instruments was achieved using a high purity indium standard. 
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Hermetic aluminum sample pans were used for all measurements. The mean result of 
three or more samples are reported for each substance. 
Cocrystal samples for DSC analysis were comprised of several large crystals 
grown by slow partial evaporation of solutions containing the reactants.  These crystals 
were isolated from solution, washed, and characterized by Raman microscopy before 
being combined to yield an adequate mass for DSC analysis. 
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2.3. RESULTS AND DISCUSSION  
2.3.1. Cocrystal solubility from eutectic concentrations 
Table 2.1 lists the eutectic concentrations ([drug]eu and [coformer]eu) for a series 
of cocrystals measured at the invariant point where two solid phases (drug and cocrystal) 
are in equilibrium with aqueous or organic solution.  All cocrystal eutectics were 
confirmed by XRPD analysis of the solid phase, isolated from equilibrium with solution, 
as exemplified in Figure 2.4 for CBZ-SUC.  In Figure 2.4, each of the isolated solid 
phases contains the equilibrium mixture of CBZ-SUC cocrystal and CBZ(form III in 
organic solvents or dihydrate in water) indicating these solids are both stable in solution.  
Cocrystal Ksp and intrinsic solubility values, that represent non-ionized drug and 
coformer in solution, were calculated from eutectic concentrations according to 
Equations 2.2 and 2.5, respectively.  For aqueous samples the pH was first used to 
calculate the non-ionized concentration of drug and coformer at the eutectic.  Cocrystal 
solubilities were multiplied by the stoichiometric coefficient to provide the associated 
drug concentration and normalized with the relevant stable crystalline drug solubility to 
provide solubility ratios ([drug]Scc/Sdrug).  For 1:1 cocrystals this ratio is the same as the 
cocrystal solubility divided by the drug solubility.   
Solubility ratios emphasize the magnitude of change in solubility achieved by 
various cocrystals and facilitate comparisons between different solvents.  The CBZ 
cocrystals studied have a range of aqueous solubility ratios from 2 to 152.  In organic 
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solvents, where coformer solubilities are closer to the solubility of CBZ, cocrystal 
solubility ratios have a lower range between 0.1 and 4.4.  The aqueous intrinsic solubility 
of CBZ-SAC is 1.2x10-3m and the solubility of CBZ form III is 1.6 x10-3m. Because 
saccharin is acidic (pKa=1.6 at 25oC) the CBZ-SAC aqueous solubility from Equation 
2.4 increases greatly in the small intestine (e.g. more than 150 times at pH=6), but CBZ 
form III does not.  This CBZ-SAC aqueous solubility is consistent with previous in vivo 
animal studies by Hickey et al. that show the cocrystal has higher CBZ blood levels 
relative to the marketed CBZ form III that persist several hours after dosing, although 
high variability was observed for the pharmacokinetic parameters.5, 42  Dissolution studies 
by Nehm et al. also have shown higher dissolution rate for CBZ-SAC relative to CBZ 
form III in pH=7 solutions.30  Table 2.1 lists coformer solubilities and the drug 
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2-Theta 
Figure 2.4: XRPD patterns of reference materials and solid phases isolated from 
suspensions at the eutectic concentration: a) CBZ(III), b) CBZ(D), and c) CBZ-SUC 
followed by solid phases isolated from d) water, e) ethanol, f) ethyl acetate, and g) 2-
propanol.  
 
The solubility ratios of the cocrystals in Table 2.1 exceed ranges previously 
reported for salt, polymorph, and amorphous forms of drug substances. Pudipeddi et al. 
have surveyed polymorph solubility ratios for fifty-five drug substances, some with 
multiple forms, to provide eighty-one solubility ratios and all the values fell below five 
with only one exception.
44
  The highest polymorph solubility ratio was 23.1 
(Premafloxacin I/III) followed by 4.7 (Acemetacin III/I).  The solubility ratio of CBZ III/I 
polymorphs in IPA was almost 1.4.  In comparison, the CBZ-GTA cocrystal ratio in IPA 
is more than four times the solubility of CBZ III.  Hancock and Parks published 
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amorphous drug solubility ratios (amorphous/crystalline) of seven compounds in a 
variety of aqueous and organic solvent systems.
45
  The maximum measured solubility 
enhancement of amorphous drug or excipients was twenty-four times (glucose in 
methanol 20
o
C) the crystalline form.  Two other pharmaceutical compounds 
(glibenclamide and polythiazide) had solubility ratios greater than five.  While the 
cocrystals in this study show a greater range of equilibrium solubility ratios than many of 
these surveyed, amorphous, polymorph, or salt forms the benefits in terms of dissolution 
rates are not known.  The rate in which any of these more soluble solid forms transform 
in solution could be a determining factor in their utility.    
 
2.3.2. Cocrystal solubility, eutectic concentration, and coformer solubility relationship 
Examination of results in Table 2.1 reveals regular patterns in the effects of 
solubility of components on eutectic concentrations and cocrystal solubilities. Within the 
series of carbamazepine cocrystals it is observed that experimentally measured 
[coformer]eu increases with coformer solubility and that [coformer]eu can be orders of 
magnitude above [drug]eu.    Based on Ksp behavior, [coformer]eu in excess of [drug]eu is 
associated with cocrystal solubility greater than drug solubility. The relationship between 
cocrystal [coformer]eu and coformer solubility is evident for carbamazepine cocrystals in 
water (Figure 2.5a).  This relationship is maintained for other cocrystals and other 
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solvents in Figure 2.5b.  Higher [coformer]eu values are associated with higher Ksp as 
predicted by Equation 2.5 and previous models.
14
 
Cocrystal solubility ratios or drug concentrations associated with cocrystal 
solubility are directly proportional to coformer solubility, as expected from the derived 
chemical potential expression (Equation 2.7).   This is shown in Figure 2.5b where both 
cocrystal and coformer solubilities are normalized by drug solubility and a clear trend is 
observed in all solvents studied.   For cocrystals of the same drug and different coformers 
the pattern is maintained, i.e. high cocrystal solubility ratios for high ratios of coformer to 
drug solubilities.  For this small series of 1:1 cocrystals it appears that a coformer 
solubility about ten times the drug solubility is needed for cocrystal solubilities to be 
greater than drug solubility.  2:1 cocrystals demonstrate the same correlation (data not 
graphed) however the slope is slightly lower as anticipated from Equation 2.5.  For each 
cocrystal, the ratio of coformer and drug concentrations at the eutectic concentration is 
also proportional with the coformer to drug solubility ratio.  
Cocrystal solubility behavior was further examined in each solvent as shown in 
Figure 2.6.  Cocrystal solubility ratio as a function of coformer solubility for each solvent 
confirms that high coformer solubility equates to high cocrystal solubility.  A notable 
exception is CBZ-NCT (positive deviation) in water where high CBZ aqueous solubility 
enhancement occurs in the presence of NCT(aq).  In ethyl acetate (least polar solvent - 
Figure 2.6c) the solubility order for three of the four coformers differ from the other 
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solvents.  Yet, cocrystal solubility remains a function of coformer solubility.  Similarly a 
proportional relationship has been suggested between the aqueous solubility of 
pharmaceutical salts and the hydrophilicity of their organic counterions.  Counterions of 
erythromycin with extended alkyl chains (i.e. more hydrophobic) decreased the aqueous 
salt solubility.
46
  Similar results have been shown for counterion studies of lincomycin 
salts.
47
  Studies of other drugs are consistent with this trend and have shown counterions 
with more hydroxyl groups (i.e. more hydrophilic) can provide higher salt solubility.
48, 49
  
Alternatively analysis of several flurbiprofen salts have not found a link between 
solubility and counterion hydrophilicity, but suggest crystal lattice interactions could 
become stronger in some instances where counterions are more polar.
50
  Whether lattice 
energies and/or component solubilities predict cocrystal or salt solubilities depends on the 
interplay between solid-state and solute-solvent interactions. 
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Figure 2.5:  a) The relationship between [coformer]eu and coformer solubility for CBZ 
cocrystals in water. Log axes are shown to aid visualization of the individual points due 
to the large range of values. The linear regression for the untransformed data in Table 2.1 
is r
2
=0.986. b) The ratio of coformer to drug solubility plotted against the cocrystal 
solubility ratio (filled circles) and the ratio of coformer to drug eutectic concentrations 
(open circles). All aqueous samples are shown in red.  Several cocrystals with the same 
coformers are labeled. [coformer]eu in a) and b) refers to the non-ionized [coformer] at 
the eutectic based on pH values listed in Table 2.1. 
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Figure 2.6: Solubility ratio of CBZ cocrystal to CBZ(D) as a function of the constituent 
coformer solubility (molal).  The graphs represent: (a) ethanol, (b) 2-propanol, (c) ethyl 
acetate, (d) water.  The points in each graph represent the cocrystal CBZ-coformer by the 
corresponding coformer component ( :GTA, +:NCT, :SUC, :SAC). 
 
2.3.3. Cocrystal coformers that increase drug solubility 
 Some coformers are capable of solubilizing the drug substance with which they 
form cocrystals.  The direct measurement of drug concentration is critical for accurately 
expressing the eutectic and calculating cocrystal solubility.  One example is the CBZ-
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NCT cocrystal where CBZ is highly solubilized by NCT(aq) (Figure 2.6d and Table 2.1).  
The [CBZ]eu is more than tenfold the solubility of CBZ(D).  Other coformers have 
minimal effect on drug solubility, with [CBZ]eu slightly above CBZ solubility in pure 
solvent, but this effect is prominent for CBZ-NCT in water.  The CBZ solubilization by 
NCT(aq), indicated by [CBZ]eu>SCBZ(D), leads to higher cocrystal solubility than expected 
by considering NCT aqueous solubility alone.   
A series of CBZ cocrystal solubilities in aqueous media were calculated by two 
approaches to highlight the importance of considering [CBZ]eu.  The first approach is 
using Equation 2.3 where Ksp = [CBZ ]eu[B]eu  and the second assumes [CBZ ]eu = SCBZ (D )  
so that Ksp = SCBZ [B]eu .  Figure 2.7 plots aqueous CBZ cocrystal solubility ratios as a 
function of coformer solubility. A direct trend between coformer and cocrystal solubility 
ratio is evident in Figure 2.7 when it is assumed that [CBZ ]eu = SCBZ (D )  (open squares).  A 
notable exception is the cocrystal hydrate CBZ-MLN (negative deviation) identified to 
have a more soluble 2:1 anhydrous form (data not shown).  Several cocrystals exhibit 
large increases in solubility when calculated using measured [CBZ]eu.  This is evident for 
cocrystals of the three most soluble coformers (NCT, GTA, and MLN).  For this group of 
highly soluble coformers the ability to solubilize CBZ is distinctly different.  [CBZ]eu 
values range from 2 to 13 times SCBZ(D), and this makes measuring [CBZ]eu critical to 
evaluating cocrystal solubility.  For these cocrystals [coformer]eu values (Table 2.1) 
follow the order of coformer solubility (MLN>GTA>NCT), but the [CBZ]eu, indicative 
of drug solubilization by coformer, has an inverse order (NCT>GTA>MLN). NCT has 
been previously shown to solubilize hydrophobic drug substances.
51
  For the low 
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solubility CBZ coformers (OXA, SUC, SAC), little or no difference is exhibited between 
cocrystal solubility calculated from Equation 2.5 and 2.6. 
  
 
Figure 2.7: Aqueous solubility ratio of CBZ cocrystals to CBZ(D) (i.e. [drug]Scc/Sdrug) 
plotted against coformer solubility. Data labels indicate the coformer component of the 
cocrystal. Cocrystal solubility calculated from Equation 2.5 ( : [drug]eu measured) or 
from Equation 2.6 ( : [drug]eu approximated by drug solubility (Sdrug) in pure solvent). 
*hydrated cocrystal 2:1 cocrystal stoichiometry  
 
2.3.4. Cocrystal stoichiometry and solubility  
Carbamazepine cocrystals of succinic, oxalic, and malonic acid are the only 2:1 
(drug:coformer) cocrystals in Table 2.1  and they exhibit a negative deviation from the 
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trend between cocrystal and coformer solubility.  Since these coformers (more soluble 
than CBZ) account for a lesser mole fraction of the cocrystal they have reduced capacity 
to impart high solubility to the cocrystal.  From Equation 2.3 it is expected that cocrystals 
with high mole fractions of the least soluble component will have less solubility 
enhancement over pure drug.  The solubility value of a 2:1 cocrystal does not equal the 
equilibrium drug concentration as in the case of a 1:1 cocrystal.  Cocrystal stoichiometry 
defines the relationship between solubility and the equilibrium drug concentration 
achieved.  
 
2.3.5. Cocrystal and drug solubility  
The solubility of cocrystal and drug exhibited a direct proportionality, as did the 
solubility of cocrystal and coformer.  Figure 2.8a shows aqueous solubility of CBZ, 
theophylline (THP), and caffeine (CAF) cocrystals with salicylic acid (SLC) as a function 
of the drug solubility.  These results indicate the cocrystal solubility trend follows drug 
solubility (CAF>THP>CBZ) for salicylic acid cocrystals. It is worth noting that SLC is 
less water soluble than CAF and THP, but more soluble than CBZ. Cocrystal solubility is 
higher than drug hydrate solubility for CBZ-SLC and higher than SLC solubility for 
CAF-SLC, thus these cocrystals are incongruently saturating. THP-SLC is congruently 
saturating with both components more soluble than cocrystal. 
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a)  
b)  
Figure 2.8: a) Aqueous solubility of salicylic acid cocrystals (with CBZ, THP, or CAF) 
plotted against the solubility of the hydrated drug.  b) Solubility of NCT cocrystals of 
CBZ and THP in water, EtOH, EtOAc, and IPA plotted against the respective NCT 
solubility.  The numerical data points represent dug solubility from Table 2.1 in mmolal. 
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Nicotinamide cocrystals of CBZ and THP listed in Table 2.1 are plotted in Figure 
2.8b to further illustrate the relationship between cocrystal and drug solubility.  Each 
numerical data point represents the drug solubility and in each solvent the more soluble 
drug has the higher cocrystal solubility.  THP aqueous solubility is greater than CBZ and 
THP-NCT has the higher aqueous solubility (far right points).  For all organic solvents 
CBZ is more soluble than THP and accordingly the CBZ-NCT cocrystals are more 
soluble.  Figure 2.8b additionally demonstrates the effect of coformer solubility on 
cocrystal solubility.  All cocrystal solubilities increase with NCT except for CBZ-NCT in 
water (negative deviation). It is clear the CBZ solubility decrease in water overshadows a 
smaller relative NCT solubility increase.  Together these NCT cocrystals of CBZ and 
THP indicate the combined effect drug and coformer solubility have on cocrystal 
solubility.  Cocrystal solubility is proportional to the solubility of both drug and coformer 
components. 
 
2.3.6. Accuracy of solubility product measurements 
The CBZ-NCT cocrystal Ksp values based on a single measurement of the eutectic 
in this paper are very similar to those previously determined by measuring cocrystal 
solubility for a variety of coformer concentrations.
14
  Ksp values (Table 2.1) for CBZ-
NCT in EtOH, IPA, and EtOAc are within the experimental error of those previously 
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reported.  Although these deviations are minimal, other systems could exhibit less 
accuracy.   
One factor that may contribute to error is the proximity of the eutectic 
concentrations to the concentrations of drug and coformer at the equilibrium cocrystal 
solubility in pure solvent.  There is close eutectic proximity if the ratio of [drug]eu to 
[coformer]eu is near the stoichiometric ratio of components in the cocrystal.  When the 
equilibrium solubility is far away from the measurable eutectic concentration it is 
necessary to make large extrapolations based on ideal Ksp behavior. In this case the solute 
activities may no longer be replaced by concentrations.  Additionally, solution 
complexation of cocrystal components can be concentration dependent. Solubility 
products based on eutectic concentrations do not account for this solution complexation 
or solubilization.   Eutectic concentrations only reflect the level of solubilization for that 
particular solution composition.  Therefore, solubility calculations from the eutectic 
concentrations may not provide a good estimate of the level of complexation or 
solubilization and, as a result, the true solubility. Accuracy could decrease for coformers 
that exhibit high drug solubilization, as reflected by Sdrug<<[drug]eu, and eutectic 
concentrations are far from stoichiometric solubility.  For these instances it would be 
prudent to measure complexation constants or activity coefficients to assure accuracy of 
Ksp and solubility calculations. 
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When designing screening methods for cocrystal solubility it is possible to 
evaluate Ksp by measuring the drug and coformer concentrations at any point where the 
solution is in equilibrium with solid cocrystal.  However, by measuring the eutectic 
concentrations it is also possible to establish the range of cocrystal thermodynamic 
stability in solution.  In either case, the prior discussion of eutectic proximity, 
complexation, and activity apply to the calculations of cocrystal solubility.  Most 
pharmaceutically relevant cocrystals have solubility higher than the drug and are 
incongruently saturating.  This means measurements based on eutectic concentrations 
will have the closest proximity and the most accuracy for a single point measurement 
used to calculate Ksp.  Solubility product calculations based on eutectic points have been 




2.3.7. Ideal solubilities from thermal properties 
Cocrystal melting temperature and enthalpy were obtained from analysis of DSC 
data shown in Figure 2.9. These cocrystals show unique fusion properties relative to their 
constituent reactants. Two cocrystals (CBZ-SAC and CBZ-OXA) have lower melt 










C, and CBZ Tm=191.1
o
C.  The other five cocrystal melt temperatures are very 
close to or between those of their reactants.  To determine the ideal solubility of 
  81 
cocrystals from Equation 2.8 the melting enthalpy was first normalized by the cocrystal 
stoichiometry.  The cocrystal enthalpy of melting listed in Table 2.2 is the measured 
value divided by the number of moles of reactant per mole of cocrystal (i.e. 2 for 1:1 
cocrystals and 3 for 2:1 cocrystals).  This method is analogous to ideal solubility values 
of drug salt forms wherein the melting enthalpy is normalized per mole of constituent 
ions.
52
   
 
 
Figure 2.9: DSC for cocrystals of: (a)THP-NCT, (b)CBZ-NCT (c)CBZ-GTA, (d)CBZ-
SAC, (e)CBZ-SUC, (f)CBZ-SLC, and (g)CBZ-OXA. 
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Table 2.2: Melt temperature and enthalpy used in calculation of ideal solubility and 



















Glutaric acid (GTA) 1.0 x10
1
 13.5 97.7 20.7 7.4 x10
-1
 - 
Nicotinamide (NCT) 7.5 x10
0
 4.9 130.6 23.8 1.5 x10
0
 - 
Succinic acid (SUC) 5.4 x10
-1
 0.6 188.1 32.4 9.0 x10
-1
 - 
Theophylline (THP) 5.8 x10
-2
 1.8 273.6 29.0 3.2 x10
-2
 - 
Salicylic acid (SLC) 1.8 x10
-2
 1.9 160.9 27.1 9.5 x10
-3
 - 
Saccharin (SAC) 1.1 x10
-2
 0.3 229.7 32.1 3.7 x10
-2
 - 
Carbamazepine (CBZ) 1.6 x10
-3
 1.4 192.1 25.6 1.1 x10
-3
 - 
Cocrystals            
THP-NCT 4.5 x10
-1



































Measured solubility for reactants and cocrystals (from Table 2.1) and 
(b)
ideal solubility 
calculated from Equation 2.8 using melt temperature and heat of fusion. Mole fractions 
were converted to molality units in water.  
(c)
The enthalpy of melting for cocrystals is 
normalized by moles of component molecules (drug + coformer) per mole of cocrystal. 
All aqueous solubility, thermal data, and ratios listed are for anhydrous crystal forms. 
 
 
The association between coformer and cocrystal melt temperature is scattered for 
the CBZ cocrystals in Table 2.2.  These five cocrystals show the same relation as an 
expanded group of eighteen CBZ cocrystals (single endotherm non-hydrate forms) 
recently reported.
23
  The linear regression for coformer and cocrystal melting in the two 
studies (r
2
=0.67-0.72) reflects a limited qualitative relationship.  This regression value is 
in agreement with previous correlations of coformer and cocrystal melt temperatures for 
different drug substances.
53, 54
 Since cocrystal lattice energy and melt temperature are 
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based in part on the lattice arrangement and intermolecular interactions it is reasonable 
that coformer and cocrystal melt temperatures do not exhibit a strict correlation. 
Experimental reactant and cocrystal aqueous solubilities also show a qualitative 
trend with melting temperature in Figure 2.10a and 10b, respectively.  The organic 
solvents appear to have a better correlation than the aqueous solubility values.  This 
observation seems reasonable given the potential of drug or coformer polar functional 
moieties for specific interactions with water and therefore deviations from ideal solubility 
behavior.   The solubility of cocrystals in ethanol and isopropanol (from Table 2.1) are 
quite linear (linear regression: r
2
>0.95) as a function of melt temperatures listed in Table 
2.2.  This correlation is apparent in Figure 2.10b where melt temperature and cocrystal 
solubility (log axis) are plotted for the four solvents.  However, from this limited data set 
it would be speculative to consider the correlation of melt temperature and solubility 
superior for either cocrystals or reactants.  The relation of cocrystal solubilities and melt 
temperatures (Table 2.2 and Figure 2.10b) is stronger than reported for aqueous kinetic 
solubility and melt temperature for cocrystals comprised of similar acidic coformers.
54
  
This data seems comparable to studies of salt forms that indicate qualitative trends 
between solubility and melt temperature.
40, 50, 52, 55, 56
  Previous reports of ephedrine salts 
have shown qualitative relations between log solubility and melt temperature with 
approximately similar levels of scatter seen in this cocrystal study.
52
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Figure 2.10: Equilibrium cocrystal and reactant solubilities or solubility ratios in 
water( ), EtOH( ), IPA(X), and EtOAc( ). Solubility as a function of melt 
temperature for (a) reactants and (b) cocrystals. (c) Experimental cocrystal solubility 
versus ideal solubility.  (d) Experimental against ideal cocrystal solubility ratio 
(cocrystal/CBZ form III).  
 
Experimental cocrystal solubilities are not well correlated with ideal values 
derived from the melting enthalpy and temperature of the crystals (Figure 2.10c).  The 
ratios of experimental aqueous solubility to ideal solubility are listed in Table 2.2 to 
emphasize these deviations.  Both aqueous and organic solvents included in Figure 2.10c 
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seem to suggest that crystal fusion properties alone are not sufficient for predicting 
cocrystal solubility.  The solution chemistry of cocrystals appears to be critical for 
describing solubility behavior.  The reactants in Table 2.2 have a better correlation 
between experimental and ideal (linear regression: r
2
=0.87-0.92) solubilities.  Still 
several instances of large deviations suggest ideal solubilities are not adequate indicators 
of drug and coformer solubility from solution measurements. The results further illustrate 
melting properties associated with the breaking of the crystal lattice are not sufficiently 
predictive of cocrystal solubility relations that involve solvent interactions. 
Ratios of the ideal cocrystal and ideal drug solubilities listed in Table 2.2 were of 
a similar order of magnitude to the solution measurements in Table 2.1. The measured 
solubility ratios of CBZ cocrystal/CBZ(III) are plotted in Figure 2.10d against the ideal 
solubility ratio. These ideal ratios have significant discrepancies with aqueous 
experimental ratios for CBZ-NCT and CBZ-GTA cocrystals where the coformer is 
known to solubilize the drug substance. Correlations for organic solvents are significantly 
better than aqueous samples.  The thermodynamic ideal solubilities seem to more 
adequately quantify the relative change between cocrystal and drug (Figure 2.10d) than 
absolute solubility values (Figure 2.10c). 
Solubility predictions have been reported for many polymorph, amorphous, and 
salt forms.  These predictions are often based on the free energy difference between the 
two solid forms.  This difference is typically estimated from fusion data combined in 
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some cases with heat capacity values.  This type of solubility prediction for amorphous 
drugs mostly overestimates the measured solubilities and is complicated by 
transformations to less soluble drug forms.  The majority of measured amorphous 
solubility ratios fell well below the predicted ranges that span about one order of 
magnitude (e.g. 48-455 for polythiazide).  In the case of amorphous glibenclamide the 
measured solubility ratio was 14 and the predicted ratio was 112-1,652 times the 
crystalline solubility.
45
  Polymorphs have shown much closer agreement between 
predicted and actual solubility ratios than these amorphous forms.  This is possibly due to 
minimal free energy differences between polymorphs, as opposed to large differences for 
crystalline and amorphous forms.  Polymorph studies of ten drug substances by 
Pudipeddi and Serajuddin provided calculated solubility ratios in good agreement with 
experimental ratios.
44
  From our limited set, it appears ideal cocrystal solubility ratio 
predictions (Table 2.2 far right column) show better agreement with solution based 
solubility ratios (Table 2.1) than is the case for amorphous systems.  Cocrystals in this 
study also have a weaker correlation than previously cited polymorph studies.  The 
potential for deviations could be high for cocrystals because they can exhibit solution 
complexation or solubilization of drug by other crystal components.  Neither of these is 
applicable to polymorphs. 
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2.4. CONCLUSIONS 
This work developed methods to predict cocrystal solubilities in pure solvent 
from measurement of eutectic concentrations.  These predictions are based on solubility 
product equations that include measured solution concentrations at the eutectic, where 
solid cocrystal and drug are in equilibrium with solution.  Results show that: (1) cocrystal 
solubility increases with the solubility of the cocrystal components, (2) coformer eutectic 
concentrations increase with cocrystal and coformer solubilities for cocrystals of the 
same drug, and (3) coformer solubility about tenfold higher than drug leads to cocrystal 
being more soluble than drug.  While it is generally expected that solubility and melting 
point are correlated, the small series of cocrystals studied show that solvent-solute 
interactions dominate over lattice energies, particularly in water. 
Eutectic concentrations are essential indicators of cocrystal stability and solubility 
and provide useful insights for cocrystal selection.  Furthermore, pharmaceutical 
processes that involve solutions can be designed with an understanding of solubility and 
stability provided by eutectic concentrations.  Solution processes such as cocrystal 
screening, synthesis, manufacture, formulation, and dosing of cocrystal drug products are 
influenced by eutectic concentrations.  The analysis of solution chemistry and phase 
behavior presented enables the calculation of true equilibrium solubility and stability 
through a single measurement of solution concentrations at The eutectic under 
equilibrium conditions. 
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2.6. APPENDIX  
X-ray powder diffraction pattern of the THP-NCT cocrystal. 
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3.  
CHAPTER 3 
COCRYSTAL EUTECTIC CONSTANTS AND 
PREDICTION OF SOLUBILITY BEHAVIOR 
Cocrystals are an emerging class of engineered solid forms and understanding 
their solution phase behavior and solubility is essential to their screening, synthesis, 
characterization, manufacture and utility.1-3  Pharmaceutical cocrystals are important for 
improving the physicochemical and biopharmaceutical properties of drugs without 
changing their chemical structure.  For the first time we are showing that the eutectic 
solution composition of cocrystal components (drug and coformer) is defined by the 
solubility of cocrystal and drug in pure solvent.  The cocrystal to drug solubility ratio ( ) 
is shown to determine the excess eutectic coformer concentration and the eutectic 
constant (Keu), which is the ratio of solution concentrations of cocrystal components at 
the eutectic.  The solution eutectic composition and cocrystal solubility ratio are a 
function of component ionization, complexation, solvent, and stoichiometry.  These 
fundamental relationships can be applied to predict the solubility and thermodynamic 
stability of new cocrystals.  
The importance of eutectic constants has been demonstrated for the enantiomeric 
purification and stability of racemic compounds.4-6  However, the relationships 
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established for racemates are not directly applicable to cocrystals where the components 
differ greatly in structural and chemical properties.  The equilibrium equations that 
specify eutectic points also differ between cocrystals and racemates.  We additionally 
seek to describe complexation and ionization effects on cocrystal eutectic and solubility 
behavior and include the relevant chemical equilibria. 
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3.1. THEORETICAL 
3.1.1. Cocrystal eutectic constants and solution equilibrium 
Three equations and equilibrium constants are considered to predict the cocrystal 
solubility, eutectic composition, and solution complexation from the eutectic of solid 
drug A and cocrystal AyBz where B is coformer: 
 





































where Sdrug, Ksp, and K11 are the drug solubility in pure solvent, cocrystal solubility 
product and complexation constant, respectively. Apparent K11 values have been shown 
as adequate quantitative descriptors of complexation for 2:1 and 1:1 cocrystals 
considered in this chapter.7  Activity coefficients are relatively constant for the dilute 
solutions and concentration ranges considered in this work.  Thermodynamic and 
apparent equilibrium constants for these expressions are proportional such that any non-
ideal mixing of solution species does not necessitate a detailed analysis of activity 
coefficients as a function of composition.  Combining the K11, Ksp and Sdrug gives the 
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For poorly water soluble drugs and more soluble coformers we consider the 
eutectic (E1) for solid drug and cocrystal in equilibrium with solution.  This eutectic is 
most relevant for describing cocrystal solubility, stability, and equilibrium behavior 
relative to the drug.  The eutectic constant (Keu) is the concentration ratio of total 
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( z y )( )
1/z
Sdrug + K11 KspSdrug
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1/z  3.1 
Cocrystal Ksp and drug solubility represent the eutectic concentrations of free components 
and are combined with the prior expression for the concentration of the eutectic complex 
based on K11.  Considerations of ionization for either component can be added to this 
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 3.2 
where [H+] is the hydrogen ion concentration and (Ka) is the dissociation constant for the 
acidic coformer or the conjugate acid of the basic drug.  In this case high pH decreases 
the solubility of basic drug and increases Keu, resulting in an increase of cocrystal 
solubility relative to the drug.  For cases of other acidic or basic components, the reader is 
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referred to recent publications on cocrystal ionization.8-10  Considering the general case of 
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 3.3 
where g and m are the total number of acidic groups for each component and j and q are 
the corresponding total number of basic groups. In this case, the eutectic constant is a 
function of the cocrystal solubility product, drug solubility, and ionization.  This equation 
simplifies to Equation 3.1 when none of the cocrystal components are ionizable 















  3.4 
where the ionization terms in Equation 3.3 for drug and coformer equal drug and coformer, 
respectively: 



































Keu can also be expressed as a function of the cocrystal to drug solubility ratio ( ) in pure 





  3.5 
where   = Scocrystal (Sdrug drug )    and   Scocrystal = Ksp coformer
z
drug
y / yyzz( )y+ z  
For a drug with known solubility, Equation 3.5 allows prediction of cocrystal 
solubility from the eutectic constant or vice versa.  For a 1:1 cocrystal (i.e. y=z=1) Keu 








Therefore, a cocrystal with five times higher solubility has a twenty five times greater 
Keu.  Furthermore, a Keu greater than one indicates the 1:1 cocrystal is more soluble than 
the drug, whereas cocrystals less soluble than the drug have Keu values below one.  The 
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predicted relationship according to Equation 3.5 is presented in Figure 3.1.  The derived 
equations apply to any ionization or temperature condition as long as the appropriate 
equilibria constants and solubilites are taken into consideration. Description of the 
temperature dependence of Keu is presented in Chapter 4. 
 
 
Figure 3.1: Plot of Keu against  from Equation 3.5 for a 1:1 cocrystal.  The color change 
of the line from red to blue is representative of the eutectic concentrations changing from 
mostly drug (low Keu) to mostly coformer (high Keu).   
 
It can also be shown for 1:1 cocrystals that the percent excess coformer at the 
eutectic (xsB) is purely a function of the solubility ratio.  The eutectic ratio of coformer to 
drug minus one divided by the eutectic ratio plus one gives the fraction of excess 
coformer relative to the total solute (drug and coformer) at the eutectic.  Here we 
substitute Keu for  as defined in Equation 3.5 for a 1:1 cocrystal: 






























[coformer]eu + [drug]eu( )
100  3.6 
A 1:1 cocrystal with xsB>0 requires a solution excess of coformer to form 
cocrystal. Conversely, cocrystal is thermodynamically stable relative to drug in pure 
solvent for cases with equal or excess [drug]eu (xsB 0). Additional eutectic considerations 
are recommended for systems that require excess drug in solution to form cocrystal or 
when coformer is less soluble than drug (following section). 
 
3.1.2. Keu values and triangular phase diagrams for cocrystals with multiple solution 
eutectic points 
The relationships presented for the eutectic constants in the previous section apply 
to the eutectic involving solid drug and cocrystal in equilibrium with solution (E1).  A 
second eutectic (E2) can be considered for solid coformer and cocrystal in equilibrium 
with solution. Either eutectic can be used to calculate cocrystal solubility behavior.  
Determining E2 can be useful in instances where coformer is less soluble than drug and 
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therefore excess drug is require to form cocrystal. The three equations and equilibrium 
constants for E2 with solid coformer B and cocrystal AyBz where A is drug are: 
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The same methods presented for E1 were followed for E2 to solve the eutectic constant 
(Keu2) that is the concentration ratio of total coformer to total drug satisfying the 
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This equation is analogous to Equation 3.4 for E1, however the component solubility and 
cocrystal Ksp are inverted. To express the Keu2 in terms of the cocrystal to component 
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Inserting the cocrystal solubility to coformer solubility ratio ( ) in pure solvent using the 







where   = Scocrystal / (Scoformer coformer )    and   Scocrystal = Ksp coformer
z
drug
y / (yyzz )y+ z  
This is comparable to Equation 3.5 for E1 in that the eutectic concentrations are a 







The E1 eutectic involving solid drug and cocrystal is shown in the Figure 3.2 
triangular phase diagram (TPD). The eutectic of solid coformer and cocrystal in 
equilibrium with solution is indicated by E2.  Here we demonstrate the Keu expressions 
for both E1 and E2 as described by the TPD.  For E1 and E2 the ratio of coformer to drug 
in solution is determined by extending a line from pure solvent through the eutectic to the 
base of the diagram to determine the points x1 and x2, respectively.  The eutectic ratio 
(Keu1) of coformer to drug at E1 is then x1 divided by (1-x1).  The same relation holds for 
E2 and x2.  It is apparent from the TPD that saturated solutions with compositions 
between E1 and E2 are thermodynamically stable conditions with respect to cocrystal.  All 
other saturated solutions for which compositions fall outside these two eutectic constants 
will correspond to regions where either pure drug or coformer is stable.  For the case of a 
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1:1 cocrystal this would mean it is stable when suspended in pure solvent (i.e. 
congruently saturating) if E1<1< E2.  Figure 3.2 represents the case where 1<E1< E2, 
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Figure 3.2: Phase diagram of cocrystal (incongruently saturating) indicating the three 
regions saturated with respect to (1) drug, (2) cocrystal, or (3) coformer. The two 
eutectics are represented by E1 and E2 with lines extending from the solvent apex to the 
base to indicate the eutectic solution compositions x1 and x2. Drug and coformer 
solubilities in pure solvent are represented by d and c, respectively. 
 
Because E1 and E2 involve different solid cocrystal components the Keu values 
have an inverse relationship to the cocrystal solubility as described above.  Keu1 for E1 of 
a 1:1 cocrystal is the square of the ratio ( ) of cocrystal solubility to drug solubility in 
pure solvent: 







Similarly for E2 the square of the cocrystal to coformer solubility ratio ( ) in pure solvent 









For 1:1 cocrystals these two eutectic constants define the relationship between cocrystal 
and component solubilities.  These equations apply to 1:1 cocrystals regardless of the 
relative solubilities of the two components in pure solvent.  Keu values from these 
equilibrium expressions and corresponding equations can be used to describe cocrystals 
comprised of a drug that is either equally, more, or less soluble than the coformer. 
 It follows from the analysis of E1 and E2 that similar equations can be derived for 
cocrystals with multiple stoichiometeries, which exhibit additional eutectics 
corresponding to two solid cocrystals with different ratios of the same components in 
equilibrium with solution.  In these cases the eutectic concentrations of the coformer and 
drug will depend on the Ksp values and solubilities of the two cocrystal forms as well as 
the solution ionization and/or complexation.  Equations for other solid phases in 
equilibrium with solution at the different eutectics involving cocrystal are presented in 
Table 3.1.  These equations can be used to determine the cocrystal solubility ratio relative 
the other solid phase from measurement of the appropriate Keu value.  Alternatively, 
  109 
known Ksp or Scocrystal values can be used together with know component solubilities to 
predict the Keu value and therefore the excess amount of a component required in solution 
to stabilize a cocrystal suspension.       
Table 3.1: Relationships of eutectic compositions and cocrystal/component solubilities 
based on ideal behavior for systems with negligible solution complexation. 
Solid phases at eutectic Keu ƒ(Ksp) Keu ƒ(Scocrystal) 




















































3.2. MATERIALS AND METHODS 
3.2.1. Calculation of solubility product from phase solubility diagrams 
Several examples taken from the literature exhibit phase solubility behavior often 
referred to as Bs type behavior illustrated in Figure 3.3.
12  To extract the relevant eutectic 
and solubility product values under equilibrium conditions, solution concentrations at 
equilibrium with the various solid phases were calculated from the original plots that 
reported initial total concentration of B and measured concentration of A at equilibrium.  
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A similar analysis was presented by Zughul and Badwan.13 As shown in Figure 3.3 the 
plateau (region II) of these phase diagrams is removed when plotting the equilibrium 
concentrations of A and B.  The mass balance of this plateau equates to the amount of 
complex precipitated from solution in proportion to the mass of solid component A 
initially added to the sample vial.  For our analysis all points in the descending portion 
(region III) are shifted toward the left most point of the plateau by a magnitude equal to 
the plateau length.  This treatment excises the portion related to the formation and 
precipitation of complex due to the excess component A present based on the 
experimental methods.  What remains is a representation of the equilibrium phase 
solubility diagram (PSD - Figure 3.3b) where the x-axis is solution concentration of 
component B.  This axis previously (Figure 3.3a) indicated the amount of ligand added 
per volume of solvent, which was not the equilibrium concentration of ligand in solution. 
The new equilibrium PSD resembles those previously published from our laboratory 
where one point, the eutectic, separates two regions (1) an ascending portion where drug 
is the stable solid phase and solution complexation produces increasing drug 
concentrations and (2) the descending portion corresponding to Ksp behavior where 
cocrystal is thermodynamically stable. 
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Figure 3.3: a) Typical literature Bs type phase solubility diagram indicating region I 
(complexation), II (conversion and precipitation of excess component A), and III 
(solubility of precipitated complex is decreased with increasing B in solution).  b) 
Conversion of Bs type PSD into equilibrium PSD where the region three is shifted to the 
leftmost end of the region II plateau. Grey segments indicate original portions of the Bs 
PSD that were shifted or removed. Schematic based on Higuchi and Connors data for the 
concentration of 1,2-dimethylbenzoylurea (A) versus catechol (B) in CCl4 at 25
˚C.7 
 
The experimental Keu values extracted are the ratio of concentrations for the left 
most point of the PSD plateau. This point is also labeled as the eutectic in Figure3.3b.  
K11 complexation constants (i.e. stability constants: Kc) were use directly as reported in 
the referenced articles, where they were calculated from region I of the phase diagrams.  
The reported K11 values for complexes from the literature were between 1 and 51 m
-1.  
The stoichiometries of the complexes were also used as reported in the referenced 
literature.  Ksp values of systems that precipitate as 2:1 complexes were determined by 
non-linear regression of the descending portion of the equilibrium PSDs according to 
previously published equations:14   




+ K11 C1Ksp   3.7 
where C1 = (2[B]total + K11




+ K11 C2Ksp   3.8 
where C2 = (2[B]total + K11
2Ksp + 2K11 Ksp[B]total ) / 2  
Both these equations were used to fit experimental data and the equation with the best 
statistical fit was used for determination of Ksp and K11 values.  Solution of these 
equations was preformed using SigmaPlot statistical/graphing software.  These two 
equations were solved with the dynamic fit function based on a minimum of five hundred 
iterations and values were used from the equation that provided the lowest standard error.  
A sample fit for benzodiazine-phenol (2:1) phase diagram determined at controlled pH is 
shown in Figure 3.4.  The Ksp of 1:1 complexes were determined from the linear slope by 
plotting substrate concentration against the inverse of the ligand concentration as 










  3.9 
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All predicted Keu and  values were calculated using Ksp and K11 values 
determined by these methods from experimental phase diagrams unless otherwise noted. 
For those samples that phase solubility diagrams were not determined the predicted Keu 




 as indicated in 
Chapter 2.  K11 values for these samples were either determine from the difference 
between [drug]eu and Sdrug or from measurement of the drug concentration as a function 
of coformer in dilute coformer solutions.  Samples for which these alternative methods 
were used based on eutectic concentrations are noted in Table 3.2 and Appendix 3.6. 
 
Figure 3.4: Ksp determined by nonlinear fit of the PSD for 2,3-diketo-1,2,3,4-
tetrahydroquinoxaline and phenol.  The solid line represents the best fit from Equations 
3.7 and 3.8 corresponding to Ksp = 8.08x10
-8M3(±4.29x10-9 SE) and K11 = 1.6M
-1. Dotted 
lines represent the 95th percent confidence interval based on the standard error.  Data 
taken from reference 16. 
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3.2.2. High performance liquid chromatography (HPLC) 
Solution concentrations of drug and ligand were analyzed by Waters HPLC 
(Milford, MA) equipped with a UV/Vis spectrometer detector. A C18 Atlantis column 
(5 m, 4.6 x 250mm; Waters, Milford, MA) at ambient temperature was used to separate 
the drug and the ligand.  A gradient method with a water, methanol, and trifluoroacetic 
acid mobile phase was used with a flow rate of 1mL/min.  Sample injection volume was 
20 L.  Absorbance of the drug and ligand analytes was monitored between 210-300nm.  
Empower software from Waters was used to collect and process the data. All 
concentrations are reported in molality (moles solute/kilogram solvent).  
 
3.2.3. X-ray powder diffraction (XRPD) 
XRPD was used to identify crystalline phases after slurrying samples to determine 
cocrystal eutectic concentrations and confirm the proper two solid phases (drug and 
cocrystal) were in equilibrium with the solution. XRPD patterns of solid phases were 
obtained with a Rigaku MiniFlex X-ray diffractometer (Danvers, MA) using Cu K  
radiation (  = 1.5418 Å), a tube voltage of 30 kV, and a tube current of 15 mA. The 
intensities were measured at 2  values from 2° to 30° with a continuous scan rate of 
2.5°/min. Samples, prior to and after slurry reactions, were analyzed by XRPD. Results 
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were compared to diffraction patterns reported in literature or calculated from crystal 
structures published in the Cambridge Structural Database.  
 
3.2.4. Materials 
Anhydrous monoclinic form III carbamazepine (CBZ(III)) was purchased from 
Sigma-Aldrich (99+% purity) and were used as received.  Carbamazepine dihydrate 
(CBZ(D)) was prepared by stirring CBZ(III) in water for at least twenty-four hours. The 
cocrystal ligands nicotinamide (NCT), glutaric acid (GTA), saccharin (SAC), anhydrous 
oxalic acid (OXA), succinic acid (SUC), and salicylic acid (SLC) were purchased from 
Sigma-Aldrich (99+% purity) and used as received.  All crystalline drugs and ligands 
were characterized by X-ray powder diffraction (XRPD) and Raman spectroscopy before 
carrying out experiments.  No impurities in the form of additional peaks were resolved 
during HPLC analysis of solutions containing the drugs or ligands in this study.  Ethanol 
(EtOH), isopropyl alcohol (IPA), and ethyl acetate (EtOAc) were obtained from Fisher 
Scientific and dried using molecular sieves prior to use.  All the cocrystals used for 
solubility studies were precipitated from ligand solutions by adding solid drug according 
to the reaction crystallization method (RCM).17, 18  Cocrystals of CBZ-NCT and CBZ-
SAC throughout the chapter refer to the form I polymorphs.19  
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3.3. RESULTS AND DISCUSSION 
3.3.1. Solution properties of cocrystals and cocrystal components 
More than forty cocrystal and solvent combinations were analyzed to examine the 
general applicability of the derived  relationships.  These cocrystals represent a diverse 
range of solution chemistry with various levels of solution complexation and ionization, 
as well as different crystal stoichiometries and supramolecular interactions.  Cocrystals 
were predominantly studied in aqueous solutions by previously reported methods.11  
Several organic solvents were used as non-ionizing alternatives or to alter component 
solubilities.  Tables 3.2 and 3.3 show the cocrystals analyzed, their components, and the 
range of several critical parameters associated with their solubility and thermodynamic 
stability.  Ksp values were calculated from the descending portion of phase solubility 
diagrams according to published methods, unless otherwise noted.14, 15, 20  Complexation 
constants were also calculated or used as reported in the literature.  Sample calculations 
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Table 3.3: Range of cocrystal and component parameters. 
 Minimum Maximum 
Keu 0.1 270 














Component solubility 5 x 10
-4
 m 10 m 
 
All cocrystals in Table 3.2 demonstrated solubility product behavior and 
measured or reported phase solubility diagrams were used to calculate Ksp values for the 
majority of these samples.  The data used for Group I-V samples to calculate Ksp values is 
shown in Figure 3.5.  Solid lines indicate the predicted solubility behavior for each 
cocrystal based on K11 values and the calculated Ksp from Equations 3.7-3.9. The 
calculated Keu, Ksp and K11 values for these cocrystals are listed in Appendix II along with 
the observed Keu values and plots of the data for each cocrystal studied.  The observed 
eutectic concentrations for group IV cocrystals were determined in Chapter 2 and the 
corresponding Keu values are listed in Appendix 3.6.  For all other cocrystals the point 
corresponding to the maximum drug concentration from the phase solubility diagrams 
(Figure 3.5 or Appendix 3.6) were used as the observed eutectic concentrations for 
determining the observed Keu values. 
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 (a)  
(b)  
Figure 3.5: Phase solubility diagrams for the cocrystals listed in Table 3.2. The solid 
lines represent the predicted solubility behavior based on the calculated Ksp and K11 
values listed in Appendix 3.6. Group I and II samples from Table 3.2 are shown in plots 
(a) and (b), respectively. Data points were taken from references in Table 3.2. 
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(c)  
(d)  
Figure 3.5: Phase solubility diagrams for the cocrystals listed in Table 3.2. The solid 
lines represent the predicted solubility behavior based on the calculated Ksp and K11 
values listed in Appendix 3.6. Group III samples from Table 3.2 are shown in plot (c) and 
IV-V samples are in plot (d). Data points were taken from references in Table 3.2. 
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The Ksp values of several cocrystals from Table 3.2 were not calculated from 
phase solubility diagrams but instead were determined from the eutectic concentrations 




 as indicated in Chapter 2.  For Ksp values determined from the 
eutectic concentrations the corresponding K11 values were also determined if the [drug]eu 
was greater than the Sdrug.  Results of the complexation analysis for carbamazepine 
cocrystals of nicotinamide and glutaric acid in water are shown in the Appendix 3.6.  
Both of these carbamazepine cocrystals exhibit high solubilization of carbamazepine in 
water. K11 values were calculated as described by Higuchi and coworkers.  For 
carbamazepine in water the K11 values were determined to be 7.6 and 3.4 m
-1
 for 
nicotinamide and glutaric acid coformers, respectively. 
 
3.3.2. Validation of solution models and calculated eutectic constants 
Eutectic constants calculated from Equations 3.3 using measured or reported Ksp, 
K11, and Sdrug values are plotted against the observed Keu in Figure 3.6.  It is clear the 
derived relationship holds whereby the eutectic constant is a function of the cocrystal 
solubility across a broad set of cocrystal components, solvents, and pH values.  For a set 
of cocrystals of one drug the most soluble cocrystals have large Keu values for the eutectic 
with cocrystal drug and solution.  High Keu can also correspond to cocrystals of highly 
soluble coformers with low relative drug solubility, as was the case of carbamazepine, 
theophylline, and caffeine cocrystals in Chapter 2.  Therefore, highly soluble cocrystals 
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require a large excess of coformer in solution to establish the eutectic condition where 
cocrystal is thermodynamically stable and to prevent conversion to pure component.  For 
the eutectic concerning drug and cocrystal it is the transformation from cocrystal to drug 
that is prevented by excess coformer.  Depending on the cocrystal and eutectic of interest 
the transformation can be between any number of cocrystal or component solvates, 
hydrates, polymorphs, or different cocrystal stoichiometries.  
Keu values for many of the carbamazepine cocrystals in organic solvents were 
found to be around one or less. In these organic solvents carbamazepine has similar or 
higher solubility than most of the more hydrophilic coformers studied.  The opposite was 
true for aqueous carbamazepine samples and their eutectic constants.  This indicates that 
1:1 cocrystals of poorly water soluble drugs with hydrophilic coformers can be readily 
synthesized or stabilized in organic solvents when Keu  1.  In these solvents cocrystal 
solubility is equal or less than drug in pure solvent (i.e.   1).  In this way, Keu can be 
used to identify conditions for solution processes involving a stable cocrystal phase.  
Considerations of coformer solubility and other eutectics (e.g. solution in equilibrium 
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To describe the deviation of predicted Keu values from observed (Figure 3.6 
dashed line) a linear regression and standard error were calculated.  Statistics for each 
group of cocrystals (Table 3.3) indicate the derived Keu expression predicts the observed 
values accounting for changes in i) cocrystal components, ii) ionization, iii) 
complexation, and iv) solvent for this distribution of cocrystals.  The results emphasize 
that Keu is a critical parameter for describing the cocrystal solubility and solution 
chemistry and Keu is experimentally accessible for high solubility cocrystals that convert 
to pure component(s) in solution.  The Keu predictions show a slightly lower correlation 
when Ksp was estimated from the eutectic coformer concentration and the drug solubility 




).  For these estimations, the drug solubility is used 
to represent the free drug concentration and any solute complexation at the eutectic is 
assumed as negligible relative to the coformer concentration.  Sdrug represents the 
solubility of drug in the absence of coformer. 
Large deviations for carbamazepine cocrystals of glutaric acid and nicotinamide 
in water are a result of inadequate prediction of Keu (Figure 3.6). This may be a 
consequence of large extrapolations between measured and predicted conditions, such as 
high eutectic coformer concentrations or the large change in solution composition.  
Assumptions of the model are not applicable to concentrated solutions and in such cases 
must be extended to include activities, higher complexes and hydrotropic behavior.  
Nicotinamide has been extensively studied for its hydrotropic behavior, aqueous self-
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association/complexation, and stacking arrangements in solution.  The solubilization of 
many hydrophobic drug substances have been demonstrated in aqueous nicotinamide 
solutions.
28-36
  Sanghvi et al. reported the range of solubilization for 11 hydrophobic 
drugs was from 1.3 to ~4000 times in 1.6 molal nicotinamide solutions.  Corresponding 
K11 values were between 0.02 and 172 M-1.35  An inflection was found around 10wt%  
(0.82 molal) nicotinamide above which drug solubilization, water conductivity, and 
surface tension rose more rapidly with increased nicotinamide corresponding to higher 
order complexation between nicotinamide and the drug substances studied.  The 
combined results of several studies of nicotinamide hydrotropic behavior agree with the 
level of solubilization we report for carbamazepine (K11=7.3m-1).32, 35, 36  Our observed 
nicotinamide eutectic concentration (Chapter 2) is 0.86 molal, which is just above the 
inflection observed for these studies of hydrotropic nicotinamide behavior.  
Carbamazepine-nicotinamide has characteristic Ksp behavior (i.e. cocrystal solubility is 
less than drug at high nicotinamide concentrations), however the PSD (Appendix 3.6) 
indicates a linear increase for carbamazepine and cocrystal solubility as a function of the 
nicotinamide concentration.  This behavior is consistent with hydrotropic nicotinamide 
solubilization reported for other drugs.   The causes of carbamazepine solubilization by 
nicotinamide and glutaric acid are the subject of ongoing research.   
A list of possible solution characteristics that could lead to deviation of predicted 
and observed Keu values are provided in Table 3.5.  These factors represent several 
possible situations and are not an exhaustive list.  A complete listing would indicate all 
  126 
parameters that are assumed in the derivation of Keu or were not expressed in equilibrium 
equations I-III.  In some cases, systems that exhibit weak complex formation (low 
complexation constants) at high coformer concentrations can change the solvent 
composition significantly such that it behaves as a solvent component.
12
  This behavior 
can lead to activity coefficients that deviate from unity or are not constant over the range 
of concentrations studied. Additional equilibrium for considering the self-association of a 
known hydrotropic component (B) include: 
 
Bsoln + Bsoln nBsoln  
 
Asoln + nBsoln ABn  soln  
Here component B self associates in solution which would increase Keu values, however a 
second equilibrium could occur where self associated coformer complexes with drug 
substance.  When multiple complexation interactions occur it becomes more difficult to 
predict the expected variance in eutectic concentrations.  Determining the mechanism(s) 
of self-association and corresponding equilibrium constants is beyond the scope of this 
work.  However, based on observed solubilization behavior nicotinamide and glutaric 
acid represent coformers that can increase drug solubility through physicochemical 
changes due to cocrystal formation as well as independent drug solubilization based on 
their self-association or solute-solvent interactions.  These types of coformers offer 
advantages because beyond having strong solid-state interactions that facilitate stable 
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cocrystal formation they also have strong solution interactions, which cause drug 
solubilization.  
Table 3.4: Statistical analysis of observed and calculated Keu with respect to linear 
behavior (dashed line) shown in Figure 3.6. 
 Cocrystals r
2
 standard error 
[a]
 
Group I-III 0.997  0.38 
Group IV 
[b]
 0.993 2.50 
    organic solvents only 0.976 0.24 
    aqueous samples only 0.992 3.13 
    variable pH samples 0.995 2.44 
    Ksp and K11 from phase diagrams 0.996 2.19 
    Ksp from single eutectic 0.926 3.34 
[a]
 The square root of the average squared deviation from the regression line. 
[b]
 Excludes 
aqueous glutaric acid and nicotinamide cocrystals. 
 
Table 3.5: Solubility behaviors that can cause deviation of predicted Keu values from 
ideal behavior as represented in Figure 3.6. 
Positive (higher predicted Keu)  Negative (lower predicted Keu)  
Solute-solute complexation (drug) 
 
Asoln + Asoln nAsoln  
Solute-solute complexation (coformer) 
 
Bsoln + Bsoln nBsoln  
Higher order drug complexation (i.e. 2:1 
drug:coformer) 
 
nAsoln + Bsoln AnBsoln  
Higher order coformer complexation (i.e. 
1:2 drug:coformer) 
 
Asoln + nBsoln ABn  soln  
Nonideal coformer solution behavior: 
coformer>1 as xcoformer 1 
(a / x)coformer = coformer > 1  
Nonideal coformer solution behavior: 
coformer<1 as xcoformer 1 
(a / x)coformer = coformer < 1  
Nonideal drug solution behavior: 
drug <1 as xcoformer 1 
(a / x)drug = drug < 1  
Nonideal drug solution behavior: 
drug>1 as xcoformer 1 
(a / x)drug = drug > 1  
Coformers that disrupt of solvent-solvent 
interactions and cause drug solubilization 
(e.g. hydrotropic coformers) 
Drugs that disrupt of solvent-solvent 
interactions and cause coformer 
solubilization (e.g. hydrotropic drugs)  
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Carbamazepine-saccharin and carbamazepine-salicylic acid cocrystals exemplify 
the relationship presented between excess coformer and the solubility ratio in equation 
3.5 because both have 1:1 stoichiometry and low solution complexation in the solvents 
studied.  For cocrystals with ionizing components it has been reported that aqueous 
solubility and stability are a function of pH.
8, 9, 27, 37
  Since carbamazepine is non-ionizing 
 increases with higher pH values for these cocrystals with acidic ligands.  Figure 3.7a 
and the data listed in Table 3.6 show the excess coformer increases with increasing pH 
values.  The various solubility ratios for different solvents can also change the excess 
coformer at the eutectic point.  The lower solubility of saccharin relative to 
carbamazepine in some organic solvents corresponds to excess eutectic carbamazepine 
concentrations (i.e. negative excess of saccharin).  In these cases  is less than one and 
saturating a solution with cocrystal will not cause conversion to drug. 
The direct relation of Keu and  is shown for carbamazepine cocrystals in Figure 
3.7b.  To emphasize the relationship (Equation 3.5) between the eutectic concentrations 
and the solubility of the crystalline forms in pure solvent the data is presented as the 
observed eutectic ratio of cocrystal components in solution (Keu, y-axis) against the 
solubility ratio of cocrystal and drug ( , x-axis).  Cocrystal solubilities increase relative to 
drug solubility in pure solvent as the [coformer]eu also increases relative to [drug]eu.  
Additionally, it is apparent from Figure 3.7b that comparing cocrystals of the 
same drug, those with low Keu values will have large solubility differences (low slope 
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region in Figure 3.7b).  However, solubility differences between two cocrystals with 
large Keu values will be relatively small (high slope region in Figure 3.7b).  When 
engineering or selecting cocrystals of the same drug for a given solvent system it is 
important to highlight the diminishing return in solubility for improving over already 
high Keu values.  This is even more pronounced for cocrystals with 2:1 or higher 
stoichiometric ratios where Keu is a function of the solubility ratio raised to a higher 
power (Equation 3.5).  
Table 3.6: Observed Keu values and calculated  values for carbamazepine cocrystals 
with acidic ligands in water as a function of pH. 











 2.80 7.62 67.6 97.1 
  2.77 7.38 63.1 96.9 
  2.58 6.03 39.8 95.1 
  2.54 5.79 40.5 95.2 
  2.08 3.72 15.4 87.8 
  1.98 3.42 14.1 86.7 
  1.17 2.17 4.3 62.0 
  1.10 2.33 3.0 85.1 
  1.07 2.11 4.0 60.0 
Salicylic acid 4.9 x10
-7
 4.87 12.10 145.0 98.6 
  4.74 10.40 102.0 98.1 
  4.46 7.63 59.7 96.7 
  1.96 1.46 2.2 36.6 
[a]
 From listed Ksp value and pH using Equation 3.5. 
[b]
 From measurement of solution 
eutectic concentrations. 
  130 
 
Figure 3.7: a) Predicted eutectic coformer excess (Equation 3.5) against observed excess. 
b) Observed Keu plotted against the cocrystal to drug solubility ratio. Curve corresponds 
to Keu =  
2
. The points in a) and b) correspond to carbamazepine cocrystals of salicylic 
acid (triangles-blue) and saccharin (circles-black) at various pHs or in different solvents. 
Solvents indicated in Table 3.2 (superscript is pH).  
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Figure 3.8 presents a flowchart to guide analysis of cocrystal solubility and 
stability. This scheme indicates steps for analyzing cocrystal solution phase including the 
case of ionizing components. The corresponding equations are based on the presented 
eutectic relationships solved in terms of cocrystal Ksp and solubility as well as Keu and . 
 
 
A.     Ksp = [A]total + [A]total (1 drug )( )
y
[B]total + [B]total (1 coformer )( )
z
B.     Scocrystal = Ksp coformer
z
drug
y / yyzzy+ z = z 1y y /zKeu( )
z /(y+ z )
Sdrug drug
 
Figure 3.8: Scheme to determine cocrystal solution phase stability for systems with ideal 
solution behavior and no complexation. 
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3.4. CONCLUSIONS 
We have demonstrated that the eutectic solution excess of a cocrystal component 
is controlled by the relative solubility of the cocrystal and the component in pure solvent.  
When the molecular structure and properties of the components differ it is the solubility 
of the cocrystal and its components (e.g. cocrystal and drug) that determine the solution 
eutectic concentrations.  Differences in cocrystal stoichiometry as well as solubility of the 
components due to ionization and complexation are critical in determining Keu.  
Therefore, cocrystal stability can be altered by solvent selection and pH. 
In summary, eutectic constants are valuable to guide cocrystal selection, synthesis 
and formulation without the materials and time requirements of traditional methods.  Keu 
values explain cocrystal solubility and phase behavior as a function of i) solvent, ii) 
ionization, and iii) solution complexation.  We have demonstrated the applicability of Keu 
toward describing the cocrystal solubility ratio and solution chemistry for a set of more 
than forty cocrystal and solvent combinations.  Equilibrium eutectic measurements can be 
used to predict cocrystal solubility in pure solvent.  
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3.6. APPENDIX 
Table 3.7: Summary data for solution behavior of cocrystals listed in Table 3.2: 

















92 1.5 0.66 ±0.8 0.74 2.6 x10
-2







51 1.2 0.59 ±0.1 0.69 4.0 x10
-2







4.6 1.1 1.0 ±0.4 0.62 1.8 x10
-2







0.5 0.7 0.23 ±0.1 0.19 8.4 x10
-2







14.8 0.6 0.30 ±0.2 0.25 4.6 x10
-2







16.7 7.4 0.67 ±0.1 0.60 1.1 x10
-1







29 8.1 0.61 ±0.1 0.58 1.2 x10
-1







18.4 1.2 0.72 ±0.1 0.32 6.7 x10
-2







8.3 0.5 0.48 ±0.1 0.44 1.9 x10
-2







5.9 0.4 0.30 ±0.2 0.47 1.9 x10
-2







14.2 0.8 0.76 ±0.4 0.86 1.9 x10
-2







8.6 1.3 3.8 ±1.6 4.8 6.7 x10
-3







1.5 0.7 1.3 ±0.6 1.7 6.3 x10
-3







7.3 1.7 7.7 ±7.7 7.5 5.2 x10
-3







3.8 2.0 20.5 ±0.9 20.9 2.2 x10
-3







1.6 1.3 8.3 ±0.7 8.6 2.1 x10
-3







4.2 1.8 15.6 ±0.5 16.0 2.1 x10
-3
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Table 3.7: continued

















4.3 0.9 0.96 ±0.1 0.88 5.9 x10
-2







5.4 1.0 1.2 ±0.2 1.3 4.4 x10
-2







3.4 0.5 0.47 ±0.1 0.45 3.8 x10
-2







9.6 0.7 0.45 ±0.1 0.45 8.9 x10
-2







23 4.5 11.5 ±0.9 11.7 1.4 x10
-3

























- 0.5 0.3 ±0.0 0.3 4.2 x10
-2







- 0.8 0.6 ±0.0 0.6 4.6 x10
-2

























- 1.8 3.2 ±0.1 2.5 5.0 x10
-2







5.7 1.5 1.1 ±0.0 1.5 6.0 x10
-2







1.1 0.7 1.1 ±0.0 1.1 1.3 x10
-1







- 2.1 37 ±11.3 27 4.6 x10
-4







- 2.0 31 ±6.2 35 4.6 x10
-4
















*0.5 2.2 3.1 ±0.1 2.9 1.4 x10
-1
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Table 3.7: continued

















*1.5 4.1 6.4 ±0.3 5.9 5.0 x10
-2







*11.4 2.4 1.4 ±0.2 0.91 4.9 x10
-2

























5.0 1.3 1.0 ±0.1 1.0 5.0 x10
-2







10.7 0.6 0.32 ±0.02 0.26 4.9 x10
-2







- 0.5 0.25 ±0.03 0.25 1.6 x10
-3
* Values calculated from eutectic concentrations as described in methods section 
[a]
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Figure 3.13: Aqueous solubility of carbamazepine as a function of nicotinamide (circles) 
and glutaric acid (triangles) at 25˚C. Dashed lines indicated the slopes used to calculate 
K11 values of 7.3 and 3.4 m
-1
 for nicotinamide and glutaric acid, respectively. 
 
 
Figure 3.14: Aqueous solubility of carbamazepine as a function of nicotinamide at 25˚C.  
Points are shown at or above the eutectic concentration where the solution is the saturated 
with respect to cocrystal (open circles) and below the eutectic (filled circles) where 
carbamazepine is saturated. 
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Sample calculation of predicted and observed Keu: 
Predicted eutectic constants were calculated from cocrystal and component solubilities 
using the reported data for the 2,3-diketo-1,2,3,4-tetrahydroquinoxaline and phenol 
system presented in Figure 3.4 and Figure 3.10 plot IV(9). Solution complexation was 
evaluated in the primary literature and a K11 value of 1.6 M
-1
 reported. Equation 1 was 
used to predict the eutectic constant from the cocrystal and component solubilities as well 









y )1/z + K11 KspSdrug
( z y )( )
1/z
Sdrug + K11 KspSdrug
( z y )( )
1/z
 
The eutectic phases are solid cocrystal and benzodiazine in equilibrium with solution, 
therefore we substitute benzodiazine solubility (2.12x10
-3
 M) and cocrystal Ksp which 
gives: 
Keu =
(8.08x10-8M3 (2.12x10-3  M)2 + 1.6M-1 8.08x10-8M3 / 2.12x10-3  M( )
2.12x10-3  M + 1.6M-1 8.08x10-8M3 / 2.12x10-3  M( )
= 8.3  
From reported data the eutectic concentrations of benzodiazine and phenol are 2.2 x10
-3
 
M and 1.9 x10
-2
 M, respectively. This corresponds to an experimental eutectic ratio of 
8.6, compared to 8.3 predicted from the cocrystal and benzodiazine acid solubilities. This 
demonstrates the procedure for determining the eutectic constant from cocrystal and 
component solubilities. Conversely a known eutectic constant, which is a convenient 





THERMODYNAMIC STABILITY OF COCRYSTALS AND 
THE TEMPERATURE DEPENDENCE OF EUTECTICS 
Eutectic constant (Keu) values are important for describing the thermodynamic 
phase stability of cocrystals in solutions.  The measurement of Keu provides information 
for predicting the solubility relation of cocrystal to its components in pure solvent as well 
as the conditions suitable for synthesis by crystallization processes from solutions.  It is 
often necessary to understand the stability of cocrystals in solutions as a function of 
temperature to identify favorable conditions for storage or synthesis and to determine 
their stability at relevant biological conditions (37˚C).  The development of models that 
describe the dependence of Keu on thermodynamic properties of the cocrystal components 
is sought to enable the calculation of cocrystal stability in suspension as a function of 
temperature.  
Pharmaceutical cocrystals that are developed for the improvement of drug 
solubility are typically comprised of components with differing solubilities. These 
components have different thermodynamic properties including melt temperature as well 
as enthalpy and entropy of fusion, solution, and mixing.  Therefore, it is intuitive that the 
solubility of the pure cocrystal components each change to a different extent for an 
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equivalent temperature change.  Furthermore, these temperature changes can lead to 
stability changes for a cocrystal in solution or suspension.  A transition temperature can 
exist for a cocrystal that separates two temperature ranges in which either cocrystal or a 
component is the stable solid phase in equilibrium with a saturated solution of a given 
composition.  The Keu of a 1:1 cocrystal can be less than one for a given temperature 
range, where cocrystal is stable when suspended in pure solvent (i.e. congruently 
saturating), or greater than one and therefore cocrystal is unstable when suspended in 
pure solvent (i.e. incongruently saturating).  In this chapter we seek to describe the effects 




4.1.1. Thermodynamic models for temperature dependence of Sdrug, Ksp, and Keu. 
The equations presented in Chapter 3 for solid drug or cocrystal component (A) 
and solid cocrystal (AB) in equilibrium with a solution can be used to determine the 
temperature dependence of Keu.  These two equilibria have associated constants (Ksp and 
Sdrug) whose temperature dependence can be described by considering the corresponding 
free energy.  For a 1:1 cocrystal the equilibrium constant and free energy change is: 
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G = RT lnKsp = H T S
 
where G, H, and S are the change in cocrystal molar free energy, enthalpy, and 
entropy of solution, respectively.  R is the universal gas constant.  Taking the partial 
derivative with respect to temperature gives the classical thermodynamic relationship 














  4.1 















  4.2 
Both these equations assume constant pressure and that the enthalpy of solution 
( Hs) is independent of temperature (i.e. no change in heat capacity). It has previously 
been shown that heat capacity values have little influence for calculations involving most 
solids that melt below 600 K.1  Furthermore, these relationships are applicable to dilute 
solutions where Raoult’s law (a2=x2) or Henry’s law holds (a2=Kx2) such that the solute 
activity equals its concentration or its concentrtion times a constant value.2  Subtracting 
Equations 4.1 and 4.2 gives the Keu temperature dependence for the eutectic of solid 












AB - 2 Hs
A
RT 2
  4.3 
where Keu = Ksp SA
2  for the eutectic (E1) equilibrium of solution, cocrystal, and drug.  
This relationship describes the temperature dependence of Keu in terms of the enthalpy of 
solution of the drug and cocrystal.  It is apparent from Equation 4.3 that Keu will increase 
with temperature if the cocrystal molar enthalpy of solution is greater than twice that of 
the drug ( Hs
AB>2 Hs
A).  However, Keu will decrease with temperature if the cocrystal 
enthalpy of solution is less than twice that of the drug.  For this case, ( Hs
AB<2 Hs
A) the 
cocrystal at high temperatures will be more stable (lower Keu value) relative to drug when 
suspended in pure solvent.  For graphical determination of the Keu temperature 






AB   4.4 
To calculate the cocrystal Keu at different temperatures Equation 4.4 is integrated 
from temperature T1 to T2 which gives: 





















From this equation, the Keu at T2 can be calculated from the Keu at T1 if the heat of 
solution of drug and cocrystal are known.  The enthalpy of solution values can be directly 
measured from solution calorimetry or calculated from solubility or Ksp measurements as 
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a function of temperature using the van't Hoff relationship. Plots of the natural logarithm 
of drug solubility or cocrystal Ksp against the inverse temperature based on the 
thermodynamic relations in Equations 4.1 and 4.2 give the slope = - Hs/R.   
The thermodynamic relationships for Keu (Equations 4.3-4.5) are specific to the 
eutectic (E1) between cocrystal, drug, and solution. The derivations for several other 
cocrystal eutectics, including those involving coformer or component B as a solid phase 
at the eutectic, are presented in Appendix 4.6.  Eutectic equations for cocrystals of 
different stoichiometries and/or different cocrystal components at the eutectic are 
summarized in Table 4.1. 
The temperature dependence of Keu can also be derived from the fusion properties 
of the cocrystal and its components.  This thermodynamic analysis has been shown for 
the eutectic behavior of a 1:1 cocrystal and is presented in Appendix 4.6.   
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Table 4.1: The eutectic constants in terms of cocrystal and component solubilities listed 
according to the solid phases at the eutectic.  Temperature dependence of Keu is also 
indicated in terms of cocrystal and component enthalpies of solution based on ideal 
solution behavior.  
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4.2. MATERIALS AND METHODS 
4.2.1. Solubility analysis of cocrystal and drug 
Heat of solution values were calculated from solubility measurements of cocrystal 
or drug at four temperatures (4, 23, 37, and 47˚C).  Cocrystal solubility products (Ksp) 
were determined from the eutectic concentrations of both components as described in 
Chapter 2.  Each drug solubility and cocrystal eutectic measurement was carried out a 
minimum of three times.  Solutions were saturated with cocrystal and/or drug by adding 
excess solid and stirring with magnetic bars at controlled temperature.  Temperature was 
controlled using a water bath and jacketed beakers to ±0.5˚C, except for 4˚C samples that 
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were placed in a cold room at controlled temperature (±1˚C).  For drug solubility 
measurements, the solid phase was isolated by centrifugation using tubes with 0.45 m 
filters and analyzed by XRPD to verify no transformations occurred.  Equilibration of 
solid drug and cocrystal phases was reached within 2-5 days and aliquots of solution were 
drawn syringes (0.2 m cellulose of PTFE filter) for measurement of the component 
concentrations by HPLC.  
 
Determination of cocrystal solubility by measuring one component concentration  
For congruently saturating cocrystals alternative methods could be used to 
determine the cocrystal Ksp and Keu using only the measurement of one component in 
equilibrium with cocrystal at various temperatures.  Assuming pure cocrystal of known 
stoichiometry a mass balance can be used to determine the coformer concentration in 
saturated cocrystal solutions.  These concentrations could be used directly to calculate Ksp 
values. For the eutectic involving solid phases of component A and the cocrystal the 
eutectic concentrations could be calculated from Ksp by Ksp=[SA]
y[B]eu
z where SA  is the 
solubility of component A and y and z indicate the cocrystal stoichiometry of the 
component A and B.  The eutectic concentrations are SA (assuming no solubilization of A 
by component B) and [coformer]eu.  A second method to calculate Ksp and Keu values at 
various temperatures is to measure only equilibrium one component equilibrium 
concentrations at different initial concentrations of the second component.  This method 
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is commonly used to construct Bs type phase diagrams where the concentration of the 
varied component reflects the initial concentration (not equilibrium). Chapter 3 indicates 
how Keu and Ksp values are calculated.  For systems where methods of analysis for 
coformer concentrations are not readily available, these alternatives could be useful.  
However, the results in this chapter use direct measurement of both cocrystal component 
concentrations at the eutectic to calculate Ksp and Keu.  
 
4.2.2. High performance liquid chromatography (HPLC) 
Solution concentrations of drug and coformer were analyzed by Waters HPLC 
(Milford, MA) equipped with a UV/Vis spectrometer detector.  A C18 Atlantis column 
(5 m, 4.6 x 250mm; Waters, Milford, MA) at ambient temperature was used to separate 
the drug and the coformer.  A gradient method with a water, methanol, and trifluoroacetic 
acid mobile phase was used with a flow rate of 1mL/min.  Sample injection volumes 
were between 10-40 L.  Absorbance of the drug and coformer analytes was monitored 
between 210-300nm.  Empower software from Waters was used to collect and process 
the data.  
 
4.2.3. X-ray powder diffraction (XRPD) 
XRPD was used to identify crystalline phases in equilibrium with solution.  At the 
eutectic point these were cocrystal and drug. XRPD patterns of solid phases were 
obtained with a Rigaku MiniFlex X-ray diffractometer (Danvers, MA) using Cu K  
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radiation (  = 1.5418 Å), a tube voltage of 30 kV, and a tube current of 15 mA. The 
intensities were measured at 2  values from 2˚ to 30˚ with a continuous scan rate of 
2.5˚/min. Solid phases were analyzed prior to and after equilibration. Results were 
compared to diffraction patterns reported in literature or calculated from crystal structures 
published in the Cambridge Structural Database.3 
 
4.2.4. Materials 
Anhydrous monoclinic form III carbamazepine (CBZ) and sulfamethazine (i.e. 
SMT) were purchased from Sigma-Aldrich (99+% purity) and used as received.  
Carbamazepine dihydrate (CBZ(D)) was prepared by stirring CBZ in water for at least 
twenty-four hours.  Hydrates of theophylline and caffeine were prepared in the same 
manner.  The nicotinamide form I (NCT) and benzoic acid (BA) coformers were obtained 
from Sigma-Aldrich (99+% purity) and used as received.  All crystalline drugs and 
coformers were characterized by XRPD and Raman spectroscopy before carrying out 
experiments.  No impurities in the form of additional peaks were resolved during HPLC 
analysis of solutions containing the drug or coformer in this study at any of the various 
temperature conditions.  Ethanol (EtOH), and ethyl acetate (EtOAc) were obtained from 
Fisher Scientific and dried using molecular sieves prior to use.  All the cocrystal used for 
solubility studies were precipitated from coformer solutions by adding solid drug 
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according to the reaction crystallization method (RCM).4, 5  Cocrystal of carbamazepine-
nicotinamide refers to the form I polymorph.6   
 
4.3. RESULTS AND DISCUSSION 
4.3.1. Carbamazepine-nicotinamide and sulfamethazine-benzoic acid 
The carbamazepine-nicotinamide (CBZ-NCT) cocrystal was previously shown to 
be thermodynamically stable at 25±1˚C when suspended in several organic solvents at all 
nicotinamide concentrations studied.7  The cocrystal had values of Keu 1 in these solvents 
and therefore was thermodynamically stable relative to carbamazepine.  CBZ-NCT 
suspended in water (pure solvent with no coformer added) was shown to be 
thermodynamically unstable at this temperature and had a corresponding Keu>1.  
Sulfamethazine-benzoic acid (SMZ-BA) in water was found to be congruently saturating 
in contrast to CBZ-NCT (incongruent).  
Measurements of the CBZ-NCT Keu in water showed values ranging from 330-
110 between 4 and 47˚C.  Similarly, SMZ-BA in water had Keu values ranging from 0.31 
to 0.15 between 23 and 90˚C.  These CBZ-NCT and SMZ-BA Keu values represent an 
approximate two to three-fold change in Keu over the temperatures studied.  No 
temperature dependence was observed for CBZ-NCT in the two organic solvents.  These 
eutectic concentrations along with the Keu values and drug solubilities are listed in Table 
4.2.  
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The aqueous CBZ-NCT Keu values between 4 and 47˚C are shown in Figure 4.1.  
Based on Equation 4.5 the predicted eutectic behavior using the calculated difference in 
carbamazepine and cocrystal heat of solution values (19.4 kJ/mol) is indicated by the 
solid line.  The derived model based on heat of solution of the solid phases at the eutectic 
fits the observed eutectic data (r2=0.98).  The inverse temperature dependence of Keu is 
observed because temperature increases the solubility of carbamazepine to a greater 
extent than the cocrystal. Keu decreases with temperature since it reflects the solubility 
ratio of the cocrystal to drug in pure solvent.  Cocrystal is less water soluble relative to 
carbamazepine because the carbamazepine solubility increase with temperature is greater 
than the cocrystal increase.   
The CBZ-NCT melt (no solvent) eutectic (CBZ and CBZ-NCT) molar ratio 
(NCT/CBZ) has been reported as approximately 0.7.8  Because the observed and 
predicted Keu is decreasing with temperature (Table 4.2) it is approaching this melt 
eutectic value.  This behavior was demonstrated for one other cocrystal and would be 
interesting to confirm of a wider range of solution temperatures and/or samples.9  The 
melt eutectic could serve as and indication for the direction of change with temperature 
for solution eutectics. 
In each solvent the cocrystals showed agreement between the observed 
temperature dependence of Keu and that calculated from the enthalpy of solution of drug 
and cocrystal (solid phases at eutectic) according to Equation 4.4.  These results 
demonstrate that Equation 4.4 can be used to determine the stability of cocrystal in 
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suspension at various temperatures if the cocrystal and drug enthalpies of solution are 
known.   
To determine the temperature dependent stability of cocrystal in these solvents the 
enthalpy of solution of cocrystal ( Hs
AB) was calculated from the solubility of cocrystal at 
different temperatures.  The same solubility measurements were performed at different 
temperatures for sulfamethazine as well as carbamazepine ( Hs
A) form III in organic 
solvents and dihydrate in water.  These enthalpy and entropy of solution values for drug 
and cocrystal were calculated graphically from Figure 4.4 using the slope as described by 
Equation 4.1.  Table 4.3 lists the slopes and the corresponding enthalpies of solution.  
The calculated enthalpies of solution for drug and cocrystal are positive in each solvent.  
This indicates that dissolution of drug and cocrystal in each solvent are entropy driven 
processes (i.e. positive entropies of solution).  Previously reported aqueous Hs values 
for carbamazepine dihydrate reported by Yoshihashi (25.2 kJ/mol) and Murphy (~24.3-
25.8kJ/mol) are in good agreement with the value determined in this work (24.9 
kJ/mol).10, 11 The measured Hs value (30.7 kJ/mol) for sulfamethazine also agrees with 




Figure 4.1: Eutectic constant of carbamazepine-nicotinamide in water as a function of 




AB=19.4 kJ/mol.  
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Table 4.2: Eutectic concentrations and Keu values for CBZ-NCT and SMZ-BA in 
aqueous and organic solvents. Concentrations are in mmolal.  
 Observed eutectic   
Solvent Keu [drug]eu [coformer]eu Sdrug Temp (˚C) 





















































































Figure 4.2: CBZ-NCT ln Keu against inverse temperature.  Error bars represent the 
standard error for each measured Keu.  Lines represent the best linear fit and the slopes are 
reported in Table 4.3. 
 
 
Figure 4.3: Plot of ln SMZ-BA Keu (open circles), Ksp (filled circles), and SMZ solubility 





Figure 4.4: Plots of ln solubility against inverse temperature for a) CBZ and b) CBZ-
NCT.  Error bars represent the standard error for each measured solubility.  Lines 
represent the best linear fit and the slopes are reported in Table 4.3.  Solvents: ethanol 
(triangles), ethyl acetate (squares), and water (diamonds). a) Water: CBZ(D). 
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Table 4.3: Enthalpy of solution for CBZ, CBZ-NCT, SMZ, and SMZ-BA calculated 
from Figure 4.4 and Figure 4.2 using the slope indicated.  The observed temperature 
dependence of  Keu as well as the predicted value from the enthalpies. All enthalpy values 
















 CBZ CBZ-NCT   




19.4 ±3.4 19.0 ±1.6 
(2285 ±191) 




0.0 ±3.9 1.2 ±0.6 
(152 ±67) 




-0.8 ±2.6 0.6 ±0.6 
(77 ±51) 
 SMZ SMZ-BA   




4.1 ±2.0 9.8 ±0.2 
(1188 ±24) 
 
CBZ-NCT was not stabilized in pure water by increasing the temperature 
however, higher temperature required lower [NCT]eu relative to [CBZ]eu to achieve 
thermodynamic cocrystal stability.  For SMZ-BA suspensions there were no observed 
transformations and the cocrystal was stable in pure water for the temperatures studied 
(23-90˚C).  Equation 4.5 indicates the aqueous transition temperature for CBZ-NCT in 
water (i.e. Keu 1) is approximately >600˚C.  This temperature is above the melting 
temperature of both components. The calculated transition temperature for SMZ-BA in 
water is approximately <-40˚C.  These transition temperatures are calculated from ideal 
solution behavior according to Equation 4.5 and can provide estimates regarding the 
extent cocrystal stability changes relative to a component.  However, properties of the 
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solvent can change significantly with temperature and these calculations are only 
approximations when extrapolating for large temperature changes.   
It is evident from the results (Table 4.3) that the temperature effect on Keu is 
solvent specific.  The aqueous Keu temperature dependence of CBZ-NCT is not 
applicable to other solvents (e.g. ethanol or ethyl acetate) that exhibit different heat of 
solution values for the cocrystal and components.   
The temperature dependence of Keu for a cocrystal-solvent system should not be 
extended to other solvents unless both the cocrystal has ideal solution behavior in both 
solvents.   For different solvents the nature and strength of solution interactions between 
solulte-solute, solvent-solvent, and solute-solvent change and therefore the solute 
activities of cocrystal and its components will exhibit different temperature dependencies.  
The interactions between solute and solvent can be quantified in terms of the enthalpy of 
mixing from known heats of fusion and solution.  For CBZ in water the enthalpy of 
mixing has been reported as approximately -11 kJ/mol at 25˚C.10  From our measured 
Hs values in ethanol and ethyl acetate and published CBZ (III) Hf data the enthalpies 
of mixing are approximately -14 and -17 kJ/mol, respectively.12  Therefore, CBZ has 
stronger solute-solvent interactions in these organic solvents than in water. The predicted 
Keu behavior changes with solvent because the nature and extent of the specific solute-
solvent interactions influences the heats of solution ( Hs= Hf+ Hmix). 
The eutectics analyzed were for cocrystal and drug (E1) in equilibrium with 
solution.  The eutectic with coformer (E2) will also have a temperature dependence based 
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on the cocrystal and coformer enthalpies of solution (Table 4.1).  The aqueous heat of 
solution reported for nicotinamide in water is 19.3 kJ/mol, which gives a calculated 
change in Keu of Hs
AB-2 Hs
B of -8.2.13  This value indicates the E2 Keu value has high 
[NCT]eu relative to [CBZ]eu at high temperature.  Therefore both the E1 and E2 Keu values 
are becoming richer with respect to the minor solution component and the cocrystal phase 
stability region is expanding with temperature. 
 
4.3.2. Observed temperature dependence of other cocrystals and racemates 
Carbamazepine- isonicotinamide and carbamazepine-3-nitrobenzamide cocrystals 
The temperature dependent solubility of (1:1) carbamazepine-isonicotinamide 
form I (CBZ-INA) and its solubility phase behavior in ethanol were studied by ter Horst 
and Cains.14  CBZ-INA form I is indicated as isostructural to CBZ-NCT.  CBZ-INA was 
reported as incongruently saturating in ethanol at 25˚C.  The CBZ-INA Keu is 1.55 
compared to the CBZ-NCT value we report of 1.0.14  Therefore, CBZ-NCT is stable in 
pure ethanol while CBZ-INA is unstable.   
van’t Hoff plots of CBZ-INA and its components were measured to construct an 
isothermal phase diagram at 25˚C.  The authors made no indications regarding a change 
in cocrystal stability as a function temperature.  Using the published enthalpy of solution 
data and the eutectic relationships we established (Equation 4.4) for the eutectic (solid 
cocrystal + CBZ) the calculated value for 2 Hs
A
- Hs
AB is 3.1.  Therefore, the 
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isostructural cocrystals of CBZ-NCT and CBZ-INA have the same temperature 




AB value in Table 4.3 is in agreement (within standard error) with the value 
calculated from reported data for CBZ-INA. It is unlikely that temperature change can be 
used to stabilize the cocrystal (Keu =1) in pure solvent because of the very small to zero 
dependence of Keu on temperature for this system, despite the CBZ-INA Keu value being 
only slightly greater than one.  
  The cocrystal of carbamazepine-3-nitrobenzamide (CBZ-NBA) was also 
reported to be congruently saturating in ethanol between 20 and 40˚C. Keu values 
extracted from the phase solubility diagrams indicate a range of 0.266 to 0.289.15  From 
published van’t Hoff data we calculate the change in 2 Hs
A
- Hs
AB to be 2.8.  The three 
coformers studied in ethanol (NCT, INA, and NBA) all have similar solubilities relative 
to CBZ (Scoformer/SCBZ ~10).  As expected from the component solubility relationships in 
Chapter 2 they are congruently saturating or only slightly more soluble than the CBZ (Keu 
~0.27-1.55).   Each cocrystal also showed very little eutectic concentration dependence 
on temperature in ethanol. 
 
Racemic compounds  
The eutectic concentrations of several racemic compounds have also been shown 
to be dependent on temperature, but in contrast were independent of the solvent.9, 16-18  
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Studies of a investigational phosphodiesterase-4 inhibitor ((+)-3-(2-[(3-cyclopropyloxy-
4-difluromethoxy)-phenyl]-2-[5-(2-(1-hydroxy-1-trifluoromethyl-2,2,2-trifluoro)-ethyl)-
thiazolyl]ethyl)pyridine N-oxide) that was isolated as a racemic compound (referred to as 
1 from here on) showed the same eutectic constant and eutectic temperature dependence 
in both n-butyl acetate and dichloroethane.9 For both solvents the average eutectic 
constant (solution concentration ratio of the two enantiomers at the eutectic) was 0.08 and 
0.06 for 24 and 5˚C, respectively.19  Therefore lower temperatures have a larger range of 
solution compositions where the racemic compound is stable in solution 
(RdlnKeu/d(1/T) -1.8).  Although enthalpies of solution were not measured, these results 
suggest the racemic compound had a higher heat of solution than the pure enantiomers.  
Presumably, the enantiomer Hs values (not measured) are similar for each solvent and 
the Hs of the racemic compound does not change significantly with respect to pure 
enantiomers for an achiral solvent.  Similar results for the temperature dependence were 
shown for racemic malic acid in acetone with slight shifts in Keu values between 20 and 
30˚C.17  In contrast no Keu change was observed for the mandelic acid racemic compound 
in water between 0 and 60˚C.18   
From these examples it was seen that racemic compounds can exhibit eutectic 
concentration changes as a function of temperature but not all systems demonstrate this 
behavior.  If the two enentiomers have the same interaction energies with solvent and if 
heteromeric (S--R) interactions between the two enantiomers are the same as homomeric 
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(S--S or R--R) interactions, then they should have equivalent solvation energies.  
Therefore, it is probable that differences in fusion enthalpies between the racemic 
compound and the pure enenatiomer contribute to heat of solution differences 
( Hsolution= Hsolvation+ Hfusion).  These heat of solution differences between a racemic 
compound and the pure enenatiomer would lead to the Keu changes observed in some 
systems mentioned.  
Enthalpy of fusion values for racemic compounds have been shown to typically 
be greater than the pure enantiomer (i.e. negative enthalpy of formation), which in part 
accounts for the relative stability and formation of the compound.20  The published 
example of the racemic compound (1) showed higher fusion enthalpy, melt temperature, 
and presumably enthalpy of solution than the pure enantiomer.  The corresponding TPD 
shows a larger stable region of (1) at low temperatures.  Based on our review of solubility 
and enthalpy data for many racemates it is anticipated that this will be the predominant 
temperature dependence (if any) for most racemic compounds.  Conversely, cocrystal 
enthalpies and temperatures of fusion have no general pattern relative to their 
components and depend on the solid-state interactions and packing achieved between the 
two components. CBZ-NCT enthalpy and melt are less than the corresponding 
carbamazepine values (data presented in chapter 2).  For other highly soluble low melting 
coformers it is more likely that the temperature and enthalpy of fusion (energy/mole 
cocrystal component) will be below the poorly soluble drug from our literature survey. It 
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could be expected that these cocrystals according to Equation 4.4 would be more stable in 
suspensions relative to the drug at higher temperatures.  This is opposite of reported and 
anticipated racemic compound the behavior, however these observations do not account 
for enthalpy of solvation which are most relevant for cocrystals with 
chemically/structurally different components.    
 
4.3.3. Eutectic temperature dependence and triangular phase diagrams (TPD) 
A schematic TPD shows the behavior for a 1:1 cocrystal with a transition 
temperature between T1 and T2 in Figure 4.5.  The Keu is inversely related to the 
temperature as in the case of CBZ-NCT and SMZ-BA in water.  The heating of solution 
to T2 corresponds to conditions where cocrystal is congruently saturating in pure solvent 
(blue point) and stable over a larger range of solution compositions. It is apparent that the 
stable cocrystal region (central region between the lines extended from the eutectic points 
to the middle of the triangle base) is lager at T2.  Solution compositions between the two 
Keu values are stable at T2 but unstable at T1.  The cocrystal represented is unstable in 
pure solvent at T1 and cocrystal dissolution leads to saturation of the drug indicated by 
the red point. 
The relationship provided in this chapter should be considered in the design of 
solvothermal cocrystal synthetic methods.  When solutions are heated or cooled the 
stability region of the cocrystal defined by the eutectic points can change.  For the system 
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in Figure 4.5, an equimolar solution of the two components at T2 where cocrystal is the 
thermodynamically stable phase can lead to crystallization of the stable drug phase at T1.  
In this example, the drug has the highest heat of solution compared to the 
cocrystal and coformer.  Cocrystals with heat of solution values greater than twice that of 
the drug would exhibit the opposite behavior, where the cocrystal is stable in solution 
below some transition temperature and unstable at higher temperatures.  Therefore it is 
important to know the enthalpy of solution of cocrystal and its pure components so that 
stability can be determined for relevant synthesis, processing, storage, and biological 
conditions. 
 
Figure 4.5: Schematic triangular 1:1 cocrystal phase diagram at two temperatures T1 
(low) and T2 (high).  The two points indicate the composition of solvent with equimolar 
components that is saturated with drug (red/ T1) cocrystal (blue/ T2).  Cocrystal is stable 
in pure solvent at T2 and unstable at T1.  Keu values at each temperature are indicated 
(Keu>1 at T1, Keu<1 at T2). 
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4.4. CONCLUSIONS 
Simple solution calorimetry can be used to calculate the thermodynamic stability 
of cocrystal in solvent as a function the temperature.  Only small amounts of material are 
required to test the enthalpies of solution and construct solution phase diagrams at a 
variety of temperature conditions using the derived thermodynamic equations.  Cocrystal 
Keu values were shown to depend on the enthalpy of solution values of the cocrystal and 
drug.  These enthalpy values are specific to a particular solvent and therefore the 
influence of temperature on cocrystal stability depends on the solvent.  
In water the CBZ-NCT Keu changed significantly from 330 to 110 for the 
temperature range studied (4-47˚C). Keu values decreased with temperatures and therefore 
heated solvent was more favorable for the stability of cocrystal. CBZ-NCT stability in 
ethanol and ethyl acetate showed no temperature dependence over this same temperature 
range.  These results were very similar to solubility phase behavior of other structurally 
similar CBZ cocrystals. The Keu temperature dependence was also determined for SMZ-
BA in water and showed that higher temperatures were more favorable to the stability of 
cocrystal (same trend as CBZ-NCT in water).  Notable differences observed with 
reported racemic compounds were that the temperature dependence, if any, favors 
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Thermodynamic models for Keu from drug and cocrystal fusion properties 
Thermodynamic relationships for the calculation of Hs of the eutectic solid 
phases can be used to determine the temperature dependence of Keu as described in this 
chapter.  An alternative to determining Hs from solution measurements can be achieved 
using Kirchhhoff’s law, which states the energy of a reversible process is equal to a series 
of irreversible processes between the same points.  Therefore, we calculate the 
irreversible enthalpy of fusion ( Hf)T of the individual eutectic solid phases at 
temperature T using the thermodynamic cycle with three processes: (1) heating solid 
phase to  Tm, (2) fusion of solid at Tm, and (3) cooling of liquid to T.  Furthermore, the 
dissolution of a crystalline drug is equivalent to the melting followed by the mixing of the 
liquid with solvent.  The Hs is then calculated as the sum of ( Hf)T and the enthalpy of 
mixing between the solvent and solute ( Hmix): 
Hs = ( H f )T + Hmix   4.6 
For cocrystal (AB) and drug (A) using Kirchhhoff’s law we define: 
( H f
AB )T = ( H f
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 4.8 
where Cp refers to the heat capacity of the liquid or solid as indicated.  From established 
Hmix relationships that account for the pair potential energies (μ) between drug (A), 
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Combining Equations 4.4, 4.6-4.9 the Keu temperature dependence from thermodynamics 
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From this equation it is noted that the enthalpies of fusion will contribute to a positive  
difference between the cocrystal and twice the drug enthalpies of fusion at their Tm will 
be a positive term if the cocrystal has lower melt temperature than the drug.  This 
relationship is made based on the direct correlation between Tm and Hf which has 
previously been reported for a variety of organic systems (i.e Walden rule).23-25  
Similarly, the difference between the cocrystal and twice the drug heat capacities can be 
significant when the temperature studied is far from their Tm values.  While the 
differences in the heat capacities of drug and cocrystal are not predictable, it is apparent 
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that the crystalline form (A or AB) with the higher Tm will have a greater influence if the 
Cp values are similar for A and AB.  Overall heat capacity terms are expected to be low 
relative to he entropy differences between the drug and cocrystal.  The final terms 
describing the contributions of mixing of the liquid cocrystal components with drug or 
solvent are typically small (tens of calories per mole) relative to the other terms. An 







A )TmA ( H f
AB )TmAB   4.11 
This equation is equivalent to 4.4 where the enthalpy of solution is replaced with 
the enthalpy of fusion.  Together these equations indicated the predicted temperature 
dependence of Keu, which can be calculated from either solution (4.4) or fusion (4.11) 
measurements of the equilibrium solid phases. 
Eutectic solid phases: 2:1 cocrystal and drug 

























To determine the Keu temperature dependence we combine the individual heat of solution 






































Eutectic solid phases: 2:1 cocrystal and 1:1 cocrystal 
Two equations for the eutectic equilibrium phases: 
 
A2Bs 2Asoln + Bsoln
Ksp(2:1) = aA
2aB
ABs Asoln + Bsoln
Ksp(1:1) = aAaB
 


















To determine the Keu temperature dependence we combine the individual heat of solution 






































Eutectic solid phases: 1:1 cocrystal and coformer 
























To determine the Keu temperature dependence we combine the individual heat of solution 












































COCRYSTAL ACTIVITY AND SOLVENT EFFECTS ON 
SOLUBILITY AND THERMODYNAMIC STABIILTY 
The cocrystal and component solubility behavior described to this point was 
based on the assumption that the activity coefficients were constant for dilute solution 
and concentration ranges considered.  In this chapter, we seek to estimate cocrystal 
solubility and eutectic behavior in different solvents from knowledge of component 
solubilities in different solvents as well as the measured cocrystal solubility in reference 
solvent.  Component solubilities are used to estimate activity coefficient ratios in 
different solvents.  In the synthesis and screening of pharmaceutical cocrystals from 
solutions, it is important to understand the effect that different solvents have on 
thermodynamic stability and solubility.  The ability to predict the stable conditions for 
cocrystals in various solvents can save considerable time and materials in the 
development and selection process.  
Solubility phase diagrams are a critical resource for the design and scale-up of 
solution cocrystallization processes.  Measuring phase solubility behavior in various 
solvent systems consumes much time and materials.  Several methods have been 
developed to reduce the resources required to generate these diagrams including 
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calorimetric methods or methods to analyze turbidity of known compositions as a 
function of temperature.1-5  These temperature and composition data are then used to 
calculate the isothermal solubility phase diagrams.  It has also been shown that isothermal 
equilibrium measurements of only the eutectic points can also be used to calculate 
cocrystal solubility phase behavior.6, 7  Despite these contributions it still requires 
considerable resources and time to analyze various solvent systems for the design and 
selection of solvent and composition for solution processes to synthesize cocrystals.  The 
objectives of this study are to (1) quantify the activity of a series of cocrystals with 
different physicochemical properties from their ideal solubility values and (2) predict 
cocrystal solution phase stability in different solvents from activity differences of the 
cocrystal components.  To test these estimations cocrystals of carbamazepine and 




5.1.1. Ideal cocrystal solubility and activity 
Melting temperatures and enthalpies of pharmaceutical crystals have found 
prevalent utility as indicators of ideal solubility.  These are readily measurable properties 
associated with the crystal lattice energy that must be overcome for dissolution to occur.  
Among structurally similar pharmaceutical crystalline drug substances, those with high 
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melt temperatures are generally recognized to possess lower solubility.8, 9  Equation 5.1 is 
a fundamental and common thermodynamic model for the relation between solubility and 
melt properties.9  For an ideal solution the solubility, XA
id (mole fraction) is a function of 











with    H f Hs
id
  5.1 
where Hs and Hf are the enthalpies of solution and fusion, respectively.  R is the 
universal gas constant and Tm is the cocrystal melting temperature. The ideal solubility 
product (Ksp
id) of a saturated cocrystal solution can also be calculated from Equation 5.1.  
For a 1:1 cocrystal Ksp
id=(XAB
id)2. 
The two main assumptions in Equation 5.1 are that enthalpy of fusion is 
temperature independent (i.e. heat capacity is zero) and is approximately equal to the 
ideal enthalpy of solution.  More involved expressions have been derived to address these 
assumptions by including additional thermodynamic parameters such as solute heat 
capacity. The equation 5.1 approximation of ideal solubility, often regarded as an upper 
solubility limit, provides a good comparison for experimental cocrystal solubilities.8  For 
an ideal solution the cocrystal activity coefficient is defined as unity. The cocrystal 
activity coefficient ( AB) for the saturated solution can be calculated from the difference 
between the ideal (XAB
id) and observed (XAB) cocrystal solubilities. 
ln AB = ln XAB
id ln XAB   5.2 
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ln AB   5.3 
The activity coefficient of a cocrystal in the saturated solution can be calculated from 
Equation 5.3 using the observed solubility (XAB) and the ideal solubility (XAB
id) from 
thermal analysis. Equation 5.3 enables the quantification of the two independent factors 
(crystallinity and solvation) that determine the solubility of cocrystals.  This relationship 
between cocrystal solubility and stability can be examined based on the effect of the 
solvent.  Similar equations can be derived for the solubility of the cocrystal components.   
It is apparent from these equations that cocrystals can alter drug solubility by both 
changing interactions of the crystalline solid (ideal solubility) and the solvation properties 
(activity coefficient).  Other methods for improving drug solubility such as cosolvents, 
additives or surfactants affect only the solvation or activity coefficient.10-12  Because 
cocrystals offer the potential to alter the solid-state contribution of the crystal lattice 
toward solubility they can supplement other solvation approaches. 
 
5.1.2.  Ksp and Keu predictions for different solvents 
If thermal properties are not readily available or measurable it is possible to use a 
measured solubility product in a reference solvent and the component solubilities to 
estimate the cocrystal solubility product in a different solvent.   First we consider the 
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cocrystal solubility product in terms on the component activities (denoted throughout this 









z   5.4 
where a, , and X are the component activities, activity coefficients, and concentrations, 
respectively. The subscript a is used to refer to the Ksp in activity not concentration terms.  
When activity coefficients are assumed to be unity (ideal solution) the cocrystal solubility 
product in terms of component concentrations is: 
Ksp = XA
yXB
z   5.5 
The solubility product of a 1:1 cocrystal in concentration terms for two different solvents 
(s1 and s2) with non-ideal solution behavior can be related by the activity coefficients.  













= Ksp,a   5.6 












  5.7 
Equation 5.7 can be used to calculate the Ksp
s2 from Ksp
s1 when the activity coefficients 
are known at the corresponding component concentrations for the two solvents.  The 
activity coefficients in a saturated component solution can also be calculated from the 
ideal and observed solubilities of each component. Concentrations and activity 
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coefficients that refer to saturated solutions of a pure component are indicated in this 














 are the component ideal solubilities. XA
o and XB
o are the measured 
component solubility values.  Ksp
s2 can be estimated from Ksp
s1 by assuming that the 
activity coefficients of the saturated component solutions are equal to the activity 
coefficients of the saturated cocrystal solution ( A
o
= A and B
o
= B).  From these 
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  5.10 
This equation provides a simple relationship to predict the cocrystal solubility in 
various solvents using only measured component solubilities and the Ksp in one solvent.  
It does not require the determination of activity coefficients or ideal solubility values.  
However, this model assumes that the activity coefficients are constant for all component 
concentrations.  Equation 5.10 uses activity coefficients for saturated component 
solutions (i.e. = o) in place of the actual values for the saturated cocrystal solution and 
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can exhibit deviations when the concentrations of cocrystal components for the cocrystal 
solution is very different from the component solubilities.  This error would be greatest 
for cocrystals with large thermodynamic solubility differences relative to one or more of 
the components.  Also, it is assumed for Equation 5.10 that the solutions are sufficiently 
dilute and that the presence of the second component B in solution does not alter A and 
vice versa.   
 This same analysis presented for prediction of Ksp values in other solvents 
(Equation 5.10) can be extended to predict Keu values for a different solvent.  Keu,a is the 
activity ratio of the two cocrystal components at the eutectic.   
Keu ,a = aBeu / aAeu = BeuXBeu / AeuXAeu  












Substituting Keu in the Keu,a expression shows the difference between the two solvents are 











= Keu ,a    
By substituting the activity coefficients with solubilities as defined by Equation 5.8 the 





















  5.11 
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  5.12 
Therefore, the eutectic constants in various solvents can be predicted based on the 
solubility of the components in each solvent based on the same assumptions that apply 
for Equation 5.10 just for the case of the eutectic concentrations (i.e. A
o
= Aeu and 
B
o
= Beu).  Changes in Keu with solvent depend on the component solubilities.  Under 
ideal conditions a solvent for which the coformer solubility is high relative to the drug 
should have a large Keu indicating the cocrystal is more soluble relative to the drug 
(Keu= (y+z)/z).  The influence of coformer solubility on cocrystal solubility was observed in 
Chapter 2 and 3.  Assuming ideal conditions any increase in coformer solubility relative 
to the drug, by either changing coformer or solvent, is expected to increase the Keu and 
the cocrystal solubility in pure solvent.  This behavior might not be observed for different 
solvents if o  for either component.   
 These ideal Ksp and Keu predictions apply to solvents where a composition exists 
such that the cocrystal solubility product is less than the product of the component 
activities (1:1 cocrystal).  This criterion establishes that the free energy of cocrystal 
formation is favored (negative) at some composition.  If no such composition exists, for 
the temperature and experimental conditions, then the cocrystal has a higher chemical 
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potential than the components and will not be thermodynamically stable and not exhibit a 
eutectic composition. 
 
5.1.3. Critical coformer activity 
The eutectic coformer activity (aBeu) is the critical concentration required to 
stabilize a cocrystal in contact with a solution or in suspension.  aBeu is important because 
it defines the phase stability regions and is the coformer activity when cocrystal and drug 
are both in equilibrium with solution.  The coformer activity has been calculated by 
dividing the measured eutectic coformer concentration by the solubility of the coformer 
in pure solvent.13  The solute activity coefficient is assumed to be constant in dilute 
solutions and the solute activity is proportional to its concentration.  Therefore, 
estimation of the eutectic coformer concentration for a solvent can be made from the 











  5.13 
where XBeu and XB
o refer to coformer concentration at the cocrystal eutectic and to 




5.2. MATERIALS AND METHODS 
5.2.1. Materials 
Anhydrous monoclinic form III carbamazepine (CBZ(III)) and anhydrous 
theophylline form II (THP) were obtained from Sigma-Aldrich (99+% purity) and used as 
received.14-16  Carbamazepine dihydrate (CBZ(D)) was prepared by stirring CBZ(III) in 
water for at least twenty-four hours.  The hydrate of theophylline was prepared in the 
same manner. Cocrystal coformers nicotinamide (NCT) and saccharin  (SAC) were 
obtained from Sigma-Aldrich (99+% purity) and used as received.  All crystalline drugs 
and coformers were characterized by X-ray powder diffraction (XRPD) and Raman 
spectroscopy before use.  No impurities in the form of additional peaks were resolved 
during HPLC analysis of solutions containing the drug or coformer in this study.  Ethanol 
(EtOH), isopropanol (IPA), and ethyl acetate (EtOAc) were obtained from Fisher 
Scientific and dried using molecular sieves prior to use.  All the cocrystals used for 
solubility studies were precipitated from coformer solutions by adding solid drug 
according to the reaction crystallization method (RCM).17, 18  Cocrystals of 
carbamazepine-saccharin and carbamazepine-nicotinamide refer to the form I 
polymorphs.19   
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5.2.2. Solubility analysis of cocrystal, drug, and coformer 
Cocrystal and components solubilities and eutectic concentrations were measured 
adding excess solid to solvent and stirring with magnetic stir bars for 2-5 days.  The 
solubilities of THP-NCT and its components were measured at 23±1˚C as described in 
Chapter 2. Nicotinamide, theophylline, and THP-NCT aqueous solubilities were 
measured under non-ionizing conditions between pH 4 and 7.  The Ksp values of THP-
NCT and CBZ-NCT (water) are listed in Chapter 2, and were calculated from the eutectic 
concentrations.  CBZ-SAC and its components were measured at 25±0.1˚C. Saccharin 
and CBZ-SAC solubilities in water were measured in solutions below pH 1 where 
saccharin is predominantly unionized.  Ksp values of CBZ-SAC and CBZ-NCT (organic 
solvents) are those reported in Chapter 3, and were calculated from multiple points in the 
phase solubility diagram at and above the eutectic coformer concentration.  Solutions 
were sampled using syringes with 0.2μm filters.  Cocrystal component concentrations 
were analyzed by HPLC.  The solid phase(s) of each sample were isolated and analyzed 
by XRPD to ensure no phase transformation occurred.   
 
5.2.3. High performance liquid chromatography (HPLC) 
Solution concentrations of drug and coformer were analyzed by Waters HPLC 
(Milford, MA) equipped with a UV/Vis spectrometer detector. A C18 Atlantis column 
(5 m, 4.6 x 250mm; Waters, Milford, MA) at ambient temperature was used to separate 
192 
the drug and the coformer.  A gradient method with a water, methanol, and trifluoroacetic 
acid mobile phase was used with a flow rate of 1mL/min.  Sample injection volumes 
were between 10-40 L.  Absorbance of the drug and coformer analytes was monitored 
between 210-300nm.  Empower software from Waters was used to collect and process 
the data. All concentrations in this chapter are reported in mole fraction. 
 
5.2.4. X-ray powder diffraction (XRPD) 
XRPD was used to identify crystalline phases in equilibrium with solution.  At the 
eutectic point these phases were cocrystal and drug.  XRPD patterns of solid phases were 
obtained with a Rigaku MiniFlex X-ray diffractometer (Danvers, MA) using Cu K  
radiation (  = 1.5418 Å), a tube voltage of 30 kV, and a tube current of 15 mA. The 
intensities were measured at 2  values from 2° to 30° with a continuous scan rate of 
2.5°/min. Solid phases were analyzed prior to and after equilibration. Results were 
compared to diffraction patterns reported in literature or calculated from crystal structures 
published in the Cambridge Structural Database.20 
 
5.2.5. Differential scanning calorimetry (DSC) 
Crystalline samples of 1-3 mg were analyzed by differential scanning calorimetry 
(DSC) using a TA instrument (Newark, DE) 2910 MDSC system equipped with a 
refrigerated cooling unit. DSC experiments were performed by heating the samples at a 
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rate of 10 K per minute under a dry nitrogen atmosphere. Temperature and enthalpy 
calibration of the instrument was achieved using a high purity indium standard. Hermetic 
aluminum sample pans were used for all measurements. The mean result of three or more 
samples is reported for each substance.  Cocrystal samples for DSC analysis were 
comprised of several large crystals grown by slow partial evaporation of solutions 
containing the components.  These crystals were isolated from solution, washed, and 
characterized by Raman microscopy before being combined to yield an adequate mass for 
DSC analysis. 
 
5.3. RESULTS AND DISCUSSION 
5.3.1. Cocrystal activity from observed and ideal solubility values 
To demonstrate cocrystal activity differences in various solvents the Ksp of 
carbamazepine-saccharin (CBZ-SAC), carbamazepine-nicotinamide  (CBZ-NCT) and 
theophylline-nicotinamide (THP-NCT) cocrystals were measured in four solvent systems. 
Ideal solubility values were calculated for these cocrystals at 25˚C based on the Equation 
5.1.  The melting temperature and enthalpy of fusion for the cocrystals and components 
used in these calculations are listed in Table 5.1.   
These cocrystals represent cases where the melting temperature is either below 
(CBZ-SAC) or between (CBZ-NCT and THP-NCT) the melt temperatures of the 
cocrystal components.  The ideal solubility for the CBZ-SAC and CBZ-NCT is between 
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that of their pure components. The Hf values for these two cocrystals (normalized per 
mole of component) are slightly above their components.  For THP-NCT the ideal 
solubility is above both THP and NCT and the cocrystal Hf is less than either 
component. These cocrystals and components represent a small sample although they 
have different fusion properties and represent a variety of structural and physicochemical 
properties.  
The activity coefficients for CBZ-SAC, CBZ-NCT, and THP-NCT in different 
solvents were calculated from Equation 5.3 using measured solubilities and the ideal 
solubilities (mole fraction) listed in Table 5.1.  The ideal solubility values represent the 
solubility limit imposed by the crystallinity of these solid forms.  It is the maximum 
achievable solubility considering the energy required to break the crystalline structure. 
Interactions between solute-solute, solute-solvent, and solvent-solvent significantly lower 
the solubilities of these components relative to the ideal solubilities in Table 5.1.  This 
solution nonideality is quantified by the activity coefficients.   
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Table 5.1: Fusion properties and ideal solubilities (Equation 5.1) of cocrystals and 
cocrystal components. Solubility and Ksp values are in mole fraction. 
 
Tm (K) Hf (kJ/mol) ideal solubility 
(Ksp
id)[b] 
cocrystal    
carbamazepine-saccharin 450.7 27.5[a] 
 
2.36 x10-2 
 (5.56 x10-4) 








drug    
carbamazepine 465.3 25.6 2.44 x10-2 
theophylline 546.8 29.0 4.89 x10-3 
coformer    
saccharin 502.8 26.9 1.20 x10-2 
nicotinamide 403.8 23.8 8.12 x10-2 
[a]The enthalpy of fusion for cocrystals is normalized by moles of component molecules 
(drug + coformer) per mole of cocrystal. [b] ideal Ksp is the square ideal solubility. 
 
Figure 5.1 shows, for each cocrystal and component, a graphic representation of 
experimental solubility values and the calculated relative contribution of the ideal 
solubility or activity coefficient ( ) in light and dark grey portions, respectively.  The 
ideal solubility portion is constant for each solvent.  This solubility limit is independent 
of the solvent and purely based on the strength of the solid-state crystalline interactions.  
The magnitude of the activity coefficient is different for each solvent.   indicates the 
extent to which specific interactions limit solubility and is independent of the crystal 
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lattice strength.  The highest component  values are observed for CBZ and SAC, which 
are the least soluble in water. The CBZ and SAC solubilities in organic solvents were 
close to the ideal behavior and  values were smaller than the aqueous value.  Both CBZ 
and SAC have lipophilic character and are more soluble in the less polar organic solvents. 
SAC  values in the organic solvents were close to one and the ideal solubility was close 
to the measured solubility. A small deviation was observed for carbamazepine in 
isopropanol, which did not correspond with the polarity of these solvents 
(EtOH>IPA>EtOAc). For NCT in water the  value was positive indicating a higher 
observed solubility relative that the ideal.  NCT is reported to exhibit self-association in 
water and significantly changes the nature of the solvent (i.e. viscosity, conductivity, 
refractive index) at high concentrations.21-23   Figure 5.1 also shows the cocrystal activity 
coefficients and ideal solubilities in each solvent.  CBZ-SAC activity coefficients showed 
a trend similar to that of carbamazepine in these solvents. CBZ-NCT also had a similar 
activity coefficient trend to that observed for CBZ-SAC in these solvents, however the 
activity coefficients were slightly higher in the organic solvents and lower in water.  This 
corresponds to the  values for nicotinamide, which increased in the less polar solvents.  
NCT and THP are more water-soluble than CBZ-SAC or its components.   values for 
THP-NCT and its components in water were lower in each case than CBZ-SAC and its 
components.  Calculated activity coefficients are listed in Table 5.2 along with the 
observed and ideal solubility data for these cocrystals and components. 
197 
 
Figure 5.1: ln solubility for a) CBZ and b) THP c) NCT d) SAC e) CBZ-SAC f) CBZ-
NCT g) THP-NCT in water, ethanol, isopropanol, and ethyl acetate. The solubilities are 
split into the ideal solubility/crystal fusion (light grey) and activity coefficient/solvation 
(dark grey) components according to Equation 5.3.  The values of each component are 
reported in Table 5.2.  
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Table 5.2: Calculated cocrystal and component  values from observed and ideal 












carbamazepine-saccharin    
ln Ksp -21.9 -12.3 -13.4 -11.6 
ln Ksp ideal -7.50 -7.50 -7.50 -7.5 
-ln  -14.4 -4.8 -5.9 -4.1 
carbamazepine-nicotinamide    
ln Ksp -15.8 -11.0 -12.6 -12.8 
ln Ksp ideal -7.0 -7.0 -7.0 -7.0 
-ln  -8.8 -4.0 -5.6 -5.8 
theophylline-nicotinamide    
ln Ksp -9.6 -11.3 -11.7 -13.4 
ln Ksp ideal -4.0 -4.0 -4.0 -4.0 
-ln  -5.6 -7.3 -7.7 -9.4 
carbamazepine     
ln Ksp -11.5 -5.3 -6.0 -5.5 
ln Ksp ideal -3.7 -3.7 -3.7 -3.7 
-ln  -7.8 -1.6 -2.3 -1.8 
theophylline     
ln Ksp -7.5 -7.1 -8.6 -7.5 
ln Ksp ideal -5.3 -5.3 -5.3 -5.3 
-ln  -2.2 -1.8 -3.3 -2.2 
saccharin     
ln Ksp -8.5 -4.5 -4.6 -4.2 
ln Ksp ideal -4.4 -4.4 -4.4 -4.4 
-ln  -4.1 0.1 -0.2 0.2 
nicotinamide     
ln Ksp -2.1 -3.0 -3.3 -4.6 
ln Ksp ideal -2.5 -2.5 -2.5 -2.5 
-ln  0.4 -0.5 -0.8 -2.1 
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5.3.2. Prediction of cocrystal solubility product and stability in other solvents 
The cocrystal Ksp measured in one solvent can be used to estimate Ksp and Keu 
values in other solvents using Equations 5.10 and 5.12.  Estimations were made for CBZ-
SAC and THP-NCT using cocrystal component solubilities in each of the four solvents to 
account for activity coefficient differences.  The observed solubility product in each 
solvent and the estimated values from three other solvents are listed in Table 5.3.   
For CBZ-SAC and THP-NCT the percent error (average estimated versus 
observed Ksp) was calculated and ranges from 28-187%.  This is similar to other reported 
cocrystal Ksp predictions, which had 27% error.1  Despite the error associated with these 
Ksp estimations, they do provide useful guidance considering the range of solubility 
values is several orders of magnitude.  The Ksp for CBZ-SAC in each of the organic 
solvents (Ksp from 1.6x10-6 to 9.1x10-6) only slightly under estimated the aqueous Ksp.  
The estimated Ksp values ranged from 1.6x10-10 to 2.7x10-10 compared the observed value 
of 3.0x10-10.  These results demonstrate that good estimations can be made for solvents 
where the Ksp values differ by four orders of magnitude (10-6-10-10).  The predictions of 
aqueous CBZ-SAC and THP-NCT  solubilities from organics solubilities showed the best 
agreement with observed values.  This could be from using organic reference solvents 
where cocrystal components exhibit more ideal behavior (low  values).  It has been 
suggested that measuring the Ksp in a reference solvent where both components have a 
high solubility (low ) to can lead to better predictions.1  
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The thermodynamic stability of CBZ-SAC in each solvent was predicted using 
observed Keu values from the other three solvents and the component solubilities 
(Equation 5.12).  Every cocrystal Keu predicted from a different solvent agreed with the 
observed cocrystal stability (Table 5.4).  All the predicted Keu values for water were 
greater than one, which agreed with the observation that CBZ-SAC is unstable 
(incongruently saturating) in water.  The predicted Keu values for the organic solvents 
were all less than one and the cocrystal was observed to be thermodynamically stable 
(congruently saturating) when suspended in these solvents.  
Phase solubility behavior is important when synthesizing cocrystal by solution 
crystallization and these results demonstrate that it is not necessary to construct phase 
diagrams for each solvent.  Solvent can be chosen based on component solubilities using 
Equation 5.12 after measuring the cocrystal Ksp or Keu in one solvent.  If a solvent of 
interest has an estimated Keu value close to one (for 1:1 cocrystal), a direct measurement 
of the Keu is reasonable to confirm the stability.  The results presented here and in 
Chapters 3 and 4 show that eutectic constants are useful for estimating the stability and 
solubility behavior of cocrystals and require limited experimental work.  
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Table 5.3: Observed (italics) and estimated Ksp values for a) CBZ-SAC and b) THP-NCT 
cocrystals from Equation 5.10 are listed by row according to solvent. Columns list the 
solvent used for reference in estimating Ksp values for the other solvents. The average 
predicted Ksp from the three solvents is listed with the standard deviation and percent 
error relative to the observed value.  All Ksp and solubility units are mole fraction. 
 predicted and observed Ksp values       













Water 3.0x10-10 1.6x10-10 1.2x10-10 2.7x10-10  9.7x10-6 1.9x10-4 1.9x10-10 7.7x10-11 38 
EtOH 8.8x10-6 4.7x10-6 3.6x10-6 8.0x10-6  5.0x10-3 1.1x10-2 6.8x10-6 2.8x10-6 44 
IPA 3.8x10-6 2.1x10-6 1.6x10-6 3.5x10-6  2.5x10-3 9.5x10-3 3.1x10-6 9.4x10-7 97 
EtOAc 1.0x10-5 5.4x10-6 4.1x10-6 9.1x10-6  4.0x10-3 1.6x10-2 6.5x10-6 3.1x10-6 28 
                   













Water 6.5x10-5 2.0x10-5 8.4x10-5 2.0x10-5  5.6x10-4 1.2x10-1 4.1x10-5 3.7x10-5 36 
EtOH 3.9x10-5 1.2x10-5 5.0x10-5 1.2x10-5  8.3x10-4 4.8x10-2 3.4x10-5 2.0x10-5 174 
IPA 6.4x10-6 2.0x10-6 8.3x10-6 1.9x10-6  1.8x10-4 3.6x10-2 3.5x10-6 2.6x10-6 58 
EtOAc 5.1x10-6 1.6x10-6 6.6x10-6 1.6x10-6  5.5x10-4 9.6x10-3 4.5x10-6 2.6x10-6 187 
 
Table 5.4: Observed (italics) and estimated Keu values for CBZ-SAC from Equation 5.12 
are listed by row according to the solvent. Columns list the solvent used for reference in 
estimating Ksp values for the other solvents. The average predicted Keu from the three 
solvents is listed with the standard deviation. 
 predicted and observed Keu values     








Water 3.29 1.71 1.33 2.88  1.97 0.82 38 
EtOH 0.35 0.19 0.14 0.31  0.27 0.11 44 
IPA 0.60 0.32 0.25 0.55  0.49 0.15 97 
EtOAc 0.62 0.33 0.25 0.56  0.40 0.19 28 
202 
5.4. CONCLUSIONS 
Ksp and Keu are based on the activities of cocrystal components in saturated 
solutions of cocrystal or cocrystal and drug, respectively and can be used to express the 
solubility and thermodynamic stability of cocrystals.  The results demonstrate that 
cocrystal component solubilities could be used to estimate the component activity 
changes in different solvents and to calculate cocrystal solubility and stability based on 
the measured Ksp in one solvent.  The assumption of ideal solution behavior and the use 
of constant activity coefficients for different solution compositions corresponded with 
high error (28-187%) for estimated Ksp and Keu values in four solvents (water, ethanol, 
isopropanol, and ethyl acetate).  Even with the large error of the estimates Keu values the 
observed stability of CBZ-SAC for each of the four solvents had good agreement with the 
estimated stability from the other solvents.  The observed Keu values in solvents where 
CBZ-SAC is congruently saturating successfully predicted incongruent behavior (water) 
and vice versa.  Using cocrystal activity coefficients to make stability predictions can 
save considerable time and materials in solvent selection for synthesis of cocrystals, 
however for nonideal solutions these estimates have large error and are imprecise 
approximations of real behavior. 
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STABILITY AND PHASE BEHAVIOR OF 
CARBAMAZEPINE-SARCOSINE ANHYDRIDE 
Principles of supramolecular chemistry including hydrogen bond interactions as 
well as drug and cofomer structural and geometric considerations have been used to 
successfully engineer many pharmaceutical cocrystals.1-13  More than fifty cocrystal 
forms have been identified for carbamazepine.14  Many of the published carbamazepine 
cocrystals are with carboxylic acid coformers.  Several of these carbamazepine cocrystals 
were discovered by our group using the reaction crystallization method (RCM) to screen 
for new cocrystals where non-stoichiometric solution concentrations of the components 
lead to cocrystal supersaturation and crystallization. Combining supramolecular 
considerations and RCM, this chapter seeks to discover cocrystals of carbamazepine with 
sarcosine anhydride and determine their solution phase behavior.  Poole and Higuchi 
reported the formation of molecular complexes between sarcosine anhydride and more 
than forty various acids, phenols, and alcohols in aqueous solutions.  The majority of the 
solid-state complexes they determined were 2:1 or higher order crystal forms (proton 
donor-sarcosine anhydride).15 Aqueous phase diagrams were presented in Chapter 3 
(Figure 3.11) for several sarcosine anhydride cocrystals to demonstrate the relationship 
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between Keu and cocrystal solubility.  The use of cofomers of amino acids and their 
derivatives (e.g. sarcosine anhydride) is attractive because they could prove to be 
nontoxic and are capable of strong hydrogen bond formation.  From the reported 
sarcosine anhydride complexes, strong interactions were observed with components that 
have an aromatic nucleus and attached electrophilic groups in positions favorable for 
making two point attachments with the nucleophilic carbonyl groups of the sarcosine 
anhydride.15  Carbamazepine is aromatic and has an amide with two hydrogens 
anticipated to form hydrogen bonds with the sarcosine anhydride carbonyl groups (Figure 
6.1).  The established rules of hydrogen bond formation indicate that the most acidic 
hydrogen atoms will form hydrogen bonds in crystal structures.  For carbamazepine these 
are the amide hydrogen atoms.  It was anticipated that these hydrogen atoms would each 
be capable of forming hydrogen bonds with the carbonyl of sarcosine anhydride.  
Furthermore it was anticipated these interactions might be preferred over carbamazepine 
amide-amide homosynthons, which occur in less than ten percent of crystals in the CSD 
that have only amide and acid functionalities.16  
 
 
Figure 6.1: Chemical structure of carbamazepine and sarcosine anhydride. 
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6.1. MATERIALS AND METHODS 
6.1.1. Materials 
Carbamazepine (CBZ) and sarcosine (SAR) anhydride were purchased from 
Sigma Chemical Company (St. Louis, MO).  Chemicals were used as received without 
further purification.  All chemicals were characterized prior to use by X-ray powder 
diffraction (XRPD) and infrared (IR) spectroscopy. XRPD of carbamazepine agreed with 
the Cambridge Structural Database (CSD) simulated X-ray pattern of form III monoclinic 
CBZ (CSD refcode: CBMZPN01).16   
 
6.1.2. Cocrystal synthesis and screening 
The synthesis and screening of CBZ-SAR cocrystals was preformed by several 
methods including RCM, partial solvent evaporation, grinding, or solvent drop grinding.  
All RCM and solvent evaporation methods were done at 25 ±0.5˚C.  A 2:1 cocrystal of 
carbamazepine-sarcosine anhydride (CBZ-SAR) was discovered by completely 
dissolving non-stoichiometric amounts (1:2 mole ratio CBZ:SAR) of the two components 
in acetonitrile and reducing the solvent by half through evaporation over two days.  The 
1:1 CBZ-SAR cocrystal was isolated from acetonitrile solution  (~1:10 molar ratio 
CBZ:SAR) that was partially evaporated at room temperature.  A second 2:1 cocrystal 
was prepared by RCM from ethanol.  Table 6.1 summarizes the conditions for screening 
and synthesis of CBZ-SAR cocrystals. 
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Table 6.1: Screening and synthesis methods and conditions for CBZ-SAR cocrystal.  All 
solution methods were done at 25˚C. Solvents are acetonitrile (ACN) and ethanol 
(EtOH). 
 
6.1.3. Eutectic concentrations of drug and coformer 
Drug and cocrystal solubilities as well as eutectic concentrations were measured 
using solutions that were saturated with drug and/or cocrystal by adding excess solid and 
stirring with magnetic bars at controlled temperature for 2-5 days.  Temperature was 
controlled using a water bath and jacketed beakers set at 25±0.5˚C.  Solid drug and/or 
cocrystal phases were equilibrated with solution for 2-5 days and aliquots of solution 
were drawn using syringes with 0.2 m cellulose filters for measurement of the 
component concentrations by HPLC.  The solid phase(s) of each sample were isolated 
and analyzed by XRPD to confirm solid phase(s) at equilibrium.  The full method for the 
determination of eutectic constants is described in chapter 2. 
Cocrystal RCM solvent 
(amount of 
components added) 










(CBZ 30-50mg/g + 
SAR 50-60mg/g) 
- 
1:1 CBZ-SAR  ACN 
(CBZ 40-100 mg/g 
+SAR 80-120mg/g) 
EtOH 
(CBZ 40mg/g +SAR 
40-60mg/g) 
ACN  
(CBZ 10-30mg/g + 
SAR 100mg/g) 
ACN 
2:1 CBZ-SAR (II) 
 
EtOH  
(CBZ 40mg/g +SAR 
SAR 15-35mg/g) 
EtOH 




6.1.4. High performance liquid chromatography (HPLC) 
Solution concentrations of drug and coformer were analyzed by Waters HPLC 
(Milford, MA) equipped with a UV/Vis spectrometer detector. A C18 Atlantis column 
(5 m, 4.6 x 250mm; Waters, Milford, MA) at ambient temperature was used to separate 
the drug and the coformer.  A gradient method with a water, methanol, and trifluoroacetic 
acid mobile phase was used with a flow rate of 1mL/min.  Sample injection volumes 
were between 10-40 L.  Absorbance of the drug and coformer analytes was monitored 
between 210-300nm.  Empower software from Waters was used to collect and process 
the data.  All concentrations in this chapter are reported in molal units unless otherwise 
noted.  The stoichiometry of the sarcosine anhydride cocrystals was initially determined 
by completely dissolving 3-5mg of each cocrystal in ~2 ml methanol and analyzing the 
solution concentration ratios by HPLC. 
 
6.1.5. X-ray diffraction 
Single crystal 
Single crystal X-ray diffraction data for the cocrystal was collected on a Bruker 
SMART APEX CCD-based X-ray diffractometer (Mo K  radiation,  = 0.71073 Å) 
equipped with a low temperature device. Empirical absorption corrections using 
SADABS were applied. Structure solution and refinement were performed with 
SHELXTL. All non-hydrogen atoms were refined anisotropically with the hydrogen 
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atoms placed in idealized positions except for those involved in hydrogen bonding which 
were allowed to refine isotropically. 
Powder 
XRPD was used to identify crystalline phases in equilibrium with solution.  At the 
eutectic point studied, these phases were 2:1 cocrystal I and CBZ III or two cocrystals 
with different stoichiometry.  XRPD patterns of solid phases were obtained with a Rigaku 
MiniFlex X-ray diffractometer (Danvers, MA) using Cu K  radiation (  = 1.5418 Å), a 
tube voltage of 30 kV, and a tube current of 15 mA.  The intensities were measured at 2  
values from 2˚ to 30˚ with a continuous scan rate of 2.5˚/min.  Solid phases were 
analyzed prior to and after equilibration.  Results were compared to diffraction patterns 
reported in literature or calculated from crystal structures published in the Cambridge 
Structural Database.16 
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6.2. RESULTS AND DISCUSSION 
6.2.1. Crystal structure of 2:1 carbamazepine-sarcosine anhydride 
Single crystal X-ray analysis revealed a 2:1 CBZ-SAR cocrystal, with structural 
features that differ from other known CBZ cocrystals.  This form is referred to as form I 
since another 2:1 cocrystal was discovered.  Examination of the CBZ-SAR form I crystal 
structure shows that it is an outlier relative to the three main branches described by 
Childs et al. in the analysis of 50 CBZ crystal structures.14   The cocrystal does not 
exhibit the ‘translational stack’, ‘inversion cup’ or ‘coformer pairing’ common to the 
majority of CBZ structures.  Only one other reported CBZ cocrystal (CBZ-10,11-
dihydrocarbamazepine) shares the CBZ-SAR space group (CSD refcode: HEMRIB).16  
Figure 6.2 shows the hydrogen bond motif for CBZ-SAR I (2:1).  The common CBZ 
carboxamide dimer is replaced by R4
2 (8)  synthon involving four N-H O hydrogen bonds 
wherein each sarcosine carbonyl group interacts with two CBZ amides.  A second R2
2(8)  
synthon involves the C-H O interaction between the CBZ carbonyl and the SAR ring.  
This C-H O interaction can be considered as a hydrogen bond according to the angle 
and distance (160.1˚ C-H O and 2.47 Å H O).17, 18  Table 6.2 summarizes the 
crystallographic properties of the 2:1 cocrystal.  Simulated and experimental XRPD 





Figure 6.2: Amide-carbonyl heterosynthons in the crystal structure of 2:1 
















Figure 6.3: Supramolecular synthons in the in 2:1 carbamazepine-sarcosine anhydride 
form I crystal structure. Left: R2
2(8) , right: R4
2 (8) . 
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Figure 6.4: Comparison of carbamazepine-sarcosine anhydride cocrystal X-ray patterns 
a) simulated pattern b) experimental XRPD of 2:1 form I.  
Formula 2(C15H12N2O), 
C6H10N2O2 
Formula weight 614.7 
Crystal system orthorhombic 
Space group Pbca 
a (Å) 11.1122(8) 
b (Å) 9.2904(6) 
c (Å) 29.537(2) 
Z 8 
V (Å3) 3049.3 
cal (g cm
-3) 2.678 
T (K) 85(2) 
R-factor 0.0399 
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6.2.2. 1:1 and 2:1 carbamazepine-sarcosine anhydride cocrystals 
Two additional crystal forms of CBZ-SAR were discovered and include a 1:1 
cocrystal and another 2:1 cocrystal referred to as form II.  The stoichiometry of these 
cocrystals was determined by dissolution and HPLC analysis.  XRPDs are shown in 
Figure 6.5.  These two forms were determined not to be solvates based on thermal 
analysis (DSC and TGA) shown in Figure 6.6 and 6.7 with the 2:1 form II.  The 1:1 
cocrystal has a lower melting temperature and a slight endotherm after the melt, which 
could be from 2:1 cocrystal formed during the melt. Figure 6.7 shows no weight loss 
before the melt that would indicate a solvate form. The TGA weight loss had two stages 
after the melt for each cocrystal.  The first and second stages of weight loss are likely 
from chemical degradation of the components after the melt.  Melting points of SAR and 
CBZ are 129 and 191˚C, respectively. 
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Figure 6.5: Comparison of carbamazepine-sarcosine anhydride cocrystal XRPD patterns 




Figure 6.6: DSC of CBZ-SAR cocrystals a) 1:1, b) 2:1 form I and c) 2:1 form II. 
 
 
Figure 6.7: TGA of CBZ-SAR cocrystals a) 1:1 (red), b) 2:1 form I (blue) and c) 2:1 
form II (black) and the approximate weight loss of the first stage after the melt. 
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6.2.3. Phase solubility diagram 
The discovered CBZ-SAR cocrystal forms were stable in different solvents and 
concentration ratios of the components (Table 6.1).  To understand the solubility behavior 
of the CBZ-SAC forms, eutectic constants and phase diagrams were measured in 
acetonitrile. 
RCM in acetonitrile generated the 2:1 form I cocrystal at low SAR concentrations 
and the 1:1 cocrystal in near saturated SAR solutions.  Eutectic points were measured to 
construct the cocrystal phase solubility diagram (Figure 6.8).  These eutectic 
concentrations are listed in Table 6.4.  Saturated solutions with concentration ratios of 
SAR to CBZ between approximately 1 and 3 are thermodynamically stable conditions for 
the 2:1 form I cocrystal.  1:1 cocrystal is stable in saturated solutions with SAR to CBZ 
concentration ratios above approximately 3.  These eutectic values agree with the 
concentration ratios used to produce the 2:1 (1:2 CBZ:SAR) and 1:1 (~1:10 CBZ:SAR) 
cocrystals by partial solvent evaporation.  The two instances where different component 
concentration ratios lead to the formation of these stable cocrystal forms are indicated in 
Figure 6.8 by dotted lines with arrows extending from the x marks. 
Most of the insoluble sarcosine anhydride complexes previously reported and 
listed in Chapter 3 were 2:1 forms discovered at low sarcosine anhydride concentrations.  
1:1 forms were not identified, but if such forms exist they could be expected to form at 
higher SAR concentrations.  For the case of multiple CBZ-SAR cocrystal 
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stoichiometries, the use of high concentrations of the most soluble component (SAR) to 
screen for cocrystals is shown to discover a more soluble cocrystal form (1:1) based on 
the eutectic concentrations and Ksp values in Tables 6.3 and 6.4.  This behavior has also 
been reported for carbamazepine-4-aminobenzoic acid (CBZ-4ABA) in ethanol where 
high concentrations of the more soluble 4-ABD lead to the formation of the more soluble 
(1:1) cocrystal.19   
 
Figure 6.8: Phase solubility diagram of CBZ-SAR in acetonitrile at 25 ±0.5˚C indicating 
the two eutectic points (filled circles). The Ksp of the 2:1 form I cocrystal (blue line) and 
the 1:1 cocrystal (red line) were calculated by fitting Equations 3.6-3.9. Marks (x) 
illustrate concentrations ratios that lead to different cocrystal forms when the volume of 
solvent is reduced.  
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Table 6.3: Eutectic concentrations for CBZ-SAR in acetonitrile. The solubility of 
CBZ(III) in acetonitrile was measured as 0.24 ±.008m. 
 
 
Table 6.4: Cocrystal solubility products for CBZ-SAR in acetonitrile calculated from 




RCM in aqueous (pH<1) saturated sarcosine anhydride solutions did not produce 
any form of the cocrystal.  To determine the cocrystal stability and to measure the 
eutectic concentrations a blend of each of the three cocrystal forms was added to 
solutions saturated with sarcosine anhydride (no CBZ) as well as to saturated solutions of 
CBZ (no SAR).  XRPD analysis of the solid phases at equilibrium after 2 days showed 
only the cocrystal components. The results indicate the components have a lower 
chemical potential in water than any of the cocrystal forms.  
 
 
Eutectic Keu [CBZ]eu (m) [SAR]eu (m) 
CBZ (III) + 2:1 CBZ-SAR (I) 0.8 ±0.1 0.23 ±8 x10-3 0.18 ±2 x10-2 
2:1 (I) + 1:1 CBZ-SAR  2.8 ±0.3 0.14 ±5 x10-3 0.39 ±2 x10-2 
Cocrystal Ksp 
2:1 CBZ-SAR (I) 1.11 x10-2 m3  ±2.1 x10-3 
1:1 CBZ-SAR 3.11 x10-2 m2 ±3.6 x10-3 
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6.3. CONCLUSIONS 
This chapter presents three new cocrystals of carbamazepine-sarcosine anhydride.  
These include two 2:1 cocrystals and a 1:1 cocrystal.  The phase solubility diagram in 
acetonitrile is characterized by a eutectic point with two cocrystal phases (2:1 form I and 
1:1 forms) as well as the eutectic point between 2:1 form I cocrystal and CBZ III, thus the 
2:1 cocrystal was stable at lower coformer concentrations than the 1:1 cocrystal.  The 1:1 
cocrystal is more soluble and requires high sarcosine concentrations to be stable in 
solution.  This behavior emphasizes the eutectic concentrations and solubility 
relationships we have previously reported to determine the cocrystal stability.19-22  The 
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7.  
CHAPTER 7 
HYGROSCOPIC ADDITIVES AND THE MECHANISMS 
BY WHICH MOISTURE GENERATES COCRYSTALS 
The physical and chemical stability of pharmaceutical solids is critically 
dependent on the presence of water.  Solid phase conversions affect the stability, safety, 
purity, and efficacy of the drug substance and drug product.  Pharmaceutical drug 
products may come into contact with water during production and formulation or at any 
point through exposure to humid environmental conditions. Drug products that 
incorporate materials containing water have the potential to transfer it to other 
components whose stability is affected by water.1  
Solid phase transformations present significant problems for pharmaceutical drug 
products when not anticipated during processing and storage. Hydrate formation is a 
common issue in the selection of solid-state drug forms and cocrystals also have the 
potential to form hydrates.  Hydrate formation is associated with a critical water activity 
that defines the activity limit below which the anhydrous form is thermodynamically 
stable.  Phase transformations of pharmaceutical solids that have been shown to depend 
on relative humidity include anhydrous to hydrate, polymorphic, and amorphous to 
crystalline transformations. 2-10  It appears that identifying the mechanisms for cocrystal 
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formation when mixed with hygroscopic additives would be of practical importance if 
cocrystals are to become pharmaceutical products. 
The research reported here is based on the premise that mixtures of cocrystal 
components with hygroscopic additives can lead to cocrystal formation from a solution 
phase when moisture is sorbed.  Earlier reports from our laboratory have shown that 
cocrystal solubility is a function of the cocrystal components in solution and is described 
by solubility product and solution speciation.11-13  Cocrystal solubility decreases as the 
liquid becomes richer in one of the cocrystal components.  The important implication of 
this mechanism is that supersaturation with respect to cocrystal can be generated by 
dissolving nonequivalent amounts of its components.  Supersaturation is dependent on 





  7.1 
If the required supersaturation for cocrystal nucleation is attained then cocrystals can 
form.  Cocrystal transformation rates have been shown to increase with increasing 
solution concentration of the more soluble component.13, 14 
The thermodynamic stability of a cocrystal relative to pure component crystal has 
been shown to vary with the concentration of components in solution.11, 13  Solvents in 
which cocrystal is more soluble than a pure component exhibit a eutectic point where the 
cocrystal solubility is equal to the solubility of the pure component (for 1:1 cocrystal).  At 
this eutectic point both crystalline forms are at equilibrium.  Above the eutectic 
  227 
concentration cocrystal is the thermodynamically stable form.  Rapid transformation of a 
component to cocrystal has been shown in aqueous media for components that readily 
transforms to a hydrate in pure water e.g., carbamazepine (CBZ) to carbamazepine-
nicotinamide (CBZ-NCT) cocrystal.13 
This work seeks to determine if cocrystal formation occurs when cocrystal 
components combined with hygroscopic additives are exposed to conditions where the 
additive sorbs water.  It is hypothesized that dissolution of the cocrystal components in 
the sorbed water can generate supersaturation and result in nucleation of the cocrystal. 
CBZ-NCT was selected from previously reported pharmaceutical cocrystals because (1) 
transformations in aqueous solutions have been observed, (2) the high aqueous solubility 
of NCT relative to CBZ, (3) carbamazepine is known to form hydrates and (4) more than 
40 CBZ cocrystals have been identified.  This chapter presents the results of cocrystal 
formation in ternary mixtures of cocrystal components, comprised of (1) a deliquescent 
additive (sucrose or fructose), and (2) a hygroscopic additive (PVP).  Many additives are 
hygroscopic and sorb some level moisture, but only certain crystalline materials exhibit 
deliquescence and have a deliquescent relative humidity (DRH) above which they 
equilibrate to form solutions that are saturated with respect to the deliquescent substance.  
Although NCT is deliquescent, its DRH is >94% and studies of mixtures with 
hygroscopic polymers were carried out at RH<DRH.  For amorphous hygroscopic 
additives the nature of the interaction can vary significantly based on the chemical and 
physical properties of the material.  For PVP is has been shown that sorption of thirty-
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weight percent water causes a Tg depression of over 150˚C and the loss of glass 
properties at ambient temperatures which corresponds to several orders of magnitude 
increase in molecular mobility.15  It is desirable to identify the mechanisms by which 
water sorption of additives with different solid-state forms (crystalline or amorphous) 
affect cocrystal formation.  Finally, factors that influence the kinetics of phase 
transformations caused by moisture sorption are studied to understand the conditions that 
are most favorable for cocrystal stability.   
 
 
7.1. MATERIALS AND METHODS 
7.1.1. Materials 
All chemicals were obtained from Sigma Chemical Company (St. Louis, MO), 
and were of USP grade.  Chemicals were used as received without further purification.  
All chemicals were characterized prior to use by X-ray powder diffraction (XRPD) and 
infrared (IR) spectroscopy. XRPD of carbamazepine agreed with the Cambridge 
Structural Database (CSD) simulated X-ray pattern of form III monoclinic CBZ (CSD 
refcode: CBMZPN01).16  Carbamazepine dihydrate (CBZ(D)) was prepared by stirring 
CBZ(III) in water for 24-48 hours. Carbamazepine-nicotinamide refers to the form I 
polymorph.17  PVP K12, K30, K40, and K90 were obtained from BASF and stored at 
0%RH in a P2O5 desiccator.  
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All solids were sieved to collect particle size fractions of <45 m, 45-63μm, and 
106-125μm.  Large crystals were hand ground prior to sieving. Samples were annealed 
and characterized again by XRPD and IR prior to using them in these studies. These 
fractions were used in preparing samples to study deliquescence and hygroscopicity by 
gravimetric sorption analysis and cocrystal formation in bulk samples at constant RH. 
The composition of the hygroscopic or deliquescent additives is expressed on a weight 
percent basis unless otherwise specified. 
 
7.1.2. Eutectic concentrations of drug and coformer 
Component solubilities and eutectic concentrations in polymer solutions (PVP 
additive) were measured using solutions that were saturated with cocrystal and/or drug by 
adding excess solid and stirring with magnetic bars at controlled temperature for 2-5 
days. Temperature was controlled using a water bath and jacketed beakers set at 
25±0.1˚C.  Equilibration of solid drug and cocrystal phases was reached within 2-5 days 
and aliquots of solution were drawn with filtered syringes (0.2 m cellulose) for 
measurement of the component concentrations by HPLC.  The solid phase(s) of each 
sample were isolated and analyzed by XRPD to verify saturation with respect to CBZ (D) 
and CBZ-NCT for the eutectic or CBZ (D) for the solubility measurements.   
 
  230 
7.1.3. Moisture sorption of solid mixtures and cocrystal formation 
The effects of the additive deliquescent relative humidity (DRH), storage RH, 
particle size, and the amount of hygroscopic component on the rate of cocrystal formation 
was studied using ternary mixtures of CBZ (III), with NCT and a hygroscopic additive 
(PVP, fructose or sucrose).  NCT is deliquescent at RH >94% (25˚C) or in blends with 
sucrose and fructose at 80% and 55% RH, respectively.20  RH was selected to produce 
conditions above and below the DRHs for the mixtures of cocrystal components with 
sucrose and fructose additives.  For mixtures of cocrystal components with PVP several 
conditions ( 75%RH) were chosen at which NCT would not contribute to the different 
moisture sorption levels.  In these studies an equimolar ratio of cocrystal components 
(CBZ/NCT) was used with the level of additive in the mixture at 0, 25, or 50 wt%.  
Raman or infrared spectroscopy was used for real-time monitoring of cocrystal formation 
and to study cocrystal formation at constant RH and temperature.13, 18  Sample weight 
before and after storage were also monitored to determine the mass of moisture sorbed. 
Desired RH conditions during storage at 25oC were generated in glass desiccators 
with appropriate saturated salt solution: K2CO3•2H2O for 43%, NH4NO3 for 62%, NaCl 
for 75%, KCl for 85%, and K2SO4 for 98%.
19  An aluminum plate with holes was 
suspended above the solution to hold samples and a 1/8th inch thick quartz glass lid was 
used to seal the chamber.  The relative humidity in the chambers was confirmed using a 
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HydroClip SC05 RH probe from Rotronics (Huntington, NY).  Probe accuracy is 
±1.5%RH / ±0.2oC. 
Solid mixtures were stored at 0%RH in P2O5 desiccators and analyzed by XRPD 
and IR prior to introduction into RH chambers. Raman or infrared spectroscopy was used 
to monitor phase transformations in the mixtures.  Raman spectroscopy was used to 
monitor transformation in all studies of CBZ/NCT mixtures with deliquescent additives.  
For these studies mixtures with 30-60mg of the components (particle size fraction 45-
63μm) were contained in Quartz cuvettes and introduced into the RH chambers.    
Infrared spectroscopy was used to monitor all phase transformations of CBZ/NCT 
mixtures with polyvinylpyrrolidone.  Solid mixtures of the components (150mg sieved 
fraction <45 m) were placed in small crystallization dishes and introduced in the RH 
chambers.  Carbamazepine and nicotinamide mixtures (1:1 mole ratio) with PVP (25 or 
50 wt%) were prepared and placed in controlled RH chambers along with equimolar 
binary mixtures of cocrystal components (no PVP) and pure PVP controls. The 
composition and storage conditions were: PVP (K12, K90), wt% PVP (25, 50%), and RH 
(43, 62, 75%).  The samples were analyzed with the Quant2 IR calibration method to 
determine the weight percents of CBZ, NCT, and cocrystal.  Samples were analyzed at 
24h, 48h, 6 and 9 days.   
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7.1.4. Raman Spectroscopy 
Raman spectra of solid phases were collected with a Kaiser Optical Systems, Inc. 
(Ann Arbor, MI), RXN1 Raman spectrometer equipped with a 785 nm laser and a fiber 
optic non-contact probe. Crystallization was monitored in situ in bulk (macroscale) with 
the probe and in microscale using a Leica DMLP (Wetzlar, Germany) Raman 
microscope. Acquisition conditions were optimized so that the spectra collected for bulk 
studies had maximum intensity around 30-40k counts. The spectra collected had a 
spectral resolution of 4 cm-1 and were collected between 100 and 3200 cm-1. A non-
contact fiber optic probe was used to collect Raman spectra through the quartz chamber 
lid.  Spectra were collected frequently over random areas of the sample for several days.  
A time course of the change in spectral features was used to monitor cocrystal formation. 
HoloReact™ software, from Kaiser Optical Systems (Ann Arbor, MI), was used for 
multivariate curve resolution to plot the change in spectral features correlating to 
components and cocrystal. The formation of CBZ-NCT was monitored between 924-
1182cm-1. Samples were promptly analyzed by XRPD and IR once removed from the 
chamber.   
 
7.1.5. Polarized Optical Light Microscopy Studies 
Particles of cocrystal components and hygroscopic additives were placed in 
contact with each other on a slide and introduced into a variable relative humidity 
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microscope stage from Surface Measurement Systems (VGI 2000M. Middlesex, UK). 
For PVP samples the components were mixed with 50wt% of additive and introduced to 
the humidity stage.  This stage provides temperature and humidity control and 
measurement capabilities for samples during optical microscopy. The stage is computer 
controlled and receives a flow of dry nitrogen that is saturated in situ with water to the 
appropriate extent as monitored by internal sensors. Water uptake, deliquescence, 
dissolution, and crystallization were visually monitored with a Leica DMPL polarizing 
optical microscope (Wetzlar, Germany). Images were collected with a Spot Insight 
FireWire 4 Megasample Color Mosaic camera controlled with Spot software (Diagnostics 
Inc, Sterling Heights, MI). Solid phases crystallized were identified by Raman 
microscopy. 
 
7.1.6. Gravimetric Vapor Sorption 
Vapor sorption studies were conducted at 25˚C by dynamic method to determine 
DRH or under constant RH to monitor the progress of moisture sorption towards 
equilibrium moisture content. Both types of gravimetric vapor sorption studies used 
samples of 5-10mg with particle size of all components between 45 and 63μm unless 
otherwise noted.  All studies were done on an SGA-100 symmetrical gravimetric 
analyzer from VTI Corp. (Hialeah, FL).  The instrument uses a microbalance (CI 
Electronics, Wiltshire, UK) to monitor sample weight and a chilled dew point analyzer 
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(Edgetech, Milford, MA) to detect and control humidity in the chamber.  Temperature 
was controlled to within 0.01oC the instrument RH resolution is ±1%.  
 
7.1.7. High performance liquid chromatography (HPLC) 
Solution concentrations of drug and coformer were analyzed by Waters HPLC 
(Milford, MA) equipped with a UV/Vis spectrometer detector. A C18 Atlantis column 
(5 m, 4.6 x 250mm; Waters, Milford, MA) at ambient temperature was used to separate 
the drug and the coformer.  A gradient method with a water, methanol, and trifluoroacetic 
acid mobile phase was used with a flow rate of 1mL/min.  Sample injection volumes 
were between 10-40 L.  Absorbance of the drug and coformer analytes was monitored 
between 210-300nm.  Empower software from Waters was used to collect and process 
the data. All concentrations in this chapter are reported in molal units unless otherwise 
noted. 
 
7.1.8. X-ray powder diffraction (XRPD) 
XRPD was used to identify crystalline phases in equilibrium with solution.  At the 
eutectic point these phases were cocrystal and drug.  XRPD patterns of solid phases were 
obtained with a Rigaku MiniFlex X-ray diffractometer (Danvers, MA) using Cu K  
radiation (  = 1.5418 Å), a tube voltage of 30 kV, and a tube current of 15 mA. The 
intensities were measured at 2  values from 2° to 30° with a continuous scan rate of 
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2.5°/min. Solid phases were analyzed prior to and after equilibration. Results were 
compared to diffraction patterns reported in literature or calculated from crystal structures 
published in the Cambridge Structural Database.16 
 
7.1.9. Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy 
IR spectra of solid phases were collected on a Bruker Vertex 70 FT-IR (Billerica, 
MA) unit equipped with a DTGS detector. Samples were placed on a zinc selenide 
(ZnSe) attenuated total reflectance (ATR) crystal accessory, and 64 scans were collected 
for each sample at a resolution of 4 cm-1 over a wavenumber region of 4000-600 cm-1. 
The Quant2 software in Opus produced a calibration based on the standards of 
components and cocrystal with cocrystal varying from 0 to 100%. The optimized 
validation method as determined by Quant2 focused on the following two regions of 
wavelength: 1600-1750 cm-1 and 1300-1450 cm-1. The validation method also applied the 
vector normalization pre-processing method to obtain the best calibration fit.  
Calibration samples (~75mg) were prepared by mixing an equimolar ratio 
carbamazepine and nicotinamide (sieved particle size <45 m) with 10-90 wt% CBZ-
NCT.  The samples were mixed and compressed (~200 psi) using a carver press to  create 
uniform discs for ATR-IR analysis.  Each standard mixture disc was analyzed three or 
more different regions to characterize the uniformity of the mixtures. The calibration 
curve only included cocrystal fractions from 0 to 60% due to variability seen with the 
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standard mixtures containing high percent cocrystal.  The calibration fit based on this 0 to 
60% cocrystal range is shown in Table 7.1. Each component of the system showed a high 
regression value.  Plots of the validation sample set for each component are presented in 
the Appendix 7.5. 
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7.2. RESULTS AND DISCUSSION 
7.2.1. Microscopy of vapor sorption and cocrystal formation 
Two hygroscopic (PVP K12 and K90) and deliquescent (sucrose) additives were 
studied to establish the mechanism for cocrystal formation during moisture sorption.  
Sucrose is deliquescent and sorbs moisture to form a saturated sucrose solution at 86% 
and in mixtures with NCT the DRH value is lowered to 80% for NCT/sucrose.20  This 
lower DRH for the NCT mixture is because NCT is deliquescent (>94% DRH) and 
combined with sucrose exhibits a eutonic composition.20   PVP is hygroscopic and sorbs 
moisture at a wide range of RH conditions.  Results presented below in Figures 7.1 and 
7.2 show that moisture can generate cocrystals when particulate systems with cocrystal 
components are exposed to conditions where they sorb moisture.  Cocrystal was formed 
in physical mixtures of components during moisture sorption even when carbamazepine 
hydrate formation was possible.   
The mechanism for deliquescence-induced CBZ-NCT formation was studied by 
Raman microscopy using a controlled relative humidity stage at 95%RH and 25˚C.  
Corresponding optical images for a system containing cocrystal components CBZ and 
NCT with crystalline sucrose additive are provided at multiple time points during this 
process in Figure 7.1.  Sucrose deliquesces rapidly over approximately the first seventy 
minutes of exposure to 95% RH and concurrent dissolution of carbamazepine and 
nicotinamide occurs (A-B).  The first appearance of cocrystal is on the surface of a CBZ 
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crystal at about 100 minutes (D).  Cocrystal formation propagates for the remainder of 
the period shown (E-F).   
A physical mixture of CBZ and NCT (1:1 mole ratio, <45 m particle size) with 
50 weight percent PVP K12 was also studied using a controlled relative humidity stage at 
75%RH and 25˚C, as shown in Figure 7.2.  The sorption was facilitated by the 
hygroscopic nature of PVP, not deliquescence, however a similar mechanism of cocrystal 
formation from solution was observed.  The sorption of moisture by PVP created a 
solution (Figure 7.2) in which cocrystal components dissolved and CBZ-NCT nucleation 
and growth occurred from the solution.  Dynamic vapor sorption of mixtures containing 
equal weight percent NCT and PVP were analyzed to confirm that NCT (DRH >94%) did 
not alter the hygroscopic nature of PVP at 75% RH.  Figure 7.3 shows that the sorption 
isotherm of PVP with NCT was very similar to pure PVP.  The percent weight change of 
this PVP/NCT mixture was scaled by the mass fraction of PVP to compare the sorption 
with pure PVP.  The hygroscopicity of the PVP accounts for the moisture sorption of the 
PVP/NCT mixture at 75% RH.  These results indicate that both deliquescent (sucrose) 
and hygroscopic (PVP) additives could cause the dissolution and solution-mediated 
transformation of cocrystal components to cocrystal.   
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Figure 7.1: Optical microscopy images showing moisture sorption, deliquescence, 
dissolution and cocrystallization in CBZ/NCT/sucrose at 25°C and 95%RH. Symbols C, 
N and S represent CBZ, NCT and sucrose respectively. From reference 20. 
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Figure 7.2: Optical microscopy images showing moisture sorption, dissolution and 




Figure 7.3: Vapor sorption isotherm for K40 (triangles), PVP K30 (squares), and 50/50 
weight percent mixture of PVP K30 and NCT (diamonds).  The weight percent change of 
the mixture is scaled by 2x to compare with the pure PVP moisture sorption.   
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7.2.2. Moisture sorption of solid mixtures and cocrystal formation 
Raman and optical microscopy show cocrystal formation from water sorbed by 
PVP and sucrose and these observed transformations were hypothesized to extend to bulk 
samples. The formation of CBZ-NCT in bulk samples (ternary mixtures of CBZ and NCT 
with PVP, sucrose, or fructose) was studied by spectroscopic analysis to monitor factors 
that affect phase changes.  
Samples with deliquescent additives 
Sucrose and fructose are deliquescent materials and both exhibit vapor sorption 
isotherms with sharp inflections at the DRH.  In mixtures with NCT the DRH values are 
80% for NCT/sucrose and 55% for NCT/fructose at 25˚C.20   Moisture sorption can lead 
to cocrystal transformations at conditions above these DRH values.  Mixtures of CBZ and 
NCT with different levels of fructose or sucrose were studied at several RH conditions.   
The progress of cocrystal formation in CBZ/NCT/sugar (fructose or sucrose) 
mixtures at 75% and 85%RH was monitored over a two-day period by Raman 
spectroscopy. The initial composition of sugar in these mixtures was 10%, 20%, or 50%. 
It is evident from Figure 7.4 that deliquescence generates cocrystals.  Significant 
cocrystal formation was observed in CBZ/NCT/sugar mixtures above their DRH, while 
no cocrystal formation was detected in mixtures below their DRH.  For instance, 
cocrystal formation occurred in sucrose and fructose mixtures at 85%RH.  In contrast, the 
samples with sucrose at 75% RH did not form cocrystal during the course of the study 
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because the RH was below their DRH values  (80% for NCT/sucrose mixture).20  The 
control sample without sugar also shows no cocrystal formation at 85% RH.  
The initial rate of transformation was highest for samples with fructose 
(NCT/fructose 55% DRH at 25˚C) at all conditions.20 Comparing these initial 
transformation rates of fructose samples shows that increased weight fractions of fructose 
and higher RH conditions lead to more rapid cocrystal formation.  The rate of 
transformation decreases with time.  Early time points have the highest transformation 
rates.  Lower rates of cocrystal formation for samples with low sugar composition and/or 
stored at low RH conditions may be associated with small volumes of water uptake and 
small domains of supersaturation leading to isolated regions of cocrystal formation in the 
bulk of the sample.  Samples with fructose at 85% RH had higher initial transformation 
rates than sucrose samples for the same level of sugar and RH.  The low DRH of the 
fructose samples corresponds to more rapid moisture sorption when introduced to the 
controlled RH chamber. The data in Figure 7.4 highlights the dependence of cocrystal 
formation rates on the mixture composition and RH. 
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Figure 7.4: Influence of RH and sugar composition on CBZ-NCT cocrystal formation in 
CBZ/NCT/sugar mixtures. Six separate panes corresponding to two relative humidity 
conditions and three different sugar compositions are shown. Each pane has the same 
time and composition axis scaling presented for the top right pane. The maximum of the 
y-axis corresponds to pure cocrystal, while the minimum corresponds to pure 
components. From reference 20. 
  
 
Samples with hygroscopic PVP additives 
PVP sorbs moisture across a wide range of RH conditions unlike the deliquescent 
additives sucrose or fructose.  PVP could cause similar transformations observed in the 
Figure 7.2 at lower relative humidity conditions. For this reason, cocrystal formation 
from PVP mixtures was studied at lower RH conditions (43% and 62%) than the mixtures 
with sucrose and fructose.  The progress of cocrystal formation in CBZ/NCT/PVP 
mixtures at 43%, 62% and 75%RH was monitored over a six-day period by infrared 
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spectroscopy. The initial composition of PVP in these mixtures was 25% or 50% of either 
PVP K12 or K90 that are low and high molecular weight polymer grades, respectively.  
Results for the levels of cocrystal formation are listed in Table 7.2 and the corresponding 
amount of water sorbed for each sample is provided in Table 7.3.  PVP K12 and K90 
samples sorbed within ±1 wt% for pure PVP control samples at each RH.  The average 
wt% value of the two PVP samples over the six days is indicated in the Table 7.3.  
Cocrystal formation was observed under all conditions and is associated with a 3-20% 
weight change due to water sorption.  The highest extent of cocrystal formation was 
observed for CBZ/NCT with 50 wt% PVP K12 at 75%RH.  These conditions resulted in 
88 wt% cocrystal formation at 6 days with 20 wt% moisture sorption.  The lowest extent 
of cocrystal formation (6-14 wt% CBZ-NCT) was with PVP K12 or K90 samples stored 
at 43%RH that sorbed 3 wt% moisture.  Mixtures with PVP K90 exhibited less cocrystal 
formation at all RH levels studied.  Polymer additives have been shown to inhibit the 
formation of CBZ(D) from anhydrous CBZ forms in aqueous solutions.21-23   CBZ(D) 
formation was not observed in the samples with PVP that sorbed moisture. The main 
factors for the amount of cocrystal formed were (1) PVP molecular weight, (2) % of 
PVP, and (3) moisture sorption/RH.  The samples with PVP K12 (low molecular weight) 
showed more cocrystal formation than high molecular weight K90 samples.   
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Table 7.2: CBZ-NCT formation from CBZ/NCT/PVP stored mixtures as function of RH.  
Cocrystal composition was quantified by infrared spectroscopy.  Values indicate the 
weight percent cocrystal formed relative the total weight of the initial cocrystal 
components. 
Chamber 43% RH 62% RH 75% RH 
Time point 24 hr 6 day  24 hr 6 day 24 hr 6 day 
Control (no PVP) 0 2 1 2 0 2 
PVP K12    
50 wt% 26 40 72 77 74 88 
25 wt% 5 26 12 72 46 87 
       
PVP K90    
50 wt% 25 23 20 19 8 25 
25 wt% 5 6 4 5 3 4 
 
Table 7.3: Moisture sorption by PVP K12/K90 observed over six days as function of RH. 
Values at 24 hours were within five percent of the six-day average.  Scaled values 
represent the moisture sorption in the mixtures with CBZ and NCT. 
 
 [a] PVP K12 and K90 showed the same moisture sorption levels (±0.75wt%).  Values 
represent the average for K12 and K90 PVP. 
 
Effect of PVP on solubility and eutectic concentrations 
Solubilities of the components and cocrystal were measured in order to determine 
whether the polymer is affecting kinetic or thermodynamic properties.  The solubility of 
carbamazepine was measured in 10-30 wt% PVP solutions.  CBZ(D) solubility increased 
 % weight change  
RH% pure PVP[a] 50 wt% PVP 25 wt% PVP 
43 12.92 6.46 3.23 
62 26.66 13.33 6.67 
75 39.93 19.97 9.98 
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approximately 20-fold for 30 wt% PVP solutions as shown in Figure 7.5.  Solutions 
containing PVP could also solubilize cocrystal and affect the stability and extent of 
cocrystal formation.   
Eutectic concentrations were measured to determine CBZ-NCT solubility and 
stability in 10wt% PVP aqueous solutions using PVP K12, K30, and K90.  The Keu of 
CBZ-NCT in pure water is higher than all of the eutectics measured in PVP solutions.  
CBZ-NCT eutectic concentrations in water are 0.85 and 5.8x10-3m for NCT and CBZ, 
respectively.  Keu values in 10 wt% PVP solutions ranges from 106-137 (Table 7.4), 
which is below the value of 147 in pure water (Chapters 2 and 3).  This indicates that the 
addition of PVP increases CBZ-NCT stability relative to the drug, and increases the 
supersaturation with respect to CBZ-NCT leading to a higher rate of cocrystal formation.  
Additionally, the Keu values increase with the PVP molecular weight (Figure 7.6a) as a 
result of the increase in the NCT eutectic concentration.  Cocrystal is less soluble in 10 
wt% PVP K12 compared to K90.  In PVP K12 solutions lower NCT concentrations are 
required for cocrystal formation.  These Keu values could account for the higher level of 
cocrystal formation seen in K12 mixtures compared to K90 mixtures at 62 and 75% RH.  
Aqueous solutions with high PVP levels have lower CBZ-NCT Keu values (Table 7.4) 
because the eutectic concentration of CBZ is increased more than NCT (Figure 7.6b-d).  
For solutions of the same PVP wt% the [CBZ]eu is similar, however the low molecular 
weight (K value) polymers have lower [NCT]eu and therefore lower Keu values. 
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Figure 7.5: Aqueous solubility of carbamazepine against wt% PVP. PVP K12 (circles), 
K30 (triangles), and K90 (squares).  K values are proportional to the polymer molecular 
weight.  
 
Table 7.4:  CBZ-NCT Keu values for aqueous solutions with PVP K12, K30, or K90 at 5-




 Keu values 
wt% K12 K30 K90 
5 - - 151±1.4 
10 106±1.8 119±0.7 137±3.5 


























































































































































7.2.3. Discussion of solution-mediated cocrystal formation 
Factors that influence the crystalline phase transformation kinetics are nucleation 
rate, growth rate, and the density and distribution of nucleation sites. Cocrystal nucleation 
and growth rates will depend on supersaturation.  Cocrystal supersaturation is a function 
of the cocrystal Ksp and component concentrations as indicated by Equation 7.1.  
Supersaturation is determined by cocrystal component dissolution , which will be dictated 
by the amount and rate of water uptake.  Non-stoichiometric concentrations of 
components in the sorbed moisture result from unequal component dissolution rates, due 
to different solubilities and/or surface areas. As the solution formed by the sorbed water 
becomes rich in one of the cocrystal components, the cocrystal solubility decreases.  This 
is indicated by region IV in the phase solubility diagram in Figure 7.7. Cocrystal 
formation will be initiated when the critical supersaturation for nucleation is achieved. 
The CBZ and NCT system is particularly interesting since their aqueous solubilities are 
so different.   Due to the higher dissolution rate of the more soluble component (NCT), 
cocrystal nucleation was observed on the surface or in the vicinity of the less soluble 
component (CBZ) in mixtures of components with sucrose (Figure 7.1).  
The interplay between moisture uptake and dissolution determines the liquid 
phase composition, supersaturation and subsequent nucleation. This is shown by the rapid 
initial cocrystal formation rates of CBZ-NCT at both low and high sugar composition 
when stored at RH above DRH.  Low levels of moisture (< 7%) are capable of producing 
the necessary cocrystal supersaturation to initiate nucleation as shown for the 
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transformation to CBZ-NCT in mixtures with 10% sucrose or fructose at 85% RH.  Also 
CBZ/NCT/PVP mixtures with 25% PVP at 43%RH showed cocrystal formation with 
approximately 3% water content. Additives can also influence nucleation by their affects 
on solution viscosity, molecular associations that precede nucleation, and to the extent 
that material surfaces serve as catalysts for nucleation.  The viscosity range of 10% PVP 
aqueous solutions is approximately 30-fold between PVP K12 and K90 (~15 and 450 
mPa*s at 23˚C).
24-26
  The viscosity difference between K12 and K90 becomes great at 
lower water levels and can influence the nucleation and growth kinetics.  It is anticipated 
that higher viscosity as well as changes in the diffusion and molecular interactions of 
cocrystal components and PVP in solution may influence nucleation and growth.  For low 
levels of moisture this would suggest a slower rate of cocrystal formation in PVP K90 
samples.  
  
Figure 7.7: Solubility of cocrystal (SAB) as a function of coformer concentration (B).  
Solubility of pure A is assumed to be independent of coformer concentration.  Eutectic 
concentration and regions of supersaturation and undersaturation are indicated. Cocrystal 
solubility in pure solvent is represented by a filled circle. Dashed arrow indicates 
component concentrations due to unequal dissolution rates of components. 
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Generally one expects the amount of moisture uptake to control the 
transformation rate based on its temporal and spatial distribution.  Low levels of 
hygroscopic additive and low moisture uptake will have the effect of reducing the regions 
of moisture sorption. Consequently, small domains of supersaturation can develop in a 
liquid phase that is not uniformly distributed throughout the sample leading to isolated 
regions of cocrystal formation.   In this case high supersaturation is initially achieved and 
the transformation rate to cocrystal is initially fast, but the rate will slow or even level off 
before extensive conversion.  This mechanism explains the slower rate and lesser extent 
of transformation to CBZ-NCT cocrystal at the lower fructose composition (10%) and 
75%RH. Also the CBZ-NCT formation for PVP samples at low RH (43 and 63%) 
increased in the first 24 hours and had little change for the following 5 days.  
CBZ/NCT/fructose exhibits faster and more extensive cocrystal formation at 20 
and 50% fructose and 85% RH compared to the 10% fructose and 75%RH sample. These 
results clearly indicate that for low fructose composition at low RH, the transformation is 
occurring with relatively low moisture uptake where solute transport tends to be limited 
to small domains of liquid phase.  Faster transformation rates with higher fraction of 
deliquescent additive at RH above DRH were also observed for CBZ/NCT/sucrose.  High 
levels of moisture sorption allow for greater exposure of components to the 
crystallization medium and to larger extent of cocrystal formation during the initial time 
period, provided the kinetics and distribution of moisture sorption maintain adequate 
supersaturation for cocrystal formation. Moisture uptake levels are associated with the 
hygroscopic nature of the mixture components, the amount of hygroscopic or 
deliquescent additive, and the RH. 
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The mechanisms for cocrystal formation reported here are valuable to design 
stable formulations and predict conditions that will result in cocrystal formation.  The 
amount of hygroscopic additive required to prevent or reverse the transformation to 
cocrystal can in principle be estimated if one knows the moisture sorption of the mixture 
at a given composition, temperature and RH, and the eutectic concentrations in the sorbed 
moisture. For example, the coformer eutectic concentration in water at which the 
solubility of the CBZ-NCT cocrystal is equal to the solubility of CBZ dihydrate is around 
0.8m. If as a first approximation it is assumed that additives do not change eutectic 
concentrations, levels of moisture sorption that lead to NCT concentrations above 0.8m 
will favor cocrystal formation and below would favor CBZ(D) and destabilization of the 
cocrystal (Figure 7.7 regions II/IV stable and I/III unstable).
14
  This behavior was also 
shown for several PVP solutions where [NCT]eu was high for K90 and less CBZ-NCT 
formation occurred in these samples (Table 7.2).  In comparison, PVP K12 had a lower 
[NCT]eu and a higher level of cocrystal formation.  
Moisture sorption and deliquescence of multiple component solid systems are a 
complex function of phase composition, relative humidity, and temperature.
27-29
  The 
study presented here has focused on identifying the mechanism by which deliquescence 





This work demonstrates that moisture sorption by hygroscopic additives can lead 
to the formation of cocrystals in physical mixtures.  Carbamazepine-nicotinamide 
cocrystal formed from component mixtures in the presence of PVP and deliquescent 
sugars.  Carbamazepine hydrate was not observed under these conditions.  The 
mechanism of cocrystal formation involved moisture uptake, dissolution of components, 
and cocrystal nucleation and growth.  Microscopic studies of these mixtures showed the 
growth of CBZ-NCT from aqueous solutions produced by moisture sorption of PVP and 
sucrose.  Dissolution can lead to solution compositions above the eutectic concentration 
where cocrystal is the stable phase. Solutions with hygroscopic additives can also effect 
the eutectic concentrations and stability of the cocrystals as was demonstrated for CBZ-
NCT in PVP solutions.  These findings have important implications for the selection of 
additives in pharmaceutical formulations and establishing conditions where cocrystal is 
stable. 
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Figure 7.8: Infrared spectroscopy validation data set for Quant2 calibration.  CBZ-NCT 







CONCLUSIONS AND FUTURE WORK 
This dissertation has focused on the thermodynamic stability and solubility of 
pharmaceutical cocrystals.  The specific goals of this dissertation were to (i) develop 
methods to measure the thermodynamic solubility of metastable cocrystals, (ii) provide 
models that describe the equilibrium phase behavior of cocrystals based on component 
and cocrystal properties, (iii) explain the effect of temperature on cocrystal 
thermodynamic stability, (iv) estimate solubility and stability for different solvents based 
on component activity coefficients and measured cocrystal solubility in one solvent, and 
(v) identify mechanisms by which hygroscopic additives affect the stability of mixtures 
of solid cocrystal components. 
A primary interest in pharmaceutical cocrystals is to improve drug solubility and 
dissolution kinetics and thereby increase drug absorption and bioavailability.  Directly 
measuring the thermodynamic solubility of many cocrystals may be difficult as their high 
solubility can lead to supersaturation and subsequent phase transformations to less 
soluble forms.  The work presented in this thesis shows that cocrystal eutectic points are 
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thermodynamically stable and allow for the measurement of cocrystal solubility and 
stability relative to their components.   
For a three-component system (components A and B and solution) at constant 
temperature and pressure, any solution composition that contains two solid phases in 
equilibrium with solution is a eutectic point (Gibbs phase rule).  Methods were developed 
to measure cocrystal eutectic points (i.e. isothermal invariant point) where a solution is in 
equilibrium with cocrystal and another solid phase (cocrystal component or component 
solvate, different stoichiometry cocrystal, cocrystal solvate).  At the eutectic both solid 
phases are equally stable and for a 1:1 cocrystal these solid phases at the eutectic have the 
same solubility. 
Methods for analysis of eutectic points and cocrystal solubility were presented for 
carbamazepine, theophylline, and caffeine cocrystals in four solvents.  Fundamental 
models were established to calculate the equilibrium constants including the solubility 
product (Ksp) and solubilization from these eutectic measurements. The advantage of 
these methods is that they are accessible and reproducible and they correspond to a 
thermodynamic equilibrium that is a reference point for describing solution phase 
behavior.  For cocrystals of the same drug, it was shown that the solubility of the 
cocrystal is proportional to the eutectic coformer concentration.  This is because a higher 
coformer concentration is required to achieve thermodynamic stability between the 
cocrystal and drug phases.  For carbamazepine cocrystals it was shown that more soluble 
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cocrystals had high eutectic coformer concentrations and were comprised of more soluble 
coformers.  
The contributions of fusion enthalpy and melting temperatures of several 
cocrystals were compared to the solubility calculated from measured eutectic points.  
These correlations showed reasonable trends for the organic solvents similar to those 
described in the literature for ideal solubilities of single component solids.  However, 
aqueous cocrystal solubility values showed considerable deviations from the ideal 
solubility behavior based on the contributions of crystallinity alone.  For this small series 
of cocrystals solvent-solute interactions, particularly in water, were dominant relative to 
the ideal solubility estimated from fusion of the crystal lattice. 
The solubility of the carbamazepine cocrystals studied was proportional to their 
component solubilities.  These correlations between the solubility of a cocrystal and its 
pure components do not account for changes in the lattice energy, which likely will cause 
deviation of these solubility trends.  Understanding both the solid-state and solution 
chemistry of cocrystals is important toward expanding cocrystal-solubility relationships.  
Future considerations of cocrystal solubility should seek to combine the observed 
solubility trends and solution models with the contribution of the crystal lattice energy. 
A eutectic constant (Keu) was established to extend the utility of cocrystal eutectic 
concentrations toward describing cocrystal solubility and stability.  Keu is the ratio of 
cocrystal component activities at the eutectic.  Keu values are fundamental indicators of 
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phase behavior and are shown to be a function of the solubility ratio ( ) of cocrystal and 
drug in pure solvent.  Keu is shown to depend on solution chemistry including i) solvent, 
ii) complexation, and iii) ionization, as does the cocrystal solubility.  The eutectic 
solution excess of a cocrystal component is controlled by the relative solubility of the 
cocrystal and component in pure solvent and was established from the analysis of more 
than forty observed and predicted Keu values that showed good agreement.  When the 
molecular structure and properties of the components differ it is the solubility of the 
cocrystal and its components (drug and coformer) that determine the solution eutectic 
composition. Differences in cocrystal stoichiometry as well as solubility of the 
components due to ionization and complexation are critical.  Therefore in the case of 
cocrystals the solution composition and stability can be altered by solvent selection.  It is 
indicated that the description of cocrystal solubility using Keu and Ksp values greatly 
improves the ability to discern and compare the true solubility of cocrystals.   
Future work can focus on estimating the nature and extend of solubilization or 
complexation between cocrystal components based on deviations between the observed 
cocrystal to drug solubility ratio and the predicted ratio from the eutectic concentrations.  
Additionally it will be useful to apply and expand the eutectic concentrations to predict 
the solution phase behavior for systems were the cocrystal solubility does not decrease 
with higher coformer concentrations because of high levels of drug solubilization in 
concentrated coformer solutions. 
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Thermodynamic relations were developed that model the temperature dependence 
of the eutectic concentrations to predict the stability of cocrystals in solutions and 
suspensions at different temperatures.  Keu dependence on temperature is determined by 
the difference in the enthalpy of solution between the component and cocrystal phases.  
When there is no difference between cocrystal and component enthalpies of solution Keu 
will be constant with temperature.  Keu and the cocrystal solubility ratio were shown to 
change with temperature when there were differences between the cocrystal and 
component enthalpies of solution. Enthalpies of solution were analyzed for 
sulfamethazine-benzoic acid as well as carbamazepine cocrystals of nicotinamide, 
isonicotinamide and 3-nitrobenzamide.  It was observed that the temperature dependence 
of the eutectic concentration was predicted from the heats of solution of the cocrystal and 
components and for carbamazepine-nicotinamide as well as sulfamethazine-benzoic acid 
in water that Keu decreased with temperature.  For carbamazepine-nicotinamide the Keu 
became closer to the observed composition ratio of binary (without solvent) eutectic for 
the lowest melting composition of the two components.  This observation would be 
interesting to explore for more systems, because it could enable prediction of temperature 
dependent solution behavior from thermal melt behavior of the cocrystal components.   
The observed change in Keu with temperature was also solvent specific.  
Carbamazepine-nicotinamide had a significant change in the cocrystal stability region in 
water and no change in ethanol and ethyl acetate.  This is because the cocrystal and 
component enthalpies of solution were not equal in water, but were equal in the other 
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solvents.  Keu was shown to be independent of temperature when the difference between 
the cocrystal and component enthalpies of solution was zero.  The cocrystal component at 
the eutectic in water was CBZ dihydrate and for the organics it was anhydrous CBZ III.   
Both temperature and solvent considerations are critical to the design of 
cocrystals synthesis and screening process.  Also it has been demonstrated that racemic 
compounds also have temperature dependent eutectic concentrations, however their 
behavior is not solvent (achiral) specific.  Future work that expands on the observed 
temperature dependence for both racemic compounds and cocrystals based on their 
enthalpies of mixing/solvation, fusion, and solution could improve the understanding of 
the eutectic behavior of cocrystals and their relations to the physicochemical properties of 
the components and solvent. 
The quantification of activity coefficients, based on ideal solution behavior, was 
carried out to predict solubility and stability in other solvents since the cocrystal chemical 
potential is independent of solvent.  The predicted stability of carbamazepine-saccharin in 
four different solvent systems corresponded to the observed stability.  The success of 
synthesizing cocrystals is critically dependent on the chemical potential of the cocrystal 
relative to the components. Cocrystal will be thermodynamically stable at some solution 
composition if the solubility product (aAaB for 1:1 cocrystal AB) of the cocrystal is lower 
than the product of the component activities.  The cocrystal component activity 
coefficients specific to a cocrystal-solvent system determine whether the cocrystal is 
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more soluble than either component in pure solvent (incongruently saturating).  For 
carbamazepine-saccharin, the component activity coefficients account for its instability in 
water while its stable in ethanol, ethyl acetate and isopropanol. 
The physical and chemical stability of pharmaceutical solids is critically 
dependent on the presence of water.  Solid phase transformations affect the stability, 
safety, purity, and efficacy of the drug substance and drug product.  Pharmaceutical drug 
products may come into contact with water during production and formulation or at any 
point through exposure to humid environmental conditions.  Drug products that 
incorporate materials containing water have the potential to transfer it to other 
components whose stability is affected by water.  Fundamental knowledge of additive 
interactions with moisture and comprehensive study of solubility behavior of cocrystals 
and their components is a prerequisite for the development of useful drug products. 
Carbamazepine-nicotinamide formed in mixtures with deliquescent (sucrose and 
fructose) additives even when carbamazepine hydrate formation was possible. 
Carbamazepine-nicotinamide was also formed in mixtures with polyvinylpyrrolidone 
(PVP), which is a common pharmaceutical additive that is hygroscopic.  The mechanisms 
responsible for cocrystal formation in cocrystal component mixtures with hygroscopic or 
deliquescent additives were identified to involve moisture uptake, dissolution of cocrystal 
reactants, cocrystal nucleation and growth.   These mechanisms are important to design 
formulations and predict conditions that control cocrystal transformations.   Cocrystal 
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solubility dependence on aqueous solution composition and chemistry are good 
predictors of cocrystal formation in the presence of hygroscopic additives.  It is clear 
from the results that cocrystal formation mechanisms can be solution mediated in the 
presence of deliquescent or hygroscopic additives or components.   The mechanism and 
potential to influence cocrystal stability has yet to be determined for hygroscopic 
additives that sorb low levels of moisture, which do not readily form a solution phase.  
This behavior could be studied at the molecular level to understand the interaction of 
water with hygroscopic additives and the potential transfer of water to cocrystal 
components.  The equilibrium state of these transformations in the presence of 
hygroscopic additives could also be confirmed using both cocrystal and components as 
starting phase(s). 
Many cocrystals presented in this work have a higher solubility than one of their 
components (often drug) and in these cases transformation of cocrystal to a less soluble 
component can occur.  Transformation of cocrystal to a less soluble form can occur until 
all cocrystal transforms or the eutectic composition is reached.  It is beneficial to explore 
methods to slow transformation kinetics of highly soluble cocrystals that are unstable in 
solution.  The inhibition of solution transformations could be achieved using additives, 
which prevent the nucleation or growth of the crystalline component(s) thereby 
maintaining supersaturation for longer periods. This area will be important for 
transferring the high thermodynamic solubility of incongruently saturating cocrystals to 
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achieve improved in vivo dissolution and performance of cocrystals.  Both the kinetic and 
thermodynamic effects of additives on the cocrystal solubility and dissolution will need 
to be characterized to optimize cocrystal formulations.  Kinetic solubility measurements 
do not typically serve as good indicators of the solubility of unstable cocrystals because 
transformations can occur.  Eutectic point measurements are indicators of the true 
solubility of a cocrystal, and can guide cocrystal selection.   
 
